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Abstract
Coronary angioplasty is established as the most common form of 
revascularisation in IHD, yet despite major advances, failure of 
microvascular revascularisation is associated with poor prognosis. 
Inflammation is important in the natural progression of atherosclerosis 
from early stages through to progression to plaque rupture and acute 
myocardial infarction. In addition inflammatory mechanisms have a 
role in mediating adverse clinical outcomes during coronary 
reperfusion and revascularisation, although the underlying 
mechanisms remain unknown.
The objective of this research was to assess the microvascular 
response to percutaneous coronary intervention (PCI) in patients with 
stable angina, and this study aimed to assess the relationship between 
changes in microvascular function in response to PCI with markers of 
systemic inflammation and endothelial activation. Also we aimed to 
detect localised myocardial inflammation in response to PCI in those 
patients who have microvascular injury following PCI.
We measured fractional flow reserve (FFR), coronary flow reserve 
(CFR) and index of microcirculatory resistance (IMR) in both the 
vessel undergoing PCI and an adjacent vessel, before and after PCI. 
We assessed the inflammatory response to PCI and the relationship 
between markers of systemic inflammation and microvascular 
function. A subgroup of 9 patients underwent radiolabelling of 
leukocytes and myocardial SPECT scans before and after PCI to 
detect areas of localised inflammation. A total of 39 patients were 
included in the study.
Patients demonstrated a heterogenous response on IMR following 
PCI. There was an increase of microvascular resistance in the vessel 
undergoing PCI in a third of subjects. There was a reduction of IMR 
in the reference vessel in response to PCI in the target vessel 
(23.7[15.8-31.4] vs. 17.9[12.4~24.1] n=34 p<0.01) Basal inflammation 
was not predictive of microvascular dysfunction but the inflammatory 
response as measured by CRP and ET-1 was associated with 
microvascular dysfunction (R=0.42 p<0.05, R=0.34 p<0.05 n=35) 
respectively. A low pre procedural IMR was strongly predictive of an 
increase in microvascular resistance post PCI (R=0.73 PcO.OOl). 
Finally no areas of increased inflammation were detected on 
myocardial SPECT scanning. In summary it is the inflammatory 
response rather than basal levels of inflammation which seem to be
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associated with microvascular dysfunction and we see a novel 
reduction in IMR in the reference vessel in response to PCI in the 
target vessel.
ACKNOWLEDGEMENTS
I sincerely thank Allah, the Most Gracious, Most Merciful for 
enabling me to pursue and complete this thesis. I am most 
grateful to Mike Fisher, my supervisor for his support, 
encouragement and enthusiasm throughout the course of this 
project. Without Mike’s assistance this thesis would never have 
been completed. I would also like to thank Professor Hart, my 
co-supervisor for his support and advice throughout the project. 
I would like to thank Linda Smith who helped me through the 
complexities of Gamma SPECT scanning and radiolabelling 
techniques. I am indebted to Ian Hufton who spent many an 
hour going through the nuclear medicine data sets with me. I 
would also like to thank Paul Browning and Nichola Cross at 
the research laboratory at Liveipool Heart and Chest Hospital 
who taught me how to perform flow cytometry and ELISA 
assays.
I am very grateful to Steven Lane who provided statistical 
advice and was always willing to help when I was struggling. I 
am very grateful Mary Palmer and Maria Parkes at Liverpool 
Heart and Chest Hospital, both of whom helped with the 
logistics of juggling cath lab lists to accommodate the study 
patients. I want to thank all the cath lab staff at LHCH who 
have been very helpful throughout. I am grateful to Mark 
Hawthorne who assisted me greatly when he was working for 
RADI. I wish to thank Moutaz and Eric both of whom made 
sure I did not give up.
Most of all I wish to thank my family, especially my wife 
Mahnaz who has endured the last couple of years with great 
patience, and has been hugely supportive, my three daughters 
Zainab, Khadija and Mariam, all of whom will be overjoyed 
this thesis has come to an end. I also am very grateful to my 
mother, brothers and sisters, all of whom have seen very little 
of me over the last few months and have been very 
understanding. Especially I wish to thank my late father and my 
eldest brother Arif, whose support and guidance got me to 
where I am today.
Finally I wish to thank the British Heart Foundation and Cordis 
for providing funding for the study.
IV
CONTENTS
Abstract ii
Acknowledgements iv
Table of Contents v
List of Figures x
List of Tables xii
Publications xiv
Glossary xv
Chapter 1 - Introduction 1
1.1 CORONARY ARTERY DISEASE 1
1.1.1 Significance of coronary artery disease 1
1.1.2 Structure of coronary artery 2
1.1.3 The role of endothelium 3
1.1.4 Pathophysiology of atherosclerosis 5
1.1.5 Role of cellular adhesion molecules and shear stress in
the pathogenesis of atherosclerosis 11
1.2 INFLAMMATION 12
1.2.1 Inflammation and cardiovascular risk 12
1.2.2 Modification of inflammation with statins 15
1.3 PERCUTANEOUS CORONARY INTERVENTION 17
1.3.1 Introduction 17
\ 3.2 Complications of PCI 19
1.3.2.1 No-Reflow phenomenon! 19
1.3.2.2 Peri-procedural MI 23
1.3.2.3 Distal embolisation theory 25
1.4 CORONARY MICROCIRCULATION 26
1.4.1 Structure of the coronary microcirculation 26
1.4.2 Function of the microcirculation 27
1.4.3 Regulation of the microcirculation 28
1.4.3.1 Metabolic factors 28
1.4.3.2 Myogenic factors 31
l A3 3 Endothelial factors 33
1.4.3.4 Vasodilators 33
1.4.3.5 Vasoconstrictors 35
V
\ A 3.6 Other factors 35
1.4.4 Clinical significance of the myocardial microcirculation 37
1.4.5 Assessment of microva scalar function 40
1.4.5.1 Introduction 40
1.4.5.2 Assessment 40
1.4.5.3 Methods of assessment 41
1.4.5.3.1 Doppler wire 42
1.4.5.3.2 Temperature sensitive pressure wire 43
1.5 SUMMARY 44
1.6 ORIGINAL HYPOTHESIS 46
Chapter 2 - Methods 47
2.1.1 Ethical approval 47
2.1.2 Project design and recruitment of subjects 41
2.2 ASSESSMENT OF MICROVASCULAR FUNCTION 48
2.2.1 Justification of method used to calculate MR 49
2.2.1.1 Coronary’flow reserve 50
2.2.1.2 Thermodilution principle to measure coronary
flow reserve 52
2.2.1.3 Doppler based assessment of microvascular
resistance (MRv) 56
2.2.1.4 Index of microcirculatory resistance (IMR) 57
2.2.1.4.1 Effect of collateral flow on IMR 59
2.2.2 Assessment of MR in this study 63
2.2.3 Assessment of collateral flow 67
2.3 MEASUREMENT OF INFLAMMATORY MARKERS
AND TROPONIN-T 68
2.3.1 HsCRP 68
23.2 IL-6 70
2.3.3 sICAM-1 71
2.3.4 sVCAM-1 12
2.3.5 Endothelin-1 73
2.3.6 sP-Selectin 14
2.3.7 Assessment of neutrophil CD11 b/CD18 activation 16
2.3.8 Measurement of cardiac troponin-T 79
VI
2A IMAGING OF MYOCARDIAL INFLAMMATION 80
2.4.1 Introduction 80
2A.2 Methods 81
2.4.2.1 Radiolabelling procedure 81
2.4.2.2 Injection of radioisotope 82
2.4.2.3 Imaging 83
2.4.2.4 Quantification 83
2.4.2.5 Quality control 85
2.5 STATISTICS 86
2.5 A Power calculation 86
2.5.2 Statistical analysis 86
Chapter 3 - Screening and Recruitment of subjects 88
3.1 INTRODUCTION 88
3.2 METHODS 88
3.2.1 Screening process and patient selection 88
3.2.2 Making patient contact 89
3.2.3 Justification of inclusion/exclusion criteria 90
3.3 RESULTS 92
33 A Screening process 92
3.3.2 Background characteristics 94
3.3.3 Evidence of reversible ischaemia pre PCI 97
3.4 DISCUSSION 100
Chapter 4 - Effect of PCI on coronary and microvascular 
physiology 103
4.1 INTRODUCTION 103
4.2 METHODS 109
4.2,1 Statistical analysis 110
4.3 RESULTS 111
43 A Procedural factors 112
43.2 General 113
433FFR/CFR 116
4.3.4 IMR 118
4.3.5 IMR resting 124
vii
1254.3.6 CFI
4.3.7 Comparison of good collateral vs. poor
collateral groups 126
4.3.8 Procedural factors and microvascular dysfunction 129
4.4 DISCUSSION 133
4.5 LIMITATIONS 148
Chapter 5 - Inflammation 152
5.1 INTRODUCTION 152
5.2 JUSTIFICATION OF USE OF CLINICAL MARKERS 154
5.3 METHODS 158
5.3.1 ELISA 159
5.3.2 Flow cytometry 159
5.3.3 Statistical analysis 160
5.4 RESULTS 161
5.4.1 The effect of PCI on circulating inflammatory
markers, adhesion molecules and endothelin-1 161
5.4.2 Baseline inflammatory markers vs. pre PCI
markers of microvascular function 168
5.4.3 Basal inflammation vs. change in microvascular
function following PCI as assessed by IMR and CFR 171
5.4.4 Comparison between the ratio of inflammatory
response at 1 hour vs. change in microvascular 
function post/pre PCI 173
5.4.5 Comparison between the ratio of inflammatory
response at 24 hours v.v. change in microvascular 
function post/pre PCI 176
5.4.6 Comparison between inflammation and resting IMR 178
5.4.6 Peri procedural myocardial injury 181
5.4.7 Linear regression models to assess the relationship
between change in IMR and independent variables 183
5.5 DISCUSSION 186
viii
5.6 LIMITATIONS 200
Chapter 6 - Imaging myocardial inflammation 202
6.1 INTRODUCTION 202
6.2 METHODS 206
6.3 RESULTS 206
6.3.1 Visual analysis
6.3.2 Quantitative analysis of myocardial inflammation 208
6.4 DISCUSSION 210
6.5 LIMITATIONS 211
Chapter 7 - Conclusion 213
References 219
IX
List of Figures
Figure 1.1- Structure of the coronary artery 3
Figure 1.2 - Prevalence maps of fatty streaks and raised
lesions in coronary arteries of young adults 6
Figure 1.3 - Early changes of atherosclerosis 8
Figure 1.4- Histological specimens of atherosclerosis variation
in the constitution of plaque 10
Figure 1.5 - Studies comparing baseline CRP levels to risk of
cardiovascular events 14
Figure 1.6- Diagram representing balloon angioplasty and
stenting of coronary artery 18
Figure 1.7- Schematic diagram representing different 
mechanisms responsible for the regulation 
of myocardial microvascular resistance 36
Figure 1.8 - Coronary microcirculation 38
Figure 1.9 - Definition of true myocardial resistance 41
Figure 2.1 - Two compartment model of coronary circulation 50
Figure 2.2 - Diagram representing intracoronary pressure wire 53
Figure 2.3 - Thermodilution curves obtained with RADI™ wire 54 
Figure 2.4 - Calculation of mean transit time of injectate 54
Figure 2.5 - Calculation of CFR thermodilution 56
Figure 2.6 - Calculation of myocardial microvascular
resistance using intracoronary Doppler 58
Figure 2.7 - Calculation of IMR 60
Figure 2.8 - Schematic of coronary circulation 60
Figure 2.9 - Calculation of IMRCorrected 62
Figure 2.10- Assessment of IMR 63
Figure 2.11- Haemodynamic data protocol 65
Figure 2.12 - Graphical representation of leukocyte populations
with flow cytometry 78
Figure 2.13 - Mean fluorescence intensity of CD1 lb PE of
leukocyte sub-population 79
Figure 2.14 - ROI analysis of summated data set 85
Figure 3.1- Flow diagram of the screening process 92
Figure 3.2 - Flow diagram representing evidence of reversible
ischaemia in the study population 99
Figure 3.3 - Location of coronary artery lesion 100
Figure 4.1- Haemodynamic data as measured by the
pressure wire 113
X
Figure 4.2 - Effect of PCI on FFR 116
Figure 4.3 - Effect of PCI on CFR measured with
thermodilution 117
Figure 4.4 - Effect of PCI on IMRunc01TCCied 118
Figure 4.5 - Effect of PCI on IMRcorrected 119
Figure 4.6 - Acute change in coronary wedge pressure
following PCI 120
Figure 4.7 - Distribution of patients according to change
in IMR 121
Figure 4.8 - Effect of PCI on mean transit time in the reference
vessel 122
Figure 4.9 - Effect of PCI on distal coronary pressure in the
reference vessel 123
Figure 4.10- Effect of PCI on IMRresling 124
Figure 4.11 - Relationship between collateral flow index
and IMR 125
Figure 5.1- Effect of PCI on HsCRP 161
Figure 5.2 - Effect of PCI on IL-6 162
Figure 5.3 - Effect of PCI on soluble ICAM-1 163
Figure 5.4 - Effect of PCI on soluble VCAM-1 164
Figure 5.5 - Effect of PCI on soluble P-selectin 165
Figure 5.6 - Effect of PCI on endothelin-1 levels 166
Figure 5.7 - Effect of PCI on neutrophil MAC-1 receptor 167
Figure 5.8 - Relationship between log IMRcon.ected target vessel
pre-PCI vs. log change IMRcon.ected target vessel 185
Figure 6.1 - Example of visual analysis of uptake
of "'"Tc-HMPAO WBC 207
Figure 6.2 - Effect of PCI on myocardial inflammation 209
XI
List of Tables
Table 3.1 - Inclusion and exclusion criteria 89
Table 3.2 - Cardiac risk factors 94
Table 3.3 - Medication history of patients prior to PCI 95
Table 3.4 - Functional classification of the severity of angina of
patients 96
Table 3.5 - Clinical characteristics of patients 97
Table 3.6 - Distribution of location of target lesion for PCI 100
Table 4.1 - Procedural characteristics of subjects
undergoing PCI 112
Table 4.2 - Effect of PCI on haemodynamic parameters 114
Table 4.3 - Comparison baseline factors between good and
Poor collateral supply 126
Table 4.4 - Difference in haemodynamic data pre and
post-PCI in patients with poor and good collaterals 127 
Table 4.5 - Microvascular resistance before and after PCI in
patients with poor and good collaterals 128
Table 4.6 - Comparison of resting microvascular resistance
between poor and good collateral groups 129
Table 4.7 - Correlation between procedural factors and
ratio of IMR post/pre-PCI 130
Table 4.8 - Baseline characteristics of patients with increase of 
IMRcorrected in the target vessel post-PCI compared 
with reduction or no change in IMRcoriected 131
Table 4.9 - Comparison of haemodynamic characteristics of 
patients with increase of IMRcorrected in the target 
vessel post-PCI 132
Table 5.1 - Relationship between baseline inflammatory
markers and pre-PCI CFR 169
Table 5.2 - Relationship between baseline inflammatory
markers and pre PCI IMR 170
Table 5.3 - Relationship between baseline inflammatory
markers and change in CFR 172
Table 5.4 - Relationship between baseline inflammatory
markers and change in IMR 173
Table 5.5 - Relationship between change in inflammatory
markers at 1 hour vs. change in CFR 174
Table 5.6 - Relationship between change in inflammatory
markers at 1 hour and change in IMR 175
Table 5.7 - Relationship between change in inflammatory 
markers at 24 hours and change in CFR
xii
176
Table 5.8 - Relationship between change in inflammatory
markers at 24 hours and change in IMR 177
Table 5.9 - Relationship between baseline inflammation
and resting IMR 179
Table 5.10-Relationship between baseline inflammation
and change in resting IMR 180
Table 5.11-Relationship between change in inflammation
and change in resting IMR 181
Table 5.12-Relationship between inflammatory markers 
and procedural factors vs. post procedural 
troponin-T 182
Table 5.13-Univariate correlation between loglMR
post/pre ratio vs. independent variables 184
Table 6.1 - Summary of quantitative detection of myocardial
inflammation with "niTc-HMPAO-WBC 208
xiii
Publications from thesis.
B Patel, L.Smith, P.Browning, G. Hart, M.Fisher. PCI causes 
reduction in microvascular resistance in the adjacent vessel 
bed. J. Am. Coll Cardiol 2009;53;A92 (2523-824)
B.Patel, L.Smith , A.Alahmar, P.Browning, G.Hart, M.Fisher.
The inflammatory response post percutaneous coronary intervention is 
associated with increased microvascular resistance in patients with 
stable angina. European Heart Journal 2009 30 (Abstract Supplement 
), 248
B.Patel, L.Smith, G. Hart, M.Fisher. The reduction in microvascular 
resistance following PCI in the adjacent vessel territory is not related 
to collateral flow index. J. Am. Coll Cardiol 2010;55;A205.E1930
B.Patel M.Fisher. Therapeutic Advances in Myocardial Microvascular 
Resistance: Unravelling the Enigma. Pharmacology & Therapeutics, 
Volume 127, Issue 2, August 2010, Pages 131-147
B.Patel, P.Browning, G.Hart, M.Fisher. Low Index of 
Microcirculatory Resistance Pre PCI Predicts Worsening 
Microvascular Function post PCI. Circulation. 2010; 122: A10843
XIV
Glossary
ACD
ACH
ACS
ACE
AMI
ARMYDA-CAM
Acid citrate dextrose
Acetylcholine
Acute coronary syndrome
Angiotensin-II converting enzyme
Acute myocardial infarction
Atorvastatin for reduction of myocardial 
damage during angioplasty-cell adhesion 
molecules
BMI
BMS
Body mass index
Bare metal stent
cAMP
CABG
CARE
CAM
CCS
CFI
CFR
CHD
CK
CKMB
COPD
CRF
CRP
CS
CTO
CV
Cyclic AMP
Coronary artery bypass grafting 
Cholesterol and recurrent events
Cellular adhesion molecule
Canadian cardiovascular society 
Collateral flow index
Coronary flow reserve
Coronary heart disease
Creatine kinase
Creatine kinase myocardial bound 
Chronic obstructive pulmonary disease 
Chronic renal failure
C- reactive protein
Coronary sinus
Computed tomography
Chronic total occlusion
Co-efficient of variance
DE Distal embolisation
DBS
DPD
Drug eluting stent
Distal protection device
EDHF
factor
EDRF
e-NOS
Endothelial derived hyperpolarising
Endothelial derived relaxing factor 
Endothelial nitric oxide synthase
ET-1 Endothelin-1
XV
ETT
ELISA
Exercise tolerance test
Enzyme-linked immunosorbent assay
FMD
PER
FDG
FITC
Flow mediated dilation
Fractional flow reserve
Fludeoxyglucose
Fluorescein isothyocyanate
Gd-DTPA Gadolinium-diethylenetriamine 
pentaacetic acid
GTN Glyceryl trinitrate
HDL
HITS
HMPAO
HsCRP
High density lipoprotein
High intensity signal? 
Hexamethylpropyleneamine oxime
High sensitivity CRP
LCAM
IHD
IL-6
IMR
Intra cellular adhesion molecule 
Ischaemic heart disease
Interleukin-6
Index of microcirculatory resistance
ISAR
JUPITER
Innovative stratification of arrythmia risk 
Justification for the use of statins in 
primary prevention:an intervention trial 
evaluating rosuvastatin
K+atp Potassium adenosine triphosphate
LAD
LDL
LMS
LV
LVEF
LVEDP
Left anterior descending
Low density lipoprotein
Left main stem
Left ventricle
Left ventricular ejection fraction
Left ventricular end diastolic volume
MAC-1
MACE
MCP-1
M-CSF
Macrophage-1 antigen
Major adverse clinical events
Monocyte chemo attractant protein 
Macrophage colony stimulating factor
MI Myocardial infarction
XVI
MFI
MRV
Mean fluorescence intensity
Myocardial microcirculatory resistance 
assessed with doppler
MPG
MR
MRI
Myocardial perfusion grade
Myocardial resistance
Magnetic resonance imaging
NO
NSTEMI
Nitric oxide
Non-ST elevation myocardial infarction
PCI
Pd
Pa
Pw
Pv
PE
PET
PIL
PKC
PLC
PMI
PSGL-1
Percutaneous coronary intervention 
Mean distal coronary pressure
Mean arterial pressure
Mean wedge pressure
Venous pressure
Phycoerythrin
Positron emission tomography
Patient information leaflet
Protein kinase C
Phophlipase C
Peri-procedural myocardial injury 
P-selectin glycoprotein ligand-1
QCA Quantitative coronary angiography
ROI Region of interest
SPECT Single photon emission computed 
tomography
STEMI ST elevation myocardial infarction
Qmyo
Qcoll
Qcor
Myocardial flow
Collateral flow
Coronary flow
RVEDP Right ventricular end diastolic pressure
SSC Side scatter
TIMI
TEG
TEC
TMR
Thrombolysis in myocardial infarction 
TIMI flow grade
TIMI frame count
Total myocardial resistance
XVII
Tx inn
Tmn(hyper)
Tmn(resl)
TnT
Mean transit time
Mean transit time at hyperaemia 
Mean transit time at rest
Troponin T
USPIO Ultra small paramagnetic iron oxide
V
V-CAM
VSMC
WBC
Volume
Vascular cellular adhesion molecule 
Vascular smooth muscle cell
White blood cell
XV111
Chapter 1 Introduction
1.1 Coronary artery disease
1.1.1 Significance of coronary artery disease
Cardiovascular disease causes more than 1 in 3 deaths in the UK accounting for almost 
200,000 deaths each year (2008b). The main causes are coronary heart disease (CHD) 
and cerebrovascular disease. CHD causes around 94,000 deaths in the UK each year 
and is the most common cause of premature death. About one fifth of premature 
deaths in men and one in ten in women are caused by CHD (Allender , 2008). CHD 
most commonly presents as acute myocardial infarction (MI) or angina, approximately 
146,000 MI occur per year in the UK (Volmink et aL, 1998) and nearly 2 million 
people in the UK either suffer from angina or have had angina at some stage in their 
lives. The prevalence of CHD increases with age, 1 in 3 men and 1 in 4 women over 
age of 75 are affected by CHD (2008a). The high prevalence of this disease results in a 
massive economic burden costing the UK economy a total of 9 billion pounds a year, 
of which 3.2 billion pounds in health care costs and the remainder in loss of 
productivity and informal care of people with CHD (Allender , 2008). Although there 
has been a significant reduction in mortality from CHD over the last decade due to 
better access to diagnosis and revascularisation services, the prevalence of CHD 
continues to rise due to factors such as the increase in the ageing population and the 
increase of type II diabetes and obesity (DH Coronary Heart Disease Policy Team, 
2008).
1.1.2 Structure of the coronary artery
The normal coronary artery consists of three layers; the intima, media and adventitia 
(Figure 1.1). The outermost layer is known as the adventitia and consists, mainly of 
collagen fibrils, tiny blood vessels, vaso vasorum (which supply the wall of the artery), 
nerve endings, fibroblasts and mast cells. Within the adventia lies the media, which is 
separated from the adventitia by the external elastic lamina. The media provides the 
vessel with elastic properties and consists of concentric layers of smooth muscle cells 
with layers of extracellular matrix composed of compound high in elastin. The media 
is separated from the innermost layer known as the intima by the internal elastic 
lamina. The intima made up of a surface layer of endothelium over a basement 
membrane consisting of type four collagen, laminin, fibronectin and other extracellular 
matrix molecules (Wight, 1989). Deep to the basement membrane is the intimal layer, 
this consists of sub endothelial connective tissue and sparse smooth muscle cells.
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Figure 1.1 Structure of the coronary artery.
Altary
Tunica intima
— Internal elastic 
lamina
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V
Schematic representing the different layers of the coronary anatomy.
Adapted from Fox and Ira, Human Physiology Sherwood publishers 1 l'h Edition.
1.1.3 The role of the endothelium
The endothelium is a single cell layer that lines the normal arterial tree which would 
cover approximately 1000m2 if opened out into a single sheet (Augustin et al., 1994). 
This layer ot cells is capable of sensing and reacting to mechanical forces within the 
lumen such as shear stress and producing and releasing various vasoactive compounds 
to maintain the equilibrium of vascular tone, as well as having potent anticoagulant
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properties. Clear evidence that the endothelium is a source of biologically active 
mediators was provided following the discovery of endothelium-derived-relaxing- 
factor (EDRF). The biological effects of EDRF were subsequently shown to be due to 
nitric oxide (NO) (Palmer et aL, 1987;Palmer et al, 1988b), and it became clear that 
NO was crucially important in the maintenance and regulation of arterial tone 
(Furchgott and Vanhoutte, 1989). Since the ground breaking discovery of NO a whole 
range of vasoactive substances have been discovered as originating from the 
endothelium which serve to regulate vessel tone. These include substances which have 
vasoconstricting properties, such as endothelin-l(ET-l), angiotensin, thromboxane A2 
and prostaglandin H2, as well as vasodilatory substances such as prostacyclin, 
bradykinin and endothelial derived hyperpolarising factor (Drexler and Hornig, 
1999;Mombouli and Vanhoutte, 1999;Verma and Anderson, 2002). Since these 
mediators have opposing properties the net effect in a finely balanced and healthy 
endothelium is the maintenance of vascular relaxation, hi addition to the regulation of 
tone, the endothelium performs a variety of other functions which maintain arterial 
homeostasis, this is due to the ability of the endothelium to produce a non adherent 
surface which resists the attachment of leukocytes and platelets by the balance of pro 
and anticoagulant factors (Edelberg et al, 2001). Endothelial cells express a 
combination of pro-coagulant and anti coagulant properties. Pro-coagulant factors 
such as plasminogen activator tissue factor and Von Willebrand factor have to be in 
equilibrium with anticoagulant factors such as heparan sulphate, thrombomodulin, 
prostacyclin and tissue type plasminogen activator. It is this equilibrium between pro
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and anticoagulant activity that allows maintenance of the flow of blood without 
formation of thrombus. However when the endothelium becomes damaged or 
dysfunctional then the balance between factors shifts in the favour of a state which 
promotes coagulation (Schafer, 1997).
In addition to the vasoactive and anticoagulant function of the endothelium there is 
also a structural function whereby the endothelium is able to secrete its own basement 
membrane and other elements of the extra-cellular matrix, including proteoglycans and 
elastic fibres (Wight, 1995;Newby and Zaltsman, 1999). The endothelium also acts as 
a barrier between the circulating cells and the subendothelial space, however there is 
some degree of permeability such that certain cell types may migrate through tight 
junctions between endothelial cells known as desmosomes. The function of 
desmosomes is predominantly to prevent diffusion of macromolecules or the migration 
of cells through the endothelium (Rubin, 1992;Schneeberger and Lynch, 1992). Any 
insult or injury to the endothelium affects the level of permeability of the endothelium, 
which is thought to be one of the earliest change in the genesis of atherosclerosis 
(Ross, 1995)(Figure 1.3).
1.4 Pathophysiology of atherosclerosis
Atherosclerosis has only been named as a pathological entity within the last century 
although there is evidence of the disease process as far back as over three thousand 
years ago in the remains of Egyptian mummies (Shattock, 1909). Great advances have
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been made in understanding the pathogenesis of atherosclerosis in the last 60 years. 
Post mortem studies of young soldiers killed in action in the Korean war described the 
presence of atherosclerosis in coronary arteries of previously healthy men (ENOS et 
al., 1953;Enos et ai, 1986). The fatty streak is often seen in even younger subjects of 
children and infants (Schwartz et al., 1967). There seems to be an increases 
distribution of atherosclerosis at areas of increased turbulence such as the origin of the 
intercostals arteries or branch point of vessels and the prevalence of these early 
changes increases with age (Stary, 1989;Strong et al, 1999) (Figure 1.2).
Figure 1.2 Prevalence maps of fatty streaks and raised lesions in coronary arteries of 
young adults.
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Isopleth maps of fatty streaks (left) and raised lesions (right) demonstrating early 
detectable changes of atherosclerosis. Strong, J.P. et al JAMA;281:727-35
One of the earliest detectable change of atherosclerosis is the decrease in 
bioavailability of nitric oxide and increased expression of cellular adhesion molecules 
in response to endothelial injury, this often precedes the permeation of lipoprotein
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particles through gap junctions between endothelial cells (Simionescu el a!., 1986), 
these coalesce and accumulate in intimal layer by binding to proteoglycans and can be 
seen with electron microscopy (Camejo et al., 1998). Once in the intima the 
lipoprotein particles undergo glycation and oxidation and become modified 
lipoproteins (Witztum and Berliner, 1998). Modified lipoproteins have a tendency to 
induce cytokines which also cause increased expression of cellular adhesion molecules 
(CAM) on the surface of the endothelial cells (Figure 1.3). When activated, CAM 
enable the multi-stage process of monocyte rolling, attachment and diapedesis (Figure 
1.3). E-selectin facilitates the capture and rolling of monocytes and, subsequent 
attachment, facilitated by activated ICAM-1 and VCAM-1, is followed by migration 
into the intima influenced by signals from other cytokines, particularly monocyte 
chemo-attractant protein l(MCP-l) (Luster, 1998;Gu etal, 1998). In the intima, other 
cytokines including monocyte colony stimulating factor (MCSF) induce monocytes 
replication and the expression of scavenger receptors enabling the uptake of modified 
lipoproteins by which monocytes develop into foam cells (Miller et al, 2003). The 
fatty streak is therefore composed of sparse vascular smooth muscle cells, foam cells 
which consist of tissue monocytes rich with lipids, and also large numbers of CD4 and 
CDS positive T- lymphocytes (Ross, 1993). The net result is a localised thickening of 
the intima (Fowler, 1980;Klurfeld, 1985). Macrophage foam cells produce further 
cytokines such as matrix metalloproteinases which stimulate smooth muscle cell 
migration from the media to the intima, smooth muscle cell proliferation and the 
production of extra-cellular matrix (Newby, 2008).
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Figure 1.3 Early changes of atherosclerosis
Endothelial dysfunction causes an increase in endothelial permeability to lipoproteins 
The response to permeation of lipoproteins is an inflammatory response and 
recruitment of monocytes, which is mediated by E-selectin, vascular cellular adhesion 
molecule-1 (VCA1W-1) and intracellular adhesion molecule-1( 1C AM -1). The first step 
is rolling of monocytes whereby the monocytes slow down on the endothelial surface, 
this is mediated by E-selectin on the endothelial cel! and carbohydrate ligand on the 
monocyte cell surface. The rolling monocyte is susceptible to signals from MCP-1, 
once stimulated by MCP-1 the monocyte expresses LFA-1, MAC-1 and VLA-4, these 
enable monocyte to attach onto the endothelial surface and subsequently to migrate 
into the vessel wall (Left). The monocytes in response to M-CSF transform to 
macrophages and subsequently engulf oxidised LDL particles in the intima resulting 
in the formation of the lipid rich foam cell. Foam cells release MMP and free radicals.
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T cells are also found in foam cells. Following this smooth muscle cells migrate into 
the intima from the media mediated by PDGF. Smooth muscle cells which have 
migrated then divide and result in growth of the plaque. Adapted from Ross NEJM 
1999.
Other chemotactic factors such as platelet derived growth factor (PDGF) also mediate 
smooth muscle cell migration and proliferation (Raines, 2004). As the plaque 
progresses, layers of foam cells and smooth muscle cells form over the free lipid 
content, the smooth muscle cells produce large quantities of collagen resulting in the 
fibro-lipid plaque. The fibrous portion of the plaque consists of a large number of 
vascular smooth muscle cells (VSMC), infiltrate of inflammatory cells and connective 
tissue. The core of the plaque is composed of lipid rich material which is the result of 
dead and dying monocytes, which after absorbing excess cholesterol derived products 
become lipid laden and die (Bjorkerud and Bjorkerud, 1996;Ross, 1999a), due to toxic 
effects of this high lipid rich content (Ross, 1993) (Figure 3). The constitution of the 
plaque can vary considerably and can range from a semi-fluid core which is high in 
lipid content to very hard fibrous plaques composing of predominantly collagen 
(Lundberg, 1985;Stary, 1992;Ueda ef a/., 1997) (Figure 1.4).
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Figure 1.4 Histological specimens of atherosclerosis variation in the constitution of
plaque
Atherosclerotic plaque with thin fibrous cap (left), fibrocalcifie plaque (right).
Adapted from Virmani R. et al. Arterioscler Thromb Vase Biol 2000:20:1262
The clinical presentation of coronary plaques can depend on the composition and 
characteristics of the lesion. If there is gradual progression of the plaque eventually 
resulting in a sufficient narrowing of the lumen to affect the flow of blood then the 
result is angina caused by myocardial ischaemia due to insufficient supply of blood to 
meet demands of myocardium. The other, and much more serious presentation is with 
acute myocardial infarction or acute coronary syndrome caused by the rupture of the 
surface of the plaque and the resulting partial or complete occlusion of the vessel 
(Shah, 1997;Maseri and Sanna, 1998). This most commonly occurs at the shoulder of 
the plaque where the cap overlies the edge of the lipid core. This exposes the contents 
of the plaque, which includes tissue factor and collagen, to react with circulating blood
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enabling a powerful pro-thrombotic stimulus which results in the formation of 
thrombus on the plaque. The thrombus can become incorporated into the body of the 
lesion causing a sudden progression in the degree of luminal narrowing (Duguid J., 
1976).
Atherosclerosis typically affects large to medium sized vessels but does not affect 
resistance vessels or the microcirculation. However there is an association between 
microvascular dysfunction and traditional cardiovascular risk factors in the absence of 
epicardial disease suggesting microvascular dysfunction may be the precursor to the 
development of obstructive coronary artery disease (Rubinshtein et aL, 2010).
1.1.5 The role of cellular adhesion molecules and shear stress in the pathogenesis 
of atherosclerosis
It has been shown that areas of arterial endothelium at sites that are known to be prone 
to the development of atherosclerotic lesions, show up-regulation of the inflammatory 
adhesion molecules VCAM-1 and E-selectin (Bell JP, 2000a). This data was obtained 
from the carotid bifurcation of the pig, an animal known to develop spontaneous 
atherosclerosis with both a histological appearance and a spatial distribution very 
similar to that of the human (Muller et aL, 1992).
Very similar changes are seen at the branch points of the intercostal arteries from the 
aorta, another site known to be prone to the development of atheroma (Bell JP, 2000b). 
The factor common to these regions is turbulent blood flow, leading to a loss of the
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normal laminar shear stress (Asakura and Karino, 1990;Milner et al., 1998).
Reduction or loss of laminar flow has been shown to be associated with adhesion 
molecule expression in vitro (Chien et al, 1998). This data suggest that upstream 
arterial disease, by virtue of producing a reduction in blood flow and hence in shear 
stress, could result in downstream up-regulation of these adhesion molecules.
Banning et al. noted that following balloon carotid angioplasty in the pig model, radio- 
labelled platelets are deposited distally in the vessel, remote from the area of arterial 
injury (Banning AP, 1995). The authors were not able to provide an explanation for 
these results, but it is notable that the region of increased platelet deposition was 
around the carotid bifurcation, which is precisely the same region in which adhesion 
molecule up regulation has been shown. A similar phenomenon has been demonstrated 
to occur in-vivo in rat models, in which platelet-leukocyte interaction with the 
formation of microemboli and plugging of small vessels has been noted (Katayama et 
al, 2000).
1.2 Inflammation
1.2.1 Inflammation and cardiovascular risk
The role of inflammation in the pathophysiology of atherosclerosis has become 
established in the last two decades. Large scale population based studies have enabled 
the use of inflammatory biomarkers to assess cardiovascular risk and shown potential 
for clinical applicability. Several large scale trials have demonstrated the increased
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risk of cardiovascular events in apparently healthy individuals with elevated baseline 
inflammatory markers as discussed below.
A substudy of the Physicians Health Study evaluated the role of elevated C-reactive 
protein (CRP) in 543 apparently healthy men who subsequently developed 
cardiovascular disease and compared with age-matched controls without 
cardiovascular events. They found baseline CRP was higher in the group of patients 
with cardiovascular events. The relative risk of myocardial infarction and stroke was 
2.9 and 1.9 respectively in highest quartile when compared with the lowest quartile of 
serum CRP levels (Ridker et al.t 1997). Similarly, of 14,916 healthy men, 202 had MI 
in 6 year follow up. When compared with age and smoking matched controls, serum 
IL-6 levels in the highest quartile had 2.3 fold increased risk of cardiovascular events 
when compared to the lowest quartile (Ridker et al., 2000b). In addition to Interleukin- 
6 (IL-6) and CRP , ICAM-1 and serum amyloid A have also been found to be 
significant predictors of future cardiovascular risk (Ridker et al, 2000a).
Elevated CRP was a greater predictor of future risk of cardiovascular events than 
serum low density lipoprotein (LDL) levels in a study of 27,939 healthy women 
followed up for 8 years (RR cardiovascular events was 2.3 and 1.3 for CRP and LDL 
respectively) (Danesh et al, 2000;Ridker et al, 2002). There are many studies which 
show a similar increase in risk of cardiovascular events if basal CRP is elevated 
(Ridker, 2003) (Figure 1.5).
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Figure 1.5 Studies comparing baseline CRP levels to risk of cardiovascular events
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Association of increased levels of CRP with myocardial infarction, stroke, peripheral
vascular disease and death from multiple studies as shown in Figure 1.5 Adapted
from (Ridker, 2003).
More recently, the largest ever meta-analysis on the association between inflammation
and cardiovascular risk was carried out on over 54 long term studies including 
approximately 160,000 patients. It compared low CRP vs. 3-fold higher CRP and 
found the RR of developing CHD was 1.63 in high CRP when adjusted just for age
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and sex, this reduced to 1.37 when conventional risk factors were adjusted for and 1.23 
if fibrinogen is also adjusted for, with similar reduction in relative risk seen with 
stroke and vascular mortality (2010). Although this study suggested the significance of 
CRP on its own may have been overestimated in previous studies due to confounding 
factors such as traditional cardiovascular risk factors, nevertheless inflammation 
remains a key risk factor.
It is not surprising conventional risk factors have an additive effect of cardiovascular 
risk to, since these in themselves promote inflammatory activation due to increased 
production of angiotensin II, oxidised LDL, pro-inflammatory cytokines produced by 
adipocytes and advanced glycation end products. These pro inflammatory mediators 
are found in conditions traditionally associated with coronary artery disease such as 
hypertension, hyperlipidaemia, diabetes and obesity (Das, 2002).
1.2.2 Modification of cardiovascular risk with statins
With the knowledge that increased inflammation is a major factor in cardiovascular 
risk, it was interesting to see if modification of inflammation was able to reduce risk. 
This question was answered by the recent discovery of the role of statins in primary 
prevention of cardiovascular events. Although statins are drugs designed to reduce 
circulating LDL and cholesterol, the pleotrophic effects are also known to have a 
potent anti-inflammatory properties. Statins exert an anti-inflammatory effect due to 
inhibition of prenylation of intra-cellular transduction proteins involved in cell
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signalling. These proteins belong to the Rho and Ras family and perform a multitude 
of functions, one of which is promotion of inflammatory signals (Liao and Laufs, 
2005).
The CARE study assessed the role of pravastatin in over 4000 patients who had a 
diagnosis of MI within 10 months. The subjects were randomised patients to either 
40mg pravastatin or placebo, and all patients had serum cholesterol levels 
<6.2immol/L and LDL mean 3.6mmol/L There was a 32% reduction in the incidence 
of stroke in the pravastatin group, these findings were interesting since at the time the 
lipid levels used for inclusion into the study were not considered significantly high 
(Plehn et al, 1999). The AFCAPS TexCAPS study assessed the role of lovastatin in 
low-moderate risk patients, this study showed benefit even in those patients in whom 
LDL was normal but with elevated CRP levels (Downs et al, 1998). More recently, 
the JUPITER study confirmed a large reduction of hospitalisation and 
revascularisation of 47% compared with placebo in patients with normal LDL 
<3.4mmol/L and CRP>2mg/L (Ridker et ah, 2008). These studies demonstrate 
cardiovascular protection by the modification of the inflammatory state to some 
degree, in addition to lowering of LDL cholesterol.
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1.3 Percutaneous coronary intervention 
1.3.1 Introduction
CHD can be treated by revascularisation or medical therapy to control symptoms and 
reduce risk of further events. Revascularisation was only possible initially with open 
heart surgery in the form of CABG until the pioneering of PCI by Andreas Gruntzig in 
1977. This involved the passage of a fixed wire balloon catheter into the coronary 
artery with the lesion and subsequent dilation of the balloon in the coronary stenosis. 
Initial experience had success rates of up to 60%, but had a high complication rate 
such as acute vessel occlusion which occurred in up to 8% of patients, most of which 
required emergency CABG (6%) (Kent et al, 1982;Detre et al, 1988). The other issue 
with balloon angioplasty was the high rate of restenosis caused by neointimal 
proliferation of smooth muscle cells, early elastic recoil and arterial remodelling in 
response to arterial injury from the balloon dilation (Austin et al, 1985).
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Figure 1.6 Diagram representing balloon angioplasty and stenting of coronary 
artery
Representation of balloon angioplasty in coronary artery with possible complications 
including elastic recoil and dissection of the intima. These initial problems with 
balloon angioplasty were resolved by placing a stent within the segment of balloon 
dilated artery. Adapted from Windecker and Meier BMJ;2000.
The incidence of acute vessel closure was addressed by Sigwart et al. by the 
development of the intracoronary stent which acted as a scaffold to keep the vessel 
open (Sigwart et ah, 1987) (Figure 1.6). The issues with restenosis persisted despite 
stenting with clinically apparent rates of up to 30% (Fischman et al., 1994;Serruys et 
al., 1994). It was apparent the predominant mechanism of restenosis following 
stenting was neointimal hyperplasia and thought to be secondary to a prolonged 
inflammatory reaction (Nakatani et al., 2001). The development of improved stent
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technology and drug therapy has substantially reduced the risk of restenosis and 
improved outcome of PCI whereby approximately 2 million procedures are performed 
annually worlwide for CHD (Smith, Jr. et al, 2006).
PCI has become increasingly popular, often due to patient preference for a procedure 
which is minimally invasive and can be performed as a day case in many 
cardiovascular centers, with return to normal activities in a few days. Current success 
rates are now well over 95% and over 80,000 PCIs are performed annually in UK. PCI 
is now four fold more common than CABG as the treatment for CHD and currently 
half of all PCIs are performed in patients with stable angina (Ludman PF, 2007).
Despite the excellent technological advances and expertise in the field of PCI there 
remains a small but significant complication rate in the form of the no-reflow 
phenomenon, poor reflow and periprocedural myocardial infarction or “cardiac 
enzyme leak”, which are both associated with increased mortality and morbidity. It is 
the underlying mechanisms behind these adverse events which are poorly understood 
and which form the basis of the hypothesis which is examined in this thesis.
1.3.2 Complications of PCI 
1.3.2.1 No-reflow phenomenon
The no-reflow phenomenon denotes the circumstance in which an artery is 
successfully opened and yet flow into the distal vessels is poor or non-existent, 
suggesting dysfunction of the resistance vessel bed. A requirement for this 
phenomenon is temporary occlusion of the artery, which can occur in the setting of
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either a myocardial infarction or following PCI. This phenomenon was described in a 
canine myocardial infarction followed by reperfusion (Kloner et al., 1974a). First 
observation in humans was made in 1985 whilst performing thallium 20land 
technetium 99 isotope scans to assess myocardial uptake and perfusion respectively in 
patients who had undergone acute MI treated with thrombolysis (Schofer et al., 1985). 
The same phenomenon was described angiographically as abnormally slow 
anterograde contrast filling in the infarct related artery (Bates et al, 1986).
The incidence of angiographic no-reflow varies from 0.6% to up to 20%, depending on 
the clinical scenario in which the PCI is performed and the type of procedure (Piana et 
al., 1994). The incidence is much greater in patients undergoing PCI to treat acute 
myocardial infarction (primary PCI), saphenous vein graft intervention and rotational 
atherectomy. There is a four fold increase in mortality (Resnic et al, 2003) and 
increased risk of MI and heart failure if no-reflow occurs (Ito et al, 1992a;Piana et al, 
1994). The most recent data suggests no-reflow is an independent predictor of 
mortality at 5 years independent of left ventricular infarct size (Ndrepepa et al, 2010). 
Although angiographic no-reflow is clearly apparent during PCI, there exists a less 
profound microcirculatory disturbance which has become apparent as the methods of 
detecting no, or poor reflow have improved with techniques such as myocardial 
contrast echo and the use of intracoronary Doppler wires. It transpires that the actual 
incidence of poor or no-reflow, particularly when assessed from the microvessel
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perspective is actually much greater than previously thought (Ito et aL, 1996b;Kern et 
al, 1999).
The underlying mechanisms responsible for no-reflow are still unclear although many 
different factors are believed to be responsible such as distal embolisation of plaque 
material and thrombus, and the interaction between platelets and leukocytes with the 
endothelium (Yoon et al., 2006;Tahk et al, 2007). Intravascular plugging of the 
microcirculation by fibrin and platelets has been shown to play a role and the use of 
platelet depleted animal models has shown marked reduction in no-reflow (Golino et 
al, 1987;Seydoux et al, 1993;Michaels et al, 2000). Studies have demonstrated 
reperfusion in the canine myocardium leads to rapid microvascular accumulation of 
leukocytes (Engler et al, 1983;Sheridan et al, 1996). The mechanism responsible is 
thought to be mediated by GDI 8 dependent leukocyte adhesion (Jerome et al, 1993). 
Furthermore leukocyte depleted blood in experimental models has shown a reduction 
in reperfusion injury (Engler et al., 1986a;Engler et al, 1986b;Byrne et al, 1992). 
Similar results have been obtained in humans undergoing CABG providing further 
evidence of leukocyte mediation playing a major role in the no-reflow phenomenon 
(Palatianos et al, 2004).
Inhibition of endothelial adhesion molecules such as ICAM-1 and sP-selectin reduce 
microvascular damage and no-reflow in a canine model of peripheral circulation 
(Jerome et al, 1994), and a recent experimental study has shown that dual inhibition
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of I.CAM-1 and sP-selectin can reduce myocardial infarct size by 65% when 
administered retrogradely to the post-capillary venules, suggesting that the role of 
cellular adhesion molecules is also crucial to reperfusion injury, and that this is most 
marked in the microcirculation (Fukushima et al., 2006). Histologically, cardiac cells 
subject to reperfusion injury demonstrate damaged endothelium with areas of regional 
swelling and large intraluminal protrusions which have in some cases appeared to have 
plugged the capillary lumen (Kloner et al, 1974b). Other structural changes are 
apparent in experimental models such as extra vascular compression of the capillaries 
(Gavin et al, 1983;Manciet et al, 1994).
The no-reflow syndrome may respond to treatment with diverse agents including 
adenosine, the NO donor sodium nitroprusside, the calcium antagonist verapamil and 
the monoclonal antibody abciximab, an inhibitor of the platelet glycoprotein Ilbllla 
receptor (Piana et al, 1994). The glycoprotein Ilbllla receptor is central to the 
interaction of activated platelets, both with connective tissue elements within the 
vessel wall, and also with leukocytes and other platelets. Although the actual 
mechanisms of both no-reflow itself and the therapeutic agents is unclear, what these 
agents have in common is the ability to inhibit the aggregation and endothelial 
attachment of platelets and leukocytes, providing further evidence for their role in the 
pathogenesis. One of the most popular theories regarding the cause of no-reflow, 
particularly in the setting of coronary intervention is the suggestion that distal 
embolisation of plaque material which gets dislodged during the procedure and
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thrombus is responsible causing initially a mechanical obstruction (Jaffe et al., 2008). 
This will be discussed later in the section titled “Distal Embolisation”.
1.3.2.2 Periprocedural myocardial infarction
Further evidence that reperfusion may be associated with downstream events is the 
phenomenon of creatine kinase (CK) “leak” following PCI (Saucedo et al, 2000;Stone 
et al, 2001). Ever since the technique of balloon angioplasty for the treatment of 
obstructive coronary artery disease was introduced, complications particularly in the 
form of myocardial infarction as detected by troponin or CK release, have been 
encountered (Gruntzig, 1978;Gruntzig et al, 1980). With the improvement in early 
technology, the rate of acute vessel closure were substantially reduced but the rates of 
myocardial enzyme release had remained static (Oh et al, 1985). There has been 
considerable discussion recently on the definition of periprocedural MI and more 
specifically what level of cardiac enzymes should be used as cut-off to define PMI 
(Thygesen et al, 2007). The incidence of PMI remains high, affecting up to 40% of 
subjects depending on the pre-intervention risk profile of the patient, the lesion 
characteristics and which definition of PMI is used (Herrmann, 2005).
The circulating enzyme CK, a marker of myocardial damage, shows small rises 
following apparently successful angioplasty and has been shown to be associated with 
a statistically and clinically significant increase in the subsequent risk of death (Stone 
et al, 2001 ;Ioannidis et al, 2003). A recent meta-analysis involving over 15,000
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patients shows an increase in mortality in patients with elevation of cardiac specific 
troponins in patients undergoing elective PCI (Nienhuis et aL, 2008). MRI studies 
have demonstrated that even with mild elevations in the myocardial enzyme creatine 
kinase-myocardial bound (CKMB) post-PCI correlate with contrast enhanced hyper­
enhancement which is synonymous with myonecrosis. Two specific patterns of 
myonecrosis are seen on MRI scanning, one at the site of stenting, supporting side 
branch occlusion theory, and one in the target vessel territory supporting downstream 
micro vascular disturbance (Ricciardi et al, 2001;Choi et al., 2004;Selvanayagam et 
a/., 2007).
Side branch occlusion is where there is a side branch of the coronary artery at the site 
of the intervention in the main vessel, and as a consequence of the angioplasty, the 
flow in the side branch is compromised causing partial or complete occlusion. 
Although in some cases the cause of rise in cardiac enzymes may be obvious such as 
the closure of side branch or vessel dissection, in the majority of cases of cardiac 
enzyme leak post-PCI, no such trigger is found (Kini et al, 1999). Certain baseline 
characteristics are strong clinical predictors of periprocedural myocardial infarction 
such as presence of multivessel disease and systemic atherosclerosis (Kini et al, 
1999). Elevated CRP levels pre procedure have also been shown to increase medium 
term mortality and risk of periprocedural MI suggesting that increased inflammatory 
state has some effect on the response and risk to the procedure (Chew et al, 2001a).
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1.3.23 Distal embolisation (DE)
It is well established that PCI causes plaque disruption which can lead to embolization 
of plaque material or thrombus distally. One of the key theories suggested for the no­
reflow phenomenon and peri procedural Ml is that of distal embolization following 
PCI (Henriques et al., 2002;Kotani et al.t 2002). The incidence of DE in patients 
undergoing primary PCI is 15%, assessed by angiography as a distal filling defect with 
an abrupt closure in one of the peripheral arteries distal to PCI site (Henriques et al.t 
2002), although the sub-clinical incidence is greater if other methods are used to detect 
adequate tissue perfusion such as contrast enhanced echo (25%) (Ito et al.t 1996a). 
Histological examination of the contents of distal protection devices have found debris 
in 75% of patients undergoing PCI (Angelini etaL, 2004). The use of distal protection 
device has been shown to eliminate DE as assessed by Okamura et al. They assessed 
the degree of DE by counting the number of High Intensity Transient Signals (HITS) 
using a Doppler wire, each HITS is indicative of DE of micro particles. In a primary 
PCI setting they were able to eliminate HITS with the use of a DPD, suggesting that 
the use of a DPD is able to prevent DE (Okamura et al., 2005).
However although it is widely accepted that DE occurs in most patients, the evidence 
the preventing DE improves outcome is equivocal (Gorog et al., 2005). Although a 
benefit has been shown in the setting of saphenous vein graft intervention, there is 
clear evidence of no benefit in native coronary arteries in terms of reduction in 
mortality or reduction in infarct size and left ventricular function (Stone et al.,
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2005;Cura et al., 2007). The lack of benefit of distal protection devices in the setting 
of primary PCI in native vessels has raised some important questions regarding the 
underlying pathophysiology of the poor reflow/ no-reflow phenomena suggesting that 
the role of DE may have been exaggerated. There is increasing evidence many of the 
complications seen with PCI may be related to processes occurring at the 
microcirculatory level.
1.4 Coronary microcirculation
1.4.1 Structure of the coronary microcirculation
The coronary circulation can be divided into three compartments; 
arteries, microcirculation, and venous. The micro circulation can be further split into 
arterioles, capillaries and venules. The epicardial compartment includes vessels 
ranging from 0.5mm-5mm, the predominant function of these vessels is to provide 
capacitance and under normal conditions they offer minimal resistance to flow. The 
small arteries then branch out into pre arterioles, which are 200|im-500iim in diameter 
and are located on the epicardial surface of the heart. These vessels maintain pressure 
at the entrance to the arterioles and are able to compensate for changes in flow. These 
develop into arterioles less than 200pm, which can be further divided into three sub 
compartments, each characterised by their size, function and predominant regulatory 
mechanism.
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1.4.3 Function of the microcirculation
There is a significant overlap between the mechanisms which regulate the flow of 
blood into the microcirculation. There is a tendency for each domain of microvessel to 
have a predominant regulating mechanism, and in the event that one mechanism 
becomes dysfunctional or is inhibited, then other mechanisms become active to 
compensate.
The largest of these arterioles are 200-100pm. Kuo et al demonstrated endothelial- 
dependent dilation was most prominent in larger arterioles and least effective in the 
smallest vessels (Kuo et al, 1995a). In these vessels, an increase in flow rate causes 
vasodilatation and a reduction in flow causes vasoconstriction (Kuo et al, 1995a). The 
medium sized micro vessels are 40-100pm and the main regulating mechanism is 
dependant on intraluminal pressure changes in the vessels. Intraluminal pressure is 
detected by vascular smooth muscle cell stretch receptors which respond to increased 
intraluminal pressure by causing vasoconstriction. Conversely, a reduction in 
intraluminal pressure causes compensatory vasodilatation due to smooth muscle 
relaxation. This pressure sensitive mechanism is known as myogenic control (Kuo et 
al, 1988a). Endothelial-dependent mechanisms are also present in medium sized 
microvessels, although the dominant mechanism is myogenic mediation (Kuo et al, 
1990b). The smallest arterioles (<30 pm) are regulated by changes in metabolic 
activity, whereby an increase in metabolic activity leads to vasodilatation (Kuo et al., 
1995b). Therefore in the microcirculation, an increase in metabolic activity initially
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causes the tiny vessels to dilate, this causes a secondary reduction in pressure 
upstream in the medium sized vessels causing myogenic dilation leading to increased 
flow further upstream in the larger arterioles causing endothelial-dependent dilation 
(Jones et ah, 1995). This self- regulating mechanism allows for an integrated 
sequential activation from the smallest vessels to the largest arterioles in response to 
increased metabolic demand.
1.4.3 Regulation of the microcirculation 
1.4.3.1 Metabolic factors
Broadly speaking, coronary flow is linearly related to myocardial oxygen 
requirements. An increase in myocardial metabolic activity must be balanced by an 
increase in the supply of nutrients and oxygen supplied by the blood to the 
myocardium. This requires an increase in the blood flow to the myocardium since the 
oxygen carrying capacity of the blood cannot be increased further. The increase in 
metabolic activity initiates the cascade described above leading to vasodilatation of all 
the microvessels. Although the precise factors and substances in the pathways 
involved in this response remain to be elucidated, adenosine and the Katp channel 
have been implicated (Berne, 1963;Komaru et ai, 1991).
Adenosine was previously thought to be the key mediator of the metabolic response 
(Berne, 1963), however it is looking increasingly less likely that adenosine is essential 
for the metabolic response. Kanatsuka el al induced an increase in metabolic demand 
by pacing canine hearts and compared this with the effects with administering
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intravenous adenosine. They found both the effect of pacing and administration of 
adenosine had similar vasodilatory effects on vessels <200pm in the microcirculation, 
although pacing also caused dilation of larger vessels up 380pm diameter, suggesting 
that other factors apart from adenosine are involved in the metabolic response to 
pacing and factors additional to adenosine appear to play a greater role in larger sized 
vessels (Kanatsuka et al., 1989). In the same experiment, the smallest vessels 
demonstrated the greatest degree of vasodilatation, demonstrating an inverse 
relationship between the size of vessel and response to pacing and adenosine. When 
the adenosine antagonist, 8-phenyltheophylline was administered concurrently with 
pacing, microvascular vasodilatation still occurred, and furthermore the levels of 
adenosine detected interstitially were below vasoactive levels, implying that adenosine 
is not an essential mediator of the metabolic response (Yada et al, 1999). The addition 
of adenosine deaminase still allowed for the autoregulatory capacity of the 
microcirculation to persist, suggesting adenosine is also not critical in autoregulation 
(Dole et al, 1985). It appears more likely that the role of adenosine in the metabolic 
response is more of a backup mechanism with other mediators having a greater role. 
Ishibashi et al were able to demonstrate this by studying the exercise induced response 
of coronary blood flow in chronically instrumented dogs. They found that when nitric 
oxide (NO) and adenosine pathways are both blocked, there is no reduction in flow 
however when the K+Atp channel is blocked, both adenosine and NO act to increase 
coronary blood flow during exercise (Ishibashi et al, 1998b). Further evidence for the 
role of adenosine and NO as backup mechanisms was that in the presence of combined
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K+atp channel blockade and adenosine receptor blockade, NO was able to produce 
approximately one quarter of the coronary vasodilatation that occurred in response to 
exercise compared with control. However with complete blockade of all three 
mediators there was total abolition of the vasodilator response to exercise (Ishibashi et 
al, 1998a).
These data suggest the K+atp channel is critical in regulating the vasodilator response 
and the roles of adenosine and NO are more of a backup mechanism which comes into 
action when the K+Atp channel is suppressed. The K+atp channel is present on smooth 
muscle cells and is activated by acidosis, ischaemia and hypoxia as well as other 
stimuli such as adenosine and prostacyclin (Komaru et ai, 2000). Activation of the 
K+atp channel causes K+to leave smooth muscle cells and hyperpolarises the cell 
membrane leading to inhibition of the voltage dependant calcium channels, thereby 
reducing intracellular calcium levels and causing smooth relaxation and vasodilatation. 
Further evidence for the pivotal role of K+Atp channel as a mediator for dilation of the 
microcirculation was provided by Sato et al. when they administered the K+Atp 
channel agonist levkromacalim in a beating canine heart model. Levkromacalim 
dilates all sizes of micro vessels but the most potent effect was in the smallest vessels 
(Sato et ai, 1994). In contrast, blocking this channel with glibenclamide (a K+atp 
channel blocker), caused a reduction in basal flow and vasoconstriction, suggesting the 
K+atp channel is also important in maintaining basal tone (Imamura et al, 
1992;Duncker et ai, 1995).
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Nitric oxide (NO) is also thought to play a role in the metabolic response in the 
microcirculation since levels of NO increase in response to increased metabolic 
activity (Bernstein et al, 1996)._However, Egashira et al. were able to demonstrate 
blockade of NO had no effect on microcirculatory vasodilatation although epicardial 
vasodilatation was attenuated (Egashira et al., 1996). It appears NO is not an essential 
mediator of the metabolic response.
1.4.3.2 Myogenic factors
The maintenance of intra-luminal pressure within fine limits in the microcirculation is 
necessary to ensure adequate transport of substances across the vascular lumen to the 
tissues. In the face of elevated intra-luminal pressure there is a risk of tissue damage 
due to oedema. In the medium sized arterioles the main mechanism involved in 
regulation of the microvascular circulation is alteration of the smooth muscle 
contractile tone in response to changes in intraluminal pressure. Kuo et al. 
demonstrated that the underlying mechanism behind the myogenic response in isolated 
microvessels is independent of endothelial function (Kuo et al., 1990a). It is thought 
that rise in intraluminal pressure activates a stretch receptor on the surface of the 
smooth muscle cell causing cation influx and subsequent depolarisation of the smooth 
muscle cell, activating the voltage gated calcium channel (L-type) and allowing for 
calcium influx into the cell (Nelson et al., 1990;Davis et aL, 1992). It is well 
established that intermediate sized arterioles (50-80pm) have the greatest degree of 
myogenic tone (Kuo et al., 1995c). A possible explanation may be the distribution of
31
L-type calcium channels in the microcirculation. Bowles et al were able to show an 
inverse relationship between vessel diameter and concentration of L-type calcium 
channels (Bowles et al, 3997). Apart from the role of the L-type calcium channel, the 
stretch sensitive Phospholipase C (PLC) may also implicated in the myogenic 
response (Park et al, 2003).
The exact mechanisms of mechano-transduction initiating and sustaining myogenic 
tone remain unclear. The mechanical stimulation of the smooth muscle cells appears to 
activate G proteins coupled to PLC, increasing PLC activity leading to elevated 
diacylglycerol levels, further activating protein kinase C (PKC). PKC increases the 
activity of non-selective cation channels, depolarizing the smooth muscle membrane 
potential and enhancing calcium entry through voltage-dependent calcium channels. 
Calphostin C (a PKC inhibitor) has been shown to inhibit the myogenic response and 
PKC agonist has enhanced the myogenic response (Miller, Jr. et al, 1997;Davis and 
Hill, 1999). In addition, there is evidence of transmural heterogeneity: studies suggest 
myogenic responses are reduced in the subendocardium compared with the 
subepicardium, this could also may explain why subendocardium is more prone to 
ischaemic injury particularly given the increased physical stresses in the 
subendocardium during the cardiac cycle (Kuo et al, 1988b). The K+ATP channel, in 
addition to its central role in the metabolic regulation, has also been implicated as a 
mediator for the myogenic response. Glibenclamide, a K+Atp channel inhibitor, has 
been shown to inhibit the myogenic response (Komaru et a/., 1991). In summary, the
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myogenic response is endothelium-independent and regulated by intracellular calcium 
levels mediated via the voltage gated calcium channels and L-type calcium channels in 
the cell membrane of the smooth muscle under the influence of PKC and PLC.
1.4.3.3 Endothelial factors
An endothelial-dependent mechanism has been identified as been responsible for flow 
mediated dilation (FMD) in coronary arterioles. Three major mediators are thought to 
be responsible; NO, endothelial derived hyperpolarising factor (EDHF), and 
prostacyclin. The production and release of these mediators are triggered by shear 
stress detected on the endothelial cell surface receptor. In addition, the endothelial cell 
layer is responsible for the production of potent vasoconstrictors and the maintenance 
of endothelial tone is dependent on a fine balance between endothelial derived 
vasoconstrictors and vasodilators.
1.4.3.4 Vasodilators
The first endothelial derived vasodilator to be discovered was prostacyclin (Moncada 
et al., 1976). Prostacyclin is synthesized in endothelial and smooth muscle cells from 
arachidonic acid by cyclooxygenase and binds to smooth muscle receptors stimulating 
an intracellular increase in cAMP via adenyl cyclase subsequently causing increase in 
cAMP and smooth muscle relaxation (Koller el al., 1993).
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NO was discovered as the main component of endothelial derived relaxing factor by 
Palmer et al (Palmer et aL, 1988a). NO is synthesized from L-arginine by the action 
eNOS, which is a calcium/ calmodulin dependent enzyme. It is a key mediator in the 
larger arterioles and production is mediated by signal transduction by receptor bound 
G proteins sensitive to shear stress, which cause an increase in intracellular calcium 
and eNOS activation. NO acts on soluble guanylate cyclase causing smooth muscle 
relaxation by inhibiting the transport of calcium into the cell, so causing a reduction in 
intracellular calcium levels and hence vasodilatation (Ignarro et al., 1999). In addition 
to shear stress, NO release is also stimulated by thrombin, serotonin adenosine 
diphosphate, histamine and bradykinin (Moncada et al., 1991). In addition to these 
vasorelaxant properties, it has subsequently become apparent that NO has anti­
inflammatory properties which seem to protect the endothelium from adhesion and 
infiltration from leukocytes by inhibition of adhesion molecules and cytokines 
(Armstrong, 2001). All of these actions are important in the development of the 
atherosclerotic plaque and it is no surprise that reduced production of NO is associated 
with both the development and progression of atherosclerosis (Lee and Libby, 1997).
More recently there has been the discovery of an additional endothelial derived 
relaxing factor which acts independently of NO and cycloxygenase pathways known 
as endothelial derived hyperpolarising factor (EDHF). Although the specific 
compound is as yet unidentified and there is much speculation to its identity. The 
discovery came about when both NO and cycloxygenase pathway were inhibited and
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an endothelial agonist administered, the surprising finding of a sparing of the 
vasodilator response suggested another endothelial derived factor was active (Chen et 
al, 1988;Feletou and Vanhoutte, 1988). If concurrent K+ channel blockers are given, 
vasodilatation is abolished thereby suggesting vasodilation is dependent on some form 
of hyperpolarising factor. EDHF seems to be released in response to shear stress and 
causes hyperpolarisation of vascular smooth muscle cells by opening calcium 
activated K+ channels (Miura et al., 2001).
1.4.3.5 Vasoconstrictors
The endothelium produces a wide variety of vasoconstrictors including thromboxane 
A2 prostaglandin angiotensin II and endothelin-1 (ET-1) (Verma and Anderson,
2002). ET-1 is produced from a large pre pro-endothelin polypeptide, endothelial 
activation causes proteolytic breakdown of pre-ET into active ET-1. ET-1 is the most 
potent vasoconstrictor known, which also stimulates leukocyte adhesion, recruitment 
and smooth muscle cell migration (Yanagisawa et al., 1988). The maintenance of 
arterial tone and healthy endothelium is dependent on a fine balance between 
endothelial derived vasoconstrictors and vasodilators, and imbalance leads to 
endothelial dysfunction.
1.4.3.6 Other factors
As well as the metabolic, myogenic and endothelial mechanisms discussed earlier, 
there are many other factors which all play a role in the control of the
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microcirculation, such as the autonomic nervous system and extravascular physical 
forces from the effect of the heating heart (Figure 1.7). Subendocardial perfusion in 
particular is reduced by physical forces related to the beating heart, partially 
explaining why the subendocardium is most prone to ischaemia and infarction.
Figure 1.7 Schematic diagram representing different mechanisms responsible for the 
regulation of myocardial microvascular resistance
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Several factors are involved regulating the tone of the microcirculation. Endothelial 
dependent regulation is mediated by the release of vasoactive mediators from 
endothelial cells in response to stimuli such as shear stress and platelet derived 
mediators. This is the dominant mechanism in larger arterioles. Myogenic regulation 
utilises stretch receptors in the smooth muscle cells of the microvessels. The activation 
of smooth muscle membrane bound ionic channels respond to changes in intraluminal
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pressure and is the dominant mechanism in medium sized vessels. Metabolic factors 
such as change in PCO2, PH and adenosine contribute to vasodilation in response to 
an increase in metabolic activity, and this is most prominent in the smallest 
microvessels. In addition neurally mediated factors and extravascular mechanical 
forces are involved in the regulation of myocardial microvascular resistance (ACh, 
Acetylcholine; ATP sensitive K+ channel; EDHF, endothelial derived
hyperpolarising factor; LVEDP, left ventricular end diastolic pressure; NO, nitric 
oxide; PKC, protein kinase C; PLC, phospholipase C; PCO2, partial pressure of 
carbon dioxide; RVEDP, right ventricular end diastolic pressure).
1.4.4 The clinical significance of the myocardial microcirculation
There is a close relationship between myocardial blood flow and oxygen tension in 
venous blood. Blood flow increases proportionally to a reduction in coronary sinus 
oxygenation, suggesting that coronary resistance vessel tone is determined by the 
equilibrium between oxygen supply and demand (Tune et al, 2004). The control of 
myocardial blood flow lies in the ability of the myocardial microvasculature to 
redistribute resistance. There are approximately forty five millilitres of blood in the 
coronary circulation at any one time. This blood volume is split equally between the 
arteries, veins and microcirculation with 90% of the blood in the microcirculation 
being in the capillaries (Kassab et al, 1994). During states of increased demand such 
as exercise, there is a large shift in distribution of blood within the coronary circulation 
secondary to arteriolar dilatation resulting in a much greater volume of blood residing
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in the micro vascular compartment (Figure 1.8). The earlier animal studies had found 
resistance is heterogeneously distributed throughout the coronary circulation with 
approximately 50% of total myocardial resistance accounted for by vessels smaller 
than 100pm. and a further 25% in vessels greater 100pm-200pm, the remaining 
resistance in vessels greater than 200pm, demonstrating small arterioles are the key 
regulators of myocardial microcirculation (Chilian et al., 1986). More recent echo 
studies in humans have showed similar findings (Jayaweera et ai, 1999). It is this 
ability to modify the resistance dynamically which gives the myocardium the ability to 
increase flow dramatically when the need arises. Hence by measuring microvascular 
resistance, important information can be obtained regarding the myocardial 
microcirculation.
Figure 1.8 Coronary microcirculation
Post mortem cast of coronary circulation(left), demonstrating the complex intricate 
nature of the coronary microcirculation which cannot he visualised with in vivo 
techniques which are effective at visualising epicardial disease such as coronary
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angiography.(right) (Reprinted by permission of the Society of Nuclear Medicine 
from; Camici PG and Rimoldi OE. The Clinical Value of Myocardial Blood Flow 
Measurement. J Nucl Med. 2010; 50(7); 1076-1087)
Microvascular injury following reperfusion, in patients with acute myocardial 
infarction, is a predictor of adverse outcome (Gibson et al., 2000;Yamamuro et a!., 
2002). In patients with hypertrophic cardiomyopathy, the degree of microvascular 
dysfunction is strongly associated with poor prognosis (Cecchi et al, 2003). A similar 
adverse association is seen with microvascular dysfunction and outcome in the 
recipients of cardiac transplants (Tona et al., 2006). The importance of micro vessel 
patency is now recognised as one of the major components in successful reperfusion 
and despite apparently normal epicardial flow, microvascular flow can be impaired 
and is strongly associated with poor prognosis (Ito et al., 2004). Since measurement of 
microvascular integrity is complex it has often been overlooked but now the use of 
techniques which can assess the microcirculation with ease during PCI could provide 
valuable prognostic information (Fearon et al., 2008). Assessment of the 
microcirculation may also provide a better understanding of the poor/no-reflow 
phenomenon, alluded to previously.
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1.4.5 Assessment of microvascular function
1.4.5.1 Introduction
As noted above, the coronary microcirculation regulates blood flow by responding to 
increased cardiac metabolic demands. Despite this important role, study of the 
microcirculation has been neglected for many years. It has been difficult to evaluate 
the function of this compartment, and doing so conflicts with the current clinical 
practice of many cardiologists, who are more familiar with dealing with the disease 
processes that affect the large epicardial arteries. The clinical importance of 
microvascular function is emerging because of improving techniques which allow for 
the objective assessment whilst in the catheter laboratory. In addition, there is a 
growing body of evidence to suggest that the microvascular compartment may show 
early changes in patients who are at risk of coronary artery disease (Halcox et ai, 
2002;Rubinshtein et al, 2010). It seems highly likely that the microcirculation is 
responsible for the poor response to revascularisation in certain patients, potentially in 
the form of the no-reflow phenomenon and peri procedural myocardial infarction. 
Pathological microvascular changes could explain the significant midterm morbidity 
and mortality associated with these complications.
1.4.5.2 Assessment
In humans, assessment of the coronary microcirculation is based on a functional rather 
than an anatomical basis due to difficulties in experimenting on human 
microcirculation in vivo. Selective coronary angiography only demonstrates the
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conduit vessels and the resistance vessels are too small to be catheterised selectively 
(Figure 1.8). Hence indirect methods are employed, using indices which reflect 
functional status, such as coronary or myocardial blood flow. Coronary and 
myocardial flow can be assessed by various methods, but coronary flow only provides 
partial information on the state of the microcirculation. Since true myocardial 
microcirculatory resistance is defined as the ratio between myocardial perfusion 
pressure and absolute myocardial blood flow, measurement of intracoronary pressure 
is essential (Figure 1.9).
Figure 1.9 Definition of true myocardial resistance
Myocardial resistance = myocardial verfusion pressure
absolute myocardial blood flow
True myocardial resistance can be calculated from myocardial perfusion pressure and 
absolute myocardial flow as shown in figure L9. Although myocardial perfusion 
pressure is relatively simple to assess, the same cannot be said for absolute 
myocardial flow.
1.4.5.3 Methods of assessment
Many techniques allowing for assessment of myocardial or coronary blood flow are 
used in the research setting. These consist of invasive and non-invasive methods and 
vary in the degree of complexity of performing the test and interpretation of results.
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By utilising simple coronary angiography measurements such as Thrombolysis In 
Myocardial Infarction (TIMI) flow grade (TFG)(1985), TIMI frame count (TFC) 
(Gibson et ah, 1996) and myocardial perfusion grade (MPG) (Hof et al., 1998), 
microvascular function can be assessed. Although these techniques are relatively 
simple to perform and interpret they do have limitations. MPG and TIMI flow grade 
are subjective measures with significant degrees of intra-observer variability (Gibson 
et al, 2000), and TFC lacks correlation to true flow (Chugh et al, 2004). Coronary 
sinus thermodilution can be used to measure global myocardial blood flow but is 
unable to provide regional assessment (Ganz et al, 1971). The advent of intracoronary 
wires such as the Doppler wire and RADI™ pressure wire have revolutionised the 
assessment of microvascular function and are valuable tools in intracoronary 
physiology.
1.4.5.3.1 Doppler wire
The Doppler wire has a tiny piezoelectric crystal embedded near the tip of the wire, 
the crystal is able to transmit and receive ultrasound frequency waves (Doucette et al, 
1992). It is possible to detect the movement of red blood cells in the vessel which 
causes a shift in ultrasound frequency. The frequency of the reflected signal is linearly 
related to blood flow, hence the magnitude of shift in velocity is proportional to blood 
velocity and hence flow, as long as vessel diameter is held constant (Franklin et al, 
1961). Currently used wires are 0.014" in diameter and are able to detect both blood 
flow velocity and intracoronary pressure simultaneously (Siebes et al, 2004).
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There are certain considerations that must be taken into account when using the 
Doppler wire. The degree of Doppler shift is dependent on the angle of difference 
between the piezoelectric crystal and the direction of blood flow. The quality of the 
signal and the value of the peak velocity detected are dependent on consistent and 
careful positioning of the wire. The comparability of two measurements made at 
different times may differ if the wire position changes, since small shifts in the angle 
of the tip of the wire produce significant changes in the measurements and it can be 
difficult to get reliable signal in up to 30% of patients (Pick et al, 2000;Barbato et al., 
2004a). The position of the Doppler sensor in relation to the lesion and any side 
branches is also important. If the sensor is placed too close to a lesion or a side branch, 
velocity measurements will be affected by increased turbulence due to flow separation 
(Doucette etaL, 1992).
1.4.5.3.2 The temperature sensitive pressure wire
The temperature sensitive pressure wire has a high fidelity sensor embedded in the 
distal portion 3cms from the tip, allowing for simultaneous measurement of 
temperature and pressure. The shaft of the wire acts as the proximal thermister by 
monitoring changes in electrical resistance which are temperature dependent.
If the wire is inserted into a coronary artery, a bolus of saline can be injected into the 
vessel, then according to the indicator dilution theory, the mean transit time (Tmn) of 
the intracoronary injectate to travel from the site of injection to the distal sensor is
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inversely related to flow (De Bruyne et ai, 2001). This technique is discussed in depth 
in Chapter 2.
Apart from invasive assessment there are many non-invasive techniques which have 
been developed which estimate myocardial and coronary flow, including myocardial 
contrast echo (Keller et a!.., 1989), PET (Araujo et al., 1991) and myocardial perfusion 
MRI (Manning et al, 1991). The advantage of these techniques over invasive 
measurements is the ability to perform serial measurements in the same patient 
without instrumentation. However for patients undergoing coronary intervention, 
intracoronary wires which either use the Doppler or thermodilution method are more 
suited. Firstly since no additional instrumentation of the coronary arteries is required 
because these wires also serve as angioplasty guide wires, and secondly acute 
physiological response to PCI can be assessed.
1.5 Summary
In summary, we have found evidence that inflammatory processes are involved in both 
early and late stages of the development of atherosclerotic lesions, with a sound 
mechanistic basis. Systemic markers of inflammation are raised at the time of acute 
ischaemic events, and the extent of the rise has prognostic significance. What remains 
unexplained, however, is the fact that revascularisation treatment is itself associated 
with a rise in inflammatory markers which is independent of the rise in troponin and 
prognostically significant (Saleh et al, 2005). We have described evidence suggesting
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that downstream events are associated with PCI, and that these events are associated 
with myocardial injury (Abdelmeguid etal., 1996). However, the mechanisms 
underlying these observations are not known.
We suggest a unifying hypothesis that attempts to link mechanistically all of the 
observations described above, with a view to possible clinical therapy. We therefore 
suggest that when flow is arrested, for instance by balloon inflation during PCI, 
leukocytes bearing the receptors for these adhesion molecules would have increased 
opportunity to adhere to the activated endothelium. This would then lead to leukocyte 
activation, which in turn would result in direct endothelial damage and expression of 
cell surface receptors for platelets by the leukocytes themselves. The resulting 
endothelial injury would lead to reduced flow in the vessel and distal microcirculation. 
We suggest this would be more likely to occur in patients who already have increased 
levels of baseline inflammation and hence endothelial activation and an increased 
propensity to microvascular dysfunction.
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1.6 Original hypotheses
1. PCI in stable coronary disease causes myocardial microcirculatory dysfunction.
2. Increased levels of generalised baseline inflammation and endothelial activation are 
associated with myocardial microcirculatory dysfunction following PCI.
3. The extent of inflammatory activation to PCI is associated with the extent of 
myocardial microcirculatory dysfunction.
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Chapter 2 Methods
2.1.1 Ethical approval
The study protocol was approved by local institutional review board and ethical 
approval has been granted by the Liverpool Research Ethics Committee and 
Administration of Radioactive Substances Advisory Committee.
2.1.2 Project design and recruitment of subjects
Subjects with a diagnosis of 1HD scheduled to undergo single vessel PCI to either the 
left anterior descending (LAD) or circumflex branches of the left coronary artery were 
prospectively recruited. Patients were selected from referrals received to the Liverpool 
Heart and Chest Hospital pooled referrals list for elective PCI. If the coronary 
angiogram confirmed significant stenosis (defined as greater than 70% stenosis) as 
assessed by the referrer and one member of the research team, and provided no 
exclusion criteria were apparent from the referral letter, then the patient was 
approached by telephone call and asked permission to send a written patient 
information leaflet. If the patient agreed to be considered for inclusion into the study 
then a full discussion regarding the details of the study took place. If deemed suitable 
to include in the study and if the patient agreed then written informed consent was 
obtained. Subjects were excluded if any factors were present which complicate the 
measurement of microvascular function or have an effect on the inflammatory
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response to PCI, these are discussed in chapter 3. Each subject acts as their own 
control since we are comparing the same patient before and after intervention.
Subjects attended the pre-assessment clinic in the cardiology outpatients department 
on the ground floor of the Liverpool Heart and Chest and Hospital where clinical 
evaluation was carried out including full medical history, drug history, physical 
examination 12 lead ECG and baseline bloods for haemoglobin, neutrophil count, 
LDL, HDL. Angina severity was assessed using the Canadian Cardiovascular Society 
(CCS) classification. Height and weight were measured and body mass index (BMI) 
calculated.
2.2 Assessment of microvascular function
In humans, assessment of the coronary microcirculation is based on a functional rather 
than an anatomical basis due to difficulties in experimenting on human 
microcirculation in-vivo. Selective coronary angiography only demonstrates the 
conduit vessels and the resistance vessels are too small to be catheterised selectively 
(Figure 1.8), hence indirect methods are employed, using indices which reflect 
functional status, such as coronary or myocardial blood flow.
Coronary and myocardial flow can be assessed by various methods, but flow only 
provides partial information on the state of the microcirculation. Since true myocardial 
microcirculatory resistance is defined as the ratio between myocardial perfusion
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pressure and absolute myocardial blood flow (Figure 1.9), measurement of 
intracoronary pressure is essential. We opted for the thermodilution method to assess 
coronary flow due to the limitations of the Doppler wire method especially since we 
wish to perform repeated measurements in different vessels and small changes in the 
angle of the sensor can produce significant changes in velocity and hence flow 
measurements.
2.2.1 Justification of method used to calculation of MR
With the use of the different methods described above, certain indices of 
microvascular function can be calculated. The most widely used is the coronary flow 
reserve (CFR).
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Figure 2.1 Two compartment model of the coronary circulation
Microvascular Component
FFR IMR
CFR
Fractional flow reserve (FFR) assesses epicardia! component, index of 
microcirculatory resistance (IMR) assesses the microvascular component and 
coronary flow reserve (CFR) assesses hath epicardial and microvascular components 
combined as shown in Figure 2.1.
2.2.1.1 Coronary flow reserve (CFR)
The CFR is the maximal possible increase in blood flow in a coronary artery compared 
to the resting state (Gould et al., 1974). This is assessed by measuring the ability of the 
microcirculation to respond to hyperaemic stimuli. The hyperaemic stimulus causes 
profound microcirculatory vasodilatation thereby increasing flow through the coronary 
artery and into the myocardial territory supplied by the vessel. CFR can be calculated 
with the formula shown below.
CFR = coronary flow at maximal hweraemia 
coronary flow at rest
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Gould et ai demonstrated a reduction in CFR once epicardial stenosis was greater than 
30%. As the degree of epicardial stenosis increases, the microcirculation dilates to 
maintain flow, although resting flow remains unaffected until the stenosis was greater 
than 80% (Gould et aL, 1974). Thus when hyperaemia is induced, the degree of 
microvascular dilatory reserve is reduced due to a pre-vasodilated microcirculation 
and hence CFR is less. The relationship between degree of epicardial stenosis and 
CFR displays a large degree of scatter largely due to the poor reliability of the 
coronary angiogram as a marker of physiological severity (White et ai, 1984). Given 
that the value of CFR is dependent on blood flow at rest, a significant amount of 
variability of CFR in the same individual may be present. CFR is also affected by 
haemodynamic factors such as blood pressure and pulse rate (Gould et ai, 1990). An 
increase in heart rate by 15 beats per minute can reduce CFR by as much as 15% due 
to an increase in resting flow (McGinn et ai, 1990). Although initially used as a 
marker of epicardial disease, CFR also detects microvascular dysfunction, since CFR 
assesses both the microcirculatory and epicardial components (Figure 2.1). In cases of 
normal epicardial vessels or no flow limiting epicardial disease, CFR can be used to 
measure microvascular function independently, since abnormal CFR would suggest 
pure microvascular dysfunction. In patients with established CAD the significance of 
an abnormal CFR is less clear and the degree of resistance offered by the epicardial 
and microvascular compartments cannot be distinguished without further investigation 
(Meuwissen et ai, 2001a).
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In summary CFR is particularly useful for microcirculatory assessment if epicardial 
vessels are normal. Although CFR has been used as detector of the physiological 
significance of epicardial stenosis, in practical terms there are better physiological 
measurements which are less dependent on microcirculatory factors and 
haemodynamic factors such as fractional flow reserve (FFR) (De Bruyne et al., 1996).
In our study, all patients have significant epicardial disease pre-PCI, and this will have 
an adverse effect on CFR, although post-PCI the effect of the epicardial disease should 
no longer be present but we know from previous studies that CFR can be reduced post- 
PCI due to increases in basal flow (Kern et al, 1999). Hence CFR will also be an 
underestimation of true MR post-PCI. Ideally we need a measure of MR which will be 
independent of epicardial stenosis and independent of baseline haemodynamic factors.
2.2.1.2 Therniodilution principle to measure coronary flow reserve
As mentioned earlier the RADI™ pressure wire can be used to calculate coronary flow 
by utilising the thermodilution method. The indicator dilution principle dictates that 
flow can be calculated in a circuit if an injection of a known quantity of indicator is 
introduced into the system and by measuring the concentration of the indicator down 
stream, flow can be calculated (Stewart, 1921). This principle was further developed to 
measure temperature of the indicator rather than concentration by measuring change in 
temperature downstream from the site of injection, this could then be used to calculate
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an estimate of flow. This technique was described by Fegler to assess cardiac output in 
a canine model (FEGLER, 1954).
With the development of intracoronary wires (Figure 2.2) such as the RADI™ wire, it 
is possible to measure temperature and pressure simultaneously within the coronary 
artery and hence estimate flow and pressure simultaneously (De et al., 2001). By 
utilising the thermodilution method, the mean transit time, defined as the time it takes 
for the bolus of injectate to travel from site of injection (the coronary guide catheter), 
to the sensor (in the coronary artery) in the distal third of the vessel, can be measured.
Figure 2.2 Diagram representing the intracoronary pressure wire.
The wire is directed down the coronary artery through the coronary guide catheter 
(blue) and beyond the lesion. The sensor located near the tip of the wire is able to 
measure changes in intracoronary pressure and temperature; hence microvascular 
resistance can be calculated.
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Figure 2.3 Thermodilution curves obtained with RADI™ wire.
CFR INJECTION CYCLE 
PRINCIPLE
The blue line represents the temperature tracing from the distal sensor, and the white 
line from the shaft which acts as the proximal sensor. The proximal sensor curve is 
used to detect the start of the injection (left). Recorded data from RADI analyser 
(right) only shows distal sensor data, there are two sets of data representative of mean 
Turn at rest (yellow line) and at hyperaemia (blue line), the shaft signal is not shown 
on the live data (right), but is used by the analyser to calculate the start time of the 
injection. The analyser calculates the T,m (red circle). The x-axis represents time in 
seconds and the y-axis represents temperature (Right)
Temperature signal 
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Figure 2.4 Calculation of mean transit time of injectate
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The mean transit time of injectate is calculated with the following equation as shown 
in Figure 2.4. Turn = mean transit time, c(t)= distal dilution curve.
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According to the indicator dilution principle flow can be calculated if we know 
volume and mean transit time of a bolus of injectate.
Volume 
Flow ftf-----------
Tmii
When using this method certain assumptions are made according to the indicator 
dilution principle, such as the volume between the injecting sites and the monitoring 
site must remain constant both at rest and during hyperaemia. Therefore the position of 
the sensor must remain unchanged between measurements. Secondly the diameter of 
the epicardial vessel must remain unchanged since with the induction of hyperaemia 
vasodilation occurs at epicardial level due to endothelial-dependent flow mediated 
dilation. To counter the effect of flow mediated dilation an epicardial vasodilator such 
as glyceryl trinitrate (GTN) can be administered. Finally there must be adequate 
mixing of the injectate with blood for the thermodilution principle to be accurate, by 
placing the sensor more distally in the vessel prevents inadequate mixing.
CFR can easily be calculated with the thermodilution technique by dividing the 
coronary follow during hyperaemia by flow at rest (Figure 2.5). This method 
correlates closely with the Doppler method in experimental and human models model 
with CFR (De et al., 2001 ;Pijls et al, 2002a). We have previously discussed the
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limitations of CFR as a measure of micro vascular function, thus another method of
measuring MR which is independent of these factors is preferable for our study.
Figure 2.5 Calculation of CFR thermodilution
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2.2.1.3 Doppler based assessment of microvascular resistance (MRV)
Using the Doppler wire a simpler measurement of MR can be made called MRV. This 
method calculates intracoronary flow by measuring the velocity of blood in the vessel, 
which is proportional to flow. Distal pressure can be measured with the same wire and 
both values into the equation below (Figure 2.6). The volume in the coronary artery is 
assumed to be constant. The administration of intracoronary nitrates minimises 
changes in intravascular volume.
Figure 2.6 Calculation of myocardial microvascular resistance using intracoronary 
Doppler
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MRV was described by Meuwissen et ai, (Meuwissen et al., 2001b). They investigated 
150 intermediate epicardial lesions in 126 patients and measured FFR and CFR. In this 
study, cut of values of less than 0.75 and 2 were used respectively as abnormal. There 
was discordance in 25% of measurements and when MRV was measured, they were 
able to show that in patients who had normal FFR but low CFR the MRV was greater 
than patients who had low FFR but normal CFR, although MRV was greatest in the 
group with low FFR and low CFR, who by definition had haemodynamically 
significant lesions by both methods. Thus the importance of measuring MRV 
particularly where the FFR and CFR does not match was, demonstrated and they 
concluded that abnormalities in MR could account for variability in haemodynamic 
measurements. The effect of microvascular resistance was thus found to be an 
important factor in a significant proportion of subjects.
2.2.1.4 Index of microcirculatory resistance (IMR)
IMR is a novel measure of microcirculatory resistance in the coronary 
microvasculature described by Fearon et al. (Fearon et al, 2003). Coronary flow can 
be assessed as described above using the thermodilution principle and the intraluminal 
pressure in the coronary artery distal to the lesion can be measured with the pressure 
wire. When both of these measurements are recorded during maximal hyperaemia, 
microvascular resistance can be calculated using the following equation (Figure 2.7).
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Figure 2.7 Calculation of IMR
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V is assumed to be constant since intracoronary nitrates are given to achieve maximal 
epicardial dilatation.
Myocardial Microvascular Resistance ~ P(i x Tm„
IMR was first measured in an experimental swine model to detect microvascular 
dysfunction. When compared with total myocardial resistance calculated from 
ultrasonic flow probe around the proximal LAD there was a good correlation between 
IMR and total myocardial resistance (TMR) (Fearon et al, 2003). A physiological 
representative model compared IMR vs. TMR in different physiological conditions 
found close correlation between true MR as induced by distal resistance clamp, and 
IMR (Aarnoudse et aL, 2004b). The advantage of minimal MR over basal 
measurements was the variability of resting tone and baseline factors were taken away, 
since the microcirculation is near maximally dilated. In addition this method was no 
longer constrained by haemodynamic factors which are variable in the resting state. 
This notion was confirmed in a human model where IMR was found to be independent
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of changes in pulse rate, blood pressure and left ventricular contractility (Ng et al, 
2006).
2.2.1.4.1 Effect of collateral flow on IMR
One of the drawbacks of using coronary flow to assess myocardial resistance is the 
assumption coronary flow equals myocardial flow. Often in patients undergoing 
measurements, significant epicardial stenosis are present, therefore coronary flow may 
not equal myocardial flow if there is significant collateralisation (Figure 2.8). Thus the 
concept of IMR was developed one step further by measuring the collateral component 
of myocardial flow, and it was suggested coronary wedge pressure should be 
measured, this could then be used to correct for the contribution of collateral flow 
(Fearon et al, 2004b). Coronary wedge pressure is the distal pressure when 
anterograde flow is totally occluded and represents combined collateral and venous 
pressure (Figure 2.8).
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Figure 2.8 Schematic of coronary circulation.
Aorta is represented on the left. Pa, aortic pressure; Pd, distal coronary pressure; P\v, 
coronary wedge pressure; Pv, venous pressure; Qcor, coronary flow; Qcoll, collateral 
flow; Qmyo, myocardial flow, as shown in Figure 2.8.
Figure 2.9 Calculation of IMRcorrectC(i
Myocardial resistance = pressure/Qmyo
Qmyo = Qcoll + Qcor
FFRmyo
Qmyo
QmyoN
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1
Qcor & -----
v Tmn
pd — pv
IMR =-------- = (pd — pv). Tmn
Qcor
This is true if Qcor = Q myo
As stenosis increases Qcoll increases Qcor decreases and Pd decreases
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By multiplying both denominator and numerator by QcorN and Qcor, the following 
equation can be derived
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, r N Fd - Pw Pa - Pv
(Pd — Ft?) x Tm:n x--------------x
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Pd — Pw
Turn x —-------—x (Pa — Pv)
Pa — Pw
assuming Pv is close to sera
Pd — Pw
— Tmn x Pa x------------
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Parotic pressure; Pd, distal coronary pressure; Pw,coronary wedge pressure;
Pv, venous pressure; Tmn,mean transit time; Qcor, coronary flow; Qcoll,collateral 
flow; Qmyo,myocardial flow(Aarnoudse etal, 2004a).
Thus we have decided to use IMR over CFR due to independence from haemodynamic 
factors and resting conditions. Simple IMR defined as Pd x Tmn is an adequate method
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in patients with no epicardial stenosis since coronary flow can be assumed to be equal 
to myocardial flow. However in our sample group, all patients have significant single 
vessel disease and thus will have some degrees of collateralisation and MR will be 
overestimated if collateral flow is not taken into account.
For the reference vessel we opted to use IMRuncorrecled since the contribution from 
collateral flow in normal vessels is assumed to be zero, hence Pw is negligible. For 
measuring MR in the target vessel we have used IMRC01TeCied since due to the presence 
of haemodynamically significant lesions there will some degrees of collateralisation, 
we would expect greater degrees of collateralisation in the more severe stenosis. It 
may be argued IMRlinc0nected can be used in the target vessel once the lesion has been 
treated. To test this assumption we opted to repeat the measurement of wedge pressure 
5 minutes post original Pw measurements in a sample of patients.
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Figure 2.10 Assessment of IMR
Data from thermodilution curves at rest (yellow) and hyperaemic (blue), arterial 
pressure red, distal pressure (green) (left). Assessment of wedge pressure (green) 
(right). Red pressure tracings=P(l; green pressure tracing-Pd.
2.2.2 Assessment of MR in this study
All subjects were fasted from 6 am on the morning of the procedure and allowed clear 
fluids until the angioplasty was performed. All patients were given with 600mg aspirin 
and 600mg clopidogrel orally, 12 hours before the procedure, as is standard practice 
for patients undergoing PCI to reduce the incidence of acute thrombosis within the 
stent, and all normal medications were continued. Prior to PCI a 16G cannula was 
inserted into a large vein in the antecubital fossa. Upon arrival to the catheter 
laboratory in the LHCH, the patient was connected to continuous ECG monitoring.
The skin was anaesthetized close to the distal radial artery 1cm proximal to the wrist 
crease with 2 mis of 2% lignocaine. A radial artery introducer needle (Cook 21G 40 
mm) was used access the lumen of the radial artery, once good flow of blood was 
visible from the lumen of the needle, a 0.018 inch introducer wire was passed into the
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vessel and the needle removed over the wire. A 6F 23cm hydrophilic radial artery 
sheath (Flexor© Check-Flo© Introducer Sets, Cook Medical, Ireland) was inserted 
over the introducer wire and left in situ, the wire was removed. A standard J-tipped 
catheter guidewire was inserted via the radial artery sheath into the ascending aorta. 6F 
coronary guide catheter was advanced over the wire into the ascending aorta. An intra 
arterial bolus of heparin sulphate was administered at dose of 75iu/kg via the guide 
catheter before the left main coronary artery was engaged with the guide catheter.
The guide catheter was used to engage left main coronary artery and coronary 
angiogram was performed. In a separate 20ml syringe, 2mls 0.1% Isosorbide dinitrate 
was added to 18mls normal saline, making a lOOmcg/ml solution. 200mcg of 
intracoronary glyceryl dinitrate was administered into the coronary artery to ensure 
maximal epicardial vasodilation and repeated every 30 minutes to prevent coronary 
spasm which can affect the haemodynamic data.
The pressure wire was calibrated, and then introduced into the guide catheter. Once the 
sensor reached the tip of the guide catheter in the left main coronary artery, the 
pressure reading from the pressure wire was equalised with arterial pressure measured 
from the tip of the guide catheter seated in the left main coronary artery. Care was 
taken to ensure there was no wedging of the guide catheter in the left main coronary 
artery which could give false low measurements of arterial pressure.
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Figure 2.11 Haemodynamic data protocol.
PCI performed 
and Pw recorded
Wire in target 
vessel, pd. pa. 
tmn at rest and 
hyperaemia pre- 
PCI recorded
Wire in reference 
vessel, pd. pa. 
tmn at rest and 
hyperaemia pre- 
PCI recorded
Wire replaced in 
reference vessel, 
pd pa tmn at rest 
and hyperaemia 
post-PC I
Wire in target 
vessel, pd pa 
tmn at rest and 
hyperaemia 
post-PC I
The wire was first passed into the reference vessel, which was the vessel without 
significant disease in which no procedure was planned. Once the wire was in the distal 
third of the vessel then an angiogram was acquired as a reference marker for the 
position of the tip of the wire. This was important to ensure that for subsequent 
readings there had been no movement of the wire in the vessel. The guide catheter was 
flushed with normal saline solution for 30 seconds and baseline recordings of pressure 
were made in real time using the RADI analyzer. Off line analysis of data was possible 
once data had been recorded. At least three rapid injections of 3mls saline at room 
temperature were injected into the coronary artery and thermodilution curves recorded 
using the RADI analyser. During injections it was important to check that the guide 
catheter was well seated in the coronary artery ostium but not wedged. Hyperaemia 
was induced by infusion of intravenous adenosine at a rate of 140mcg/kg/min (De et 
cii, 2003) via a Baxter Flo-Guard 6201 infusion pump, the patients arm was kept 
straight during infusion. The patient was advised prior to starting the infusion to
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anticipate the onset of chest tightness and breathlessness, both of which are common 
side effects of intravenous adenosine infusion. Patients were advised to breathe 
normally and avoid breath holding. Following continuous two minute infusion of 
adenosine to achieve a state of steady state of hyperaemia three injections of 3mls 
saline at room temperature were repeated with the safety reservoir syringe and 
hyperaemic aortic and distal coronary pressures were recorded. The adenosine infusion 
was kept running until all these measurements were completed. Throughout these 
measurements great care was taken to ensure little or no movement of the tip of the 
wire by repeated x-ray screening to check position of the tip of the wire. At this stage 
resting and hyperaemic Pa, Pd and Tmn had been recorded in the reference vessel pre- 
PCI.
The pressure wire was removed from the reference vessel and equalisation with aortic 
pressure was checked once again before the wire was passed into the target vessel 
(Figure 2.11). Once the wire was passed beyond the lesion and the tip of the wire was 
well into the distal third of the vessel a further angiogram was repeated to be used as a 
reference for the target vessel.
The guide catheter was flushed with normal saline solution and baseline and 
hyperaemic measurements of pressure and mean transit time were recorded as 
described previously. This provided a set of pre-intervention haemodynamic 
parameters in the target vessel. The angioplasty procedure was then performed in the
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standard manner. Details of the procedure including number of inflations, duration of 
inflations, type of stents used and complications were all recorded. During the PCI 
wedge pressure was measured following the first 30 second balloon inflation at 
hyperaemia. We repeated measurement of wedge pressure in 17 patients five minutes 
after first balloon inflation. Once PCI was completed and satisfactory result was 
obtained the position of the distal tip of the wire was checked to see if no movement 
had occurred from the position used to measure the pre-intervention parameters. The 
guide catheter was flushed with normal saline for 30 seconds. Baseline and 
hyperaemic measurements of aortic and coronary pressure, and mean transit time were 
recorded in the target vessel post-PCI as described previously. The wire was then 
repositioned to the reference artery to the reference point recorded earlier, once again 
the equalisation of the pressure wire was checked to ensure no signal drift had 
occurred. The catheter was flushed with normal saline solution for 30 seconds. 
Baseline and hyperaemic measurements of pressure and mean transit time were 
recorded as described earlier (Figure 2.10). From these recorded parameters, all the 
data for the calculation of IMRres, IMRhyp, CFR and FFR was available and these 
indices were calculated as described above.
2.2.3 Assessment of collateral flow
We calculated pressure derived collateral flow index (CFI), which is measure of 
collateral function (Billinger et al., 2001). This was calculated by measuring the 
coronary wedge pressure during balloon occlusion and calculating the component of
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distal coronary pressure which was derived from collaterals. The following formula 
was used to calculate CFI in our study.
CFI=(Pw-Pv)/(Pa-Pv)
Pm wedge pressure; Pr> venous pressure ; Pu, aortic pressure.
We did not measure right atrial pressure in our study and estimated Pv to be 5mmHg 
for the purpose of calculating CFI.
Each time the wire was repositioned the calibration/equalisation of the wire was 
checked to ensure there had been no drift in signal. In the event of a drift in signal, a 
correction was made during calculations to account for the degree of drift. A final 
angiogram taken with the wire removed to ensure a good angiographic result. At the 
end of the procedure the radial artery sheath was removed and a TR band applied over 
the radial artery puncture site to maintain haemostasis.
All haemodynamic data were recorded digitally for off-line analysis on RADIVIEW™ 
software v.2.0.
2.3 Measurement of inflammatory markers and troponin-T
Blood sample was taken in all subjects before, 1 hour post and 24 hour post-PCI. 30ml 
of blood was taken from a vein in the arm. The blood was transferred into the 
corresponding collecting tubes. The samples were immediately taken to the lab and
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centrifuged at 3000rpm for 10 minutes. The serum was transferred to labelled 
microtubes and stored at -80°C. To avoid intra-assay variation the assays were 
analysed in batch. All the samples were analysed in duplicate at the research 
laboratory LHCH expect for troponin-T, which was analysed at RLUH clinical 
chemistry department within 6 hours.
2.3.1 HsCRP
HsCRP assays were measured using the R and D HsCRP quantakine© ELISA kits. 
(R&D Systems Europe, Ltd. 19 Barton Lane, Abingdon Science Park, Abingdon, 
0X14 3NB) This assay utilises the sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for CRP was pre-coated onto a microplate. The samples 
and standard were pipetted into the wells. HsCRP present in the samples were bound 
by the antibody in the plate.
Samples and standard were diluted by 100-fold by adding 10j.il of sample or standard 
to 990pl of calibrator diluent (buffered protein base with preservative). lOOpl of assay 
diluent was added to each well and 50pl of diluted sample or standard is added per 
well. The wells were covered and incubated at room temperature for 2 hours. Each 
well was washed with 400pl of wash buffer solution (buffered surfactant) with a 
manifold dispenser 4 times. Any remaining wash buffer was aspirated and the plate 
inverted and blotted against paper towels. 200pl of conjugate (mouse monoclonal 
antibody against CRP conjugated to horseradish peroxidase) was added to each well.
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The wells were covered and incubated at room temperature for 2 hours. Each well was 
washed and aspirated 4 times and any remaining buffer blotted against paper towels. 
12.5mls stabilised of hydrogen peroxide and 12.5mls of stabilised 
tetramethylbenzidine were mixed together 15 minutes before use to form the substrate 
solution. 200pl of substrate solution was added to each well. And incubated at room 
temperature and wrapped in foil to protect from light. After 30 minute incubation 50pi 
of 2N sulphuric acid was added to each well to stop the reaction.
The optical density of each well was measured using a Wallac Victor2 1420 Multilabel 
counter (PerkinEJmer Life. Sciences, Boston, MA, USA). Results were analysed with 
and interpreted with Wallac 1420 manager V2.0. The wavelength on the well reader 
was set at 450nm and wavelength correction set to 540nm.
A standard curve was created with Origin 6.0, by plotting absorbance for each 
standard on y-axis and CRP concentration on the x-axis, to get the line of best fit a log 
transformation was performed for concentration of CRP. A linear regression analysis 
was performed on the line of best fit and this was used to calculate the amount of 
detectable CRP in the samples. Since the samples were diluted 100 fold, a correction 
calculation was performed to give the final value of CRP per sample. All samples were 
performed in duplicate and the mean was used. The mean detectable minimum dose of 
CRP is O.Olng/ml with this assay. The coefficient of variation was 4.4% at 4.79ng/ml 
and 8.3% at 18.9ng/ml.
70
2.3.2 IL-6
IL-6 assays were measured using the R and D human IL-6 quantakine© ELISA kit. 
(R&D Systems Europe, Ltd. 19 Barton Lane, Abingdon Science Park, Abingdon, 
0X14 3NB) This assay utilises the sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for human IL-6 was pre-coated onto a microplate. The 
samples and standard are pippetted into the wells. IL-6 present in the samples war 
bound by the antibody in the plate.
The methods used for measuring IL-6 is similar to CRP described above. The only 
difference was that serum samples were not diluted. The coefficient of variation of the 
assay was 4.2% at 16.8pg/ml and 2.0% at 186pg/ml.
2.3.3 sICAM-1
sICAM-1 assays were measured using the R and D sICAM-1 Quantakine© ELISA kit 
(R&D Systems Europe, Ltd. 19 Barton Lane, Abingdon Science Park, Abingdon, 
0X14 3NB). This assay utilises the sandwich enzyme immunoassay technique. Rat 
monoclonal antibody specific for sICAM-1 was pre-coated onto a microplate. The 
samples and standard are pipetted into the wells. sICAM-1 present in the samples were 
bound by the antibody in the plate.
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Samples and standard were underwent dilution by 20-fold, 20pl of sample or standard 
added to 380pl of calibrator diluent (buffered protein base with preservative). lOOpl 
of sICAM-1 conjugate (monoclonal antibody against human sICAM-lwith horseradish 
peroxidase) was added to each well followed by the addition oflOOpl of diluted sample 
or standard per well. The wells were covered and incubated at room temperature for 
1.5 hours on a horizontal orbital microplate shaker (0.12" orbit) set at 500 rpm. Each 
well was washed with 400pl of wash buffer (buffered surfactant) with a manifold 
dispenser 4 times. Any remaining wash buffer was aspirated and the plate inverted and 
blotted against paper towels. 12.5mls stabilised of hydrogen peroxide and 12.5mls of 
stabilised tetramethylbenzidine were mixed together 15 minutes before use to form the 
substrate solution. lOOpl of substrate solution was added to each well and wrapped in 
foil to protect from light. After 30 minute incubation period, 50pJ of 2N sulphuric acid 
was added to each well to stop the reaction.
The optical density of each well was measured using a Wallac Victor2 1420 Multilabel 
counter (PerkinElmer Life. Sciences, Boston, MA, USA). Results were analysed with 
and interpreted with Wallac 1420 manager V2.0. The wavelength on the well reader 
was set at 450nm and wavelength correction set to 540nm.
A standard curve was created with Origin 6.0, by plotting absorbance for each 
standard on y-axis and sICAM-1 concentration on the x-axis, to get the line of best fit 
a log transformation was performed for concentration of sICAM-1. A linear regression
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analysis was performed on the line of best fit and this was used to calculate the amount 
of detectable sICAM-lin the samples. Since the samples were diluted 20 fold, a 
correction calculation was performed to give the final value of sICAM-1 per sample. 
All samples were performed in duplicate and the mean was used. Coefficient of 
variation is 3.6% at 4.61ng/ml and 5.0% at 19.6ng/ml.
sVCAM-1
sVCAM-1 assays were measured using the R and D sVCAM-1 quantakine© ELISA 
(R&D Systems Europe, Ltd. 19 Barton Lane, Abingdon Science Park,. Abingdon, 
0X14 3NB ) This assay utilises the sandwich enzyme immunoassay technique. A rat 
monoclonal antibody specific for sVCAM-1 has been pre-coated onto a microplate. 
The technique used for measuring soluble levels of VC AM-1 is identical to sICAM-1 
as described earlier. The mean CV intra assay precision is 2.3% at 583ng/ml and 3.6% 
at 2421ng/ml.
2.3.5 Endothelin-l
ET-1 assays were measured using the R and D ET-1 Quantiglo© ELISA kit (R&D 
Systems Europe, Ltd. 19 Barton Lane, Abingdon Science Park,. Abingdon, 0X14 
3NB ). This assay utilises the sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for ET-1 was pre-coated onto a microplate. The samples 
and standard are pipetted into the wells. ET-1 present in the samples was bound by the 
antibody in the plate.
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IOOjliJ of assay diluent Weis added to each well followed by 100 (il of sample or 
standard per well. The wells were covered and incubated at room temperature for 1.5 
hours at room temperature on a horizontal orbital microplate shaker (0.12" orbit) set at 
500 rpm. Each well was washed with buffer 400pl (buffered surfactant) with a 
manifold dispenser 4 times. Any remaining wash buffer was aspirated and the plate 
inverted and blotted against paper towels. 200pl of conjugate (mouse monoclonal 
antibody against ET-1 conjugated to horseradish peroxidase) was added to each well. 
The wells were covered and incubated at room temperature for 3 hours on the 
microplate shaker. Each well was washed with 400pi and aspirated 4 times and any 
remaining buffer blotted against paper towels. 8 mis stabilised of hydrogen peroxide 
and 4 mis of stabilised enhanced luminol were mixed together 15 minutes before use 
to form the working glo reagant. lOOpl of working glo reagent was added to each well 
and incubated at room temperature and protected from light for 10 minutes. The 
relative light units (RLU) of each well was measured using a Wallac Victor2 1420 
Multilabel counter (PerkinElmer Life. Sciences, Boston, MA, USA). Results were 
analysed with and interpreted with Wallac 1420 manager V2.0.
A standard curve was created with Origin 6.0, by plotting absorbance for each 
standard on y-axis and ET-1 concentration on the x-axis, to get the line of best fit a log 
transformation was performed for concentration of ET-1. A linear regression analysis 
was performed on the line of best fit and this was used to calculate the amount of
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detectable ET-lin the samples. All samples were performed in duplicate and the mean 
was used. The coefficient of variation was 3.3% at 1.78pg/ml and 2.6% at 90.9pg/ml.
2.3.6 sP-selectin
sP-selectin assays were measured using the R and D sP-selectin quantakine© ELISA 
kit (R&D Systems Europe, Ltd. 19 Barton Lane, Abingdon Science Park,. Abingdon, 
0X14 3NB) This assay utilises the sandwich enzyme immunoassay technique. A 
mouse monoclonal antibody specific for sP-selectin has been pre-coated onto a 
microplate. The samples and standard are pippetted into the wells. sP-selectin present 
in the samples are bound by the antibody in the plate. Samples and standard were 
diluted 20-fold by adding 15pl of sample or standard to 285pl of calibrator diluent 
(buffered protein base with preservative). lOOpl of sP-selectin conjugate (monoclonal 
antibody against human soluble sP-selectin with horseradish peroxidase) was added to 
each well followed by addition of lOOpl of diluted sample or standard per well. The 
wells were covered and incubated at room temperature for 1 hour. Each well was 
washed with 400pl of wash buffer (buffered surfactant) with a manifold dispenser 4 
times. Any remaining wash buffer was aspirated and the plate inverted and blotted 
against paper towels. 12.5mls stabilised of hydrogen peroxide and 12.5mls of 
stabilised tetramethylbenzidine were mixed together 15 minutes before use to form the 
substrate solution. lOOpl of substrate solution was added to each well and incubated at 
room temperature and wrapped in foil to protect from light for 15 minutes. 50pl of 2N 
sulphuric acid was added to each well to stop the reaction.
75
The optica] density of each well was measured using a Wallac Victor2 1420 Multilabel 
counter (PerkinElmer Life. Sciences, Boston, MA, USA). Results were analysed with 
and interpreted with Wallacl420 manager V2.0. The wavelength on the well reader 
was set at 450nm and wavelength correction set to 540nm.
A standard curve was created with Origin 6.0, by plotting absorbance for each 
standard on y-axis and sP-selectin concentration on the x-axis, to get the line of best fit 
a log transformation was performed for concentration of sP-selectin. A linear 
regression analysis was performed on the line of best fit and this was used to calculate 
the amount of detectable sP-selectin in the samples. Since the samples were diluted 
20-fold, a correction calculation .was performed to give the final value of sP-selectin 
per sample. The mean CV intra assay precision is 7.9% at 1.2ng/ml and 8.8% at 12.9 
ng/ml.
2.3.7 Assessment of neutrophil MAC-1 receptor CDllb/CD18 activation
Blood samples were collected into tubes containing liquid potassium EDTA (Becton 
Dickinson; 0.25% final concentration), mixed gently and kept at room temperature 
before analysis within 30 minutes, hi separate tubes, 50u.l of whole blood was 
incubated with 5pl of fluorescein isothyocyanate (FITC) labelled CD45 and 5gl of 
phycoerythrin (PE) labelled mouse anti-CD 1 lb or PE labelled mouse immunoglobulin 
isotype control (BD Pharmingen). Cell preparations were incubated for 1 hour with
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gentle mixing at 4°C followed by erythrocyte lysis and cell fixation by incubating for 
10 minutes at room temperatures with equal volumes of optilyse B (Becton Coulter 
Ltd) followed by the addition of 500pl of distilled water and further incubation for 10 
minutes at room temperature.
All flow cytometric measurements were performed using Becton Dickinson 
FACScalibur, flow cytometer. Day to day alignment and calibration of this instrument 
was achieved with commercial preparations of fluorescent micro-spheres (Coulter 
electronics Ltd, Luton, Bedfordshire, UK). Leukocyte populations were isolated by 
CD45 fluorescence and forward and side scatter dot plots. The mean fluorescence 
intensity (MFI) of 10,000 cells was measured and compared to that of control cells 
incubated with matched PE-labelled isotope controls.
Neutrophils could be distinguished from monocytes and lymphocytes by the 
combination of low angle forward and right angled side scattered light, a cytogram of 
each cell population was generated (Figure 2.12).
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Figure 2.12 Graphical representation of leukocyte populations with flow cytometry
CD45 FITC
Figure 2.12 demonstrates dot plot to show separation of WBC populations based on 
side scatter (SSC) and CD45 FITC. Regions were drawn around the Neutrophil (Rl), 
Monocyte (R2) and Lymphocyte (R3) subpopulations and CD1 lb PE fluorescence 
from 10,000 events collected from each region was analysed (Figure 2.13).
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Figure 2.13 Mean fluorescence intensity of CD1 lb PE of leukocyte sub-population
Region 2 (Monocyte) 
CDIIb PE Fluorescence
GDI lb PE
(FL2)
Histogram to show peak CD1 lb PE fluorescence from a leukocyte subpopulation (eg 
Region 2-Monocytes) and analysis of Mean Fluorescence Intensity (MFI) as shown in 
Figure 2.13.
2.3.8 Measurement of cardiac troponin-T
All patients had levels of troponin T measured pre-PCI and 24 hours post PCI.
In this study troponin-T was determined using the third generation 
electrochemiluminescent immunoassay (ECLIA) on the Roche El70 
immunoassay analyzer (Roche Diagnostics, UK). The assay utilizes the 
‘sandwich’ principle, with a biotinylated monoclonal troponin-T specific 
‘capture’ antibody and a ‘detection’ antibody labelled with a ruthenium complex, 
which is also troponin-T specific. The upper reference limit (99th percentile) for 
the cardiac troponin-T assay is 0.01pg/l. However, due to poor precision of the
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assay at this level, a troponin-T level with a 10% Coefficient variation or less has 
been used to indicate myocardial necrosis. For the assay we used, this level is 
0.045^ig/1. Thus for the purpose of our study we have classified peri-procedural 
myocardial injury as elevation of troponin-T above 0.04pg/J.
2.4 Imaging of myocardial inflammation 
2.4.1 Introduction
There are many potential ways of imaging inflammation although imaging 
inflammatory changes in the myocardium can be challenging. Contrast enhanced MRI 
has been shown to detect inflammatory myocardial changes in patients diagnosed with 
myocarditis (Friedrich et al, 1998a).
More recently it is possible to detect and quantify myocardial microvascular 
inflammation using microbubbles in an experimental model which can adhere to 
leukocytes (Lindner et ai, 2000b).To investigate the possible mechanisms of 
downstream arterial effects, we employed radio-labelling of leukocytes with 
subsequent visualisation by SPECT scanning. The principle of blood cell labelling is 
that lipophilic radiometal-chelate complexes such as Tc99 are able to enter the cell 
membrane of the leukocytes, once inside the Tc99 is transformed into a hydrophilic 
complex and irreversibly bound (Peters, 1994b). This technique requires that 
leukocytes are separated from intravenous blood and labelled in vitro. We decided to 
pursue this method due to the availability of local expertise.
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2.4.2 Methods
We performed a pilot study on the first nine patients investigated. Each patient had a 
radiolabelled leukocyte scan performed on two occasions; the 1st 7 days prior to PCI, 
the 2nd 24 hours post angioplasty, to determine both baseline uptake of leukocytes in 
the myocardium and identify any changes following angioplasty.
2.4.2.1 Radiolabelling procedure
On each occasion a 51ml sample of blood was withdrawn from a vein in the 
antecubetal fossa with a 16-G butterfly needle, into a syringe containing 9 mis ACD 
solution (consisting of 0.73g of anhydrous citric acid, 2.2g of sodium citrate 2.45g of 
dextrose monohydrate in lOOmls water) to prevent coagulation. The mixture of blood 
and acid citrate dextrose was gently mixed by turning the syringe end over end a few 
times. 15mls of the blood-ACD solution was dispensed into a sterile centrifugation 
tube and centrifuged at 2000g for 10 minutes at room temperature. The cell free 
plasma was separated from the cell rich pellet for use later.
4.5mls of 10% 2-hydroxyethyl starch 200kDa (HES sedimenting agent) was added to 
syringe with the remaining 45mls of blood-ACD and gently mixed, the syringe was 
placed upright at room temperature, thus allowing the erythrocytes to sediment, for 
between 30-45 minutes. The supernatant, which consisted of platelet and leukocyte 
rich plasma was collected in a sterile centrifuge tube by attaching a 16-G butterfly 
needle to the syringe and gently injecting without disturbing the erythrocytes. This cell
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rich supernatant was centrifuged at 150g for 5 minutes. This resulted in a leukocyte 
rich sediment and platelet rich supernatant. The supernatant was removed and the 
pellet was re-suspended in 1ml of cell free plasma. "mTc-HMPAO (Ceretec, 
Amersham Health,UK) was freshly prepared as follows; 5ml of phosphate buffered 
saline containing monosodium phosphate and dibasic phosphate in 4.5ml of normal 
sodium chloride solution, was added to a vial containing a freeze dried mixture of 
0.5mg HMPAO, 7.6pg stannous chloride dehydrate and 4.5mg sodium chloride. The 
vial was gently swirled for 10 seconds until complete dissolution of the powder. 1ml 
of the freshly prepared 99ll!Tc-HMPAO was added to the mixed leukocyte cell 
suspension and incubated at room temperature for 10 minutes with gentle swirling of 
the tube periodically to prevent sedimentation of cells. After incubation 5mls of cell 
free plasma was added to the tube and centrifuged for 5 minutes at 150g. The 
radiolabelled pellet was resuspended in 3mls cell free plasma ready for injection.
2.4.2.2 Injection of radioisotope
The labelled cells were re-injected intravenously slowly into the patients within 1 hour 
of labelling with a 16-G butterfly needle. In the post-angioplasty studies, blood was 
taken for labelling prior to the angioplasty and the labelled leukocytes reinjected 1 
hour after the angioplasty.
82
2A.2.3 Imaging
Eight patients completed both the pre and post angioplasty 99niTc-HMPAO-WBC 
imaging protocol. In all instances, both pre & post angioplasty, SPECT images were 
acquired 24 hours post reinjection of the radiolabelled leukocytes on the RLUH’s 
General Electric Medical Solutions’ Infinia gamma camera system. A Low Energy 
General Purpose (LEGP) Parallel Hole Collimator was used for all imaging, recording 
for 120 seconds per view. A 180° semicircular orbit was used, with 6° per view. An 
image matrix of 128 x 128 pixels was used with a pixel size of 3.32mm.
2.4.2.4 Quantification
A physicist in nuclear medicine, who was unaware of the clinical details of each 
patient graded the planar and SPECT images as positive (uptake of "niTc-HMPAO- 
WBC clearly seen in the myocardium) or negative, and performed the quantification of 
uptake described below.
Leukocytes do not normally localise in the myocardium, but do localise in the spleen 
and (to a lesser extent) the liver. There is also a small quantity localised in bone 
marrow, including the sternum. The quantification is based on the analysis of 
background corrected uptake observed in the region where the heart would be 
visualised if a tracer with myocardial uptake was used. To generate slices containing 
this volume, the following algorithm was applied; Both the baseline and post-PCI data 
sets were processed with filtered back projection (EBP) SPECT reconstruction using a 
high resolution metz filter with order = 40 on the Nuclear Diagnostics (NUD)
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HERMES processing station. The coronal data sets for both studies were created and 
stored. Using the NUD Multimodality software, the coronal data sets were registered 
and aligned together. The coronal slices posterior to the sternum and transverse slices 
superior to the spleen were summated (The same slices summated for both baseline 
and post-PCI datasets to ensure approximately the same anatomy was compared).The 
myocardial ROI was defined to be the region in the chest to the left of the midline, 
superior to the spleen/liver and posterior to the sternum. This ROI includes the 
myocardium and some adjacent non-myocardial anatomy. A background ROI was 
chosen contra-lateral to the myocardial ROI. An example of the ROIs applied is seen 
in Figure 2.14, The ROI from the baseline study were copy and pasted onto the post- 
PCI summated image to reduce the variation arising from manually defined ROIs 
between post and pre scans. Uptake of "mTc-HMPAO-WBC was calculated in the 
myocardial and background ROI as follows; The total number of counts was divided 
by the number of pixels in the ROI to give counts/pixel. Each pixel was a summated 
frame of 27 voxels, each voxel measures 3.2mm x 3.2mm x 3.2mm. Hence we were 
able to calculate counts/mm3 for both regions. We subtracted counts/pixel myocardial 
from counts/pixel background to show the overall difference in uptake in the 
myocardial region compared with the background ROI. We then compared the 
diffeience between pOSt“PCI(Rolmyo-ROIbackground) — piC-PCI(Rolmyo-ROIbackground).
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Figure 2.14 ROI analysis of summated data set
Example of ROI placement on summated anterior coronal slices pre-PCI (left) post- 
PCI (right) as seen in Figure 2.14. The bright uptake seen in both images on the right 
represents uptake in the spleen. Some uptake is seen in each image opposite to the 
spleen, this represents uptake in the liver. The red box represents myocardial ROI and 
the yellow box represents background ROI.
2.4.2.5 Quality control
The periodic intrinsic uniformity and centre of rotation quality control tests were also 
successfully performed to ensure adequate system performance during the period of 
this research trial.
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2.5 Statistics
2.5.1 Power calculations
The power calculation was based on two measures per individual—a measure of 
microvascular function on both the unaffected vessel and the target vessel, and a 
measure of inflammatory activation. These were obtained both pre and post 
intervention. There were two main analyses: a regression analysis using pre­
intervention (baseline) inflammatory markers as predictors of the post-intervention 
microvascular function, and a correlation analysis of the pre-post change in 
microvascular function versus pre-post change in inflammatory marker measures. To 
determine the requirement for patient numbers, a power analysis based on correlation 
was carried out. On the null hypothesis of no correlation between microvascular 
function and inflammation, with 80% power at the 5% significance level, to detect a 
correlation of 0.5 would require 30 subjects, and a correlation of 0.4 would require 48 
subjects, assuming normally distributed data. We therefore elected to enrol 
approximately 50 patients to the main body of the study.
2.5.2 Statistical analysis
Data was checked for normality and reported as mean+/-SEM if normally distributed 
or median and inter quartile range if not normally distributed. Comparisons between 
baseline factors was performed with either %2or Fisher’s exact test as appropriate. 
Comparisons were made between pre and post-haemodynamic parameters in the same 
individuals with Student’s paired t-test or Wilcoxon rank as appropriate. Comparisons
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between impaired data were made with unpaired t-test or Mann-Whitney U test as 
appropriate. Results were classed as significant if P<0.05. Correlation co-efficient 
were calculated using Pearson’s co-efficient or Spearman’s rank as appropriate. To 
obtain normally distributed data IMR was naturally log transformed. Multivariate 
analysis of linear regression was performed using change in IMR as the dependent 
variable. Those variables in the univariate analysis with P<0.25 were included in the 
multivariate linear analysis using backward selection procedure. Data analysis was 
performed using SPSS statistical software version 17.0 (SPSS Inc. Chicago Illinois).
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Chapter 3 Screening and recruitment
3.1 Introduction
Interventional studies by their nature involve complex invasive procedures, which 
even in non-research clinical setting are associated with many anxieties for patients. 
Additional procedures required for the study add to the uncertainty. Recruitment is 
further complicated by the fact that patients have recently been diagnosed as having 
ischaemic heart disease and have been told they require an invasive procedure 
(coronary angioplasty) which in itself has risks of 0.5% of major complications such 
as myocardial infarction and stroke. Furthermore the nuclear imaging arm of the study, 
which involved the administration of a radioactive isotope, adds anxiety for the 
subjects. The purpose of this chapter is to describe the screening and recruitment 
process of the study and describe the background characteristics of patients.
3.2 Methods
3.2.1 Screening process and patient selection
In order to identify subjects who would be suitable for inclusion into the study we 
screened patients from the pooled referral list for PCI at the Liverpool Heart and Chest 
Hospital. If the referral letter suggested single vessel PCI and no exclusion criteria 
were apparent from the referral letter then the patient was selected for making contact 
regarding provision of a patient information leaflet.
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3.2.2 Making patient contact
The selected patients were approached via telephone call to ask if they would be 
interested in receiving a patient information leaflet and if they would be willing to 
consider inclusion into the study. Following a period of at least 48 hours, the patient 
was contacted again and asked if they would consider meeting for further discussion 
regarding study. The patients who agreed were met by myself in the pre-assessment 
clinic and the rationale for the study was explained as well as exactly what would be 
involved for the patient and potential risks involved in taking part in the study. During 
this visit, inclusion and exclusion criteria were confirmed. If the patient agreed to 
partake in the study then written informed consent was obtained. Medical history, 
Canadian cardiac society (CCS) angina score and cardiovascular examination were 
performed and recorded.
Table 3.1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Single vessel LAD or
circumflex lesion
ACS/MI in last 3 months
Indication for PCI STEMI anytime
Age >18 Multi vessel disease
Previous CABG
Previous PCI
Serum creatinine >200pmol/1
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Asthma or severe COPD
Short left main stem or separate origin
of LAD or circumflex artery
Chronic total occlusion of the target vessel
Left ventricular ejection fraction less than 40%
Chronic inflammatory disease
3.2.3 Justification of inclusion /exclusion criteria
Table 3.1 summarises the inclusion/exclusion criteria for the study. Patients with AMI, 
or acute coronary syndrome in the last three months were excluded due to the known 
effects of microvascular dysfunction and the inflammatory response to infarction in 
this group of patients. Patients with LVEF<40%, or whom had suffered STEMI or had 
evidence of akinetic areas on ventriculography or echocardiography were excluded, 
since there would be marked microvascular abnormalities in the region of myocardium 
affected by the infarct. Patients with asthma and severe COPD were excluded in view 
of the contra-indication of adenosine use, which is required for hyperaemia. Patients 
with angiographic significant two vessel disease were excluded since we needed 
patients in whom single vessel PCI was indicated. Patients with short left main stem or 
separate origin of LAD and circumflex artery were excluded since good engagement 
of the left main stem was required for accurate measurements of mean transit time of 
bolus of saline injected down the left main stem. Patients with active inflammatory
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disease requiring the need for immunosuppressive drugs were excluded because of 
potential interaction with the inflammatory response to PCL Patients with serum 
creatinine >200pmol/l were excluded due to increased risk of contrast induced 
nephropathy. Chronic totally occluded coronary arteries were also excluded in view of 
the inability to obtain accurate pre-PCI mean transit times.
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3.3 Results
3.3.1 Screening process
Figure 3.1 Flow diagram of the screening process
Consented 43 Declined 40
Excluded
Excluded
Stable
angina
LAD/Cx .
Completed
Study
Suitable
single vessel 
disease
Multi vessel 
disease
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The screening process lasted from 39 months from July 2006 till September 2009. We 
screened 597patients with stable angina who had undergone coronary angiography 
and were referred for PCI, of these 194 patients were identified with single vessel 
disease. Out of 194, 124 patients had either left anterior descending or circumflex 
artery stenosis. 43 patien ts were excluded due to the presence of one or more 
exclusion criteria. This left 83 patients eligible for the study, of which 40 declined to 
partake, hence 43 patients were consented (Figure 3,1).
Of the 43 patients who were included in the study 4 patients were excluded during the 
study, 1 patient had ventricular fibrillation immediately following passing the wire 
through the target lesion, one patient was found to have a haemodynamicaily 
insignificant lesion (FFR>0.8) and hence no PCI was performed, one patient had 
significant lesion in reference vessel territory thus requiring two vessel PCI and one 
patient had dissection of target vessel and was excluded due to a lengthy procedure.
Out of 39 patients present to completion, there was no complete reference vessel data 
in 5 patients, 2 of which were unable to tolerate the final infusion of adenosine. In 
another 2 patients we were unable to get a stable thermodilution curve. This was 
because in both cases the reference vessel was a small circumflex artery and 
hyperaemic mean transit time was unrecordable since this was less than the lowest 
level detectable by the wire. In one patient there was malfunction of the pressure wire 
for the final measurements. 4 patients have no complete target vessel data due to
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unrecordable Tmn which was a result of low amplitude of the thermodilution curve in 3 
patients, in all of these cases the underlying cause was very tight stenosis of the 
coronary artery in question. In one patient we were unable to pass the pressure wire 
through the stenosis and had to use a standard angioplasty wire to negotiate the lesion. 
All 39 patients had single de-novo lesion in either the LAD or circumflex territory, the 
clinical angiographic and procedural characteristics are defined in Tables 3.2-3.4.
Flow cytometry was performed in 34 patients.
3.3.2 Background characteristics 
Table 3.2 Cardiac risk factors
n=39
Diabetes Mellitus 23.1%
Diabetes Mellitus (On insulin) 2.4%
Hypertension 64.1%
Hyperlipidaemia 97.4%
Smokers current 17.9%
Smokers ex (quit in last 12/12) 23.1%
Family history of IHD 61.5%
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The majority of patients were male (69.2%), mean age of subjects was 58.2 years and 
all patients were symptomatic with angina. 23.1% of patients had diabetes and of these 
only 1 patient was on insulin (3%), 64.1% of were hypertensive on treatment and most 
patients were diagnosed with pre-existing hyperlipidaemia (97.4%). 61.5% of subjects 
had positive family history of IHD (Table 3.2).
Table 3.3 Medication history of patients prior to PCI
Drug Therapy n=39
Aspirin 94.8%
Clopidrogel 10.3%
Beta blockers 74.4%
Long acting nitrates 35.9%
Calcium channel antagonists 48.7%
Nicorandil 23.1%
Statins 94.9%
Angiotensin converting 
enzyme antagonists
46.2%
Angiotensin II receptor antagonists 10.3%
Diuretics 12.8%
Drug history is outlined in Table 3.3. The background characteristics and drug history 
suggest a population with multiple risk factors and on multiple drug therapy for 
ischaemic heart disease.
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Table 3.4 Functional classification of the severity of angina of patients
Canadian cardiac society angina score n=39
I Angina occurs with strenuous, 10.3%
rapid or prolonged exertion.
II Slight limitation of ordinary activity. 48.7%
Ill Marked limitations of ordinary physical activity. 41%
IV Inability to carry on any physical activity without 0%
discomfort - anginal symptoms may be present at rest
Two patients were in class I CCS, these were symptomatic at a high workload and 
were not keen on taking anti-anginal medications. The rest of the patients were in 
either class II or III as shown in Table 3.4.
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Table 3.5 Clinical characteristics of patients. *mean+/-SEM (95%CI).
Age* 60.49 ± 1.36 (57.73-63.24)
Height, cm* 171.95 ± 1.78 (168.34-175.55)
Weight, kg* 87.6 ±2.27 (82.99-92.18)
BMI* 30.01 ±0.7 (28.59-31.44)
Pulse rate* 62.76 ± 1.85 (59.0-66.5)
Systolic blood pressure, mmHg* 137.4 ±3.3 (130.6-144.1)
Diastolic blood pressure, mmHg* 71.3 ± 1.7 (67.9-74.6)
Haemoglobin, g/dl* 13.81 ±0.19(13.41-14.16)
White cell count, xlOy/l 8.01 ±0.21 (7.57-8.44)
Neutrophil count, x 1 OVl 4.90 ±0.17(4.49-5.31)
Total cholesterol, mmol/1* 4.01 ±0.14(3.74-4.29)
LDL cholesterol, mmol/1* 1.92 ±0.09 (1.77-2.13)
Summary of baseline clinical characteristics are outlined in Table 3.5.
3.3.3 Evidence of reversible ischaemia pre PCI
Most patients referred for angioplasty for stable angina present to the hospital in the 
rapid access chest pain clinics following referral from their GP. The majority of 
patients undergo some form of non invasive testing to differentiate between cardiac 
and non cardiac chest pain. The rapid access chest pain clinic provides a prompt
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consultation with a cardiologist and a nurse practioner, during this consultation there is 
the opportunity to perform a functional assessment of cardiac ischaemia and an 
assessment often in the form of an exercise tolerance test (EXT). In our data set, out of 
39 patients, 34 patients had EXT, of which 31 were positive for evidence of reversible 
myocardial ischaemia and three were negative. 3 patients of these 34 who were 
positive, also had myocardial perfusion scan performed with which was also positive.
2 out of the 3 patients with negative EXX had a myocardial perfusion scan which was 
negative for inducible ischaemia. One of patients who had negative EXX had a stress 
echo which was negative. Xwo patients had myocardial perfusion scans who were 
unable to tolerate EXX and three patients had no test of reversible ischaemia pre 
procedure (Figure 3.2).
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Figure 3.2 Flow diagram representing evidence of reversible ischaemia in the study 
population
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Figure 3.3 Location of coronary artery lesion
Figure 33 and Table 3.6 demonstrate the pattern of coronary artery disease in our 
study population.
Table 3.6 Distribution of location of target lesion for PCI
Proximal LAD ■1 43.6 %
Mid LAD M 33.3%
Circumflex CD 20.5%
Obtuse marginal M3 2.6%
3.4 Discussion
This chapter describes the task of studying patients for a complex interventional study 
with coronary artery disease and the baseline characteristics of the study population. 
Recruiting patients into clinical interventional cardiology studies is a challenging task, 
we found it particularly difficult to meet the entry criteria since most patients at
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presentation had multi-vessel disease. During the recruitment period there were some 
important changes in the trends of management of IHD particularly the threshold at 
which referral for revascularisation is made. The recent Courage study compared 
optimal medical management vs. PCI for treatment of stable angina, (Boden et ah, 
2007). The study suggested there was no difference to rates of death, myocardial 
infarction and other cardiovascular events between PCI, but there is a significant 
increase in freedom from angina in the PCI group. We suspect this study may have 
changed practice and led to a decrease in the referral rate for PCI in stable angina 
patients. Similar trends have been confirmed from a large PCI registry in the US 
(Ahmed et a!.,) As with previous studies our data had similar prevalence of cardiac 
risk factors. Furthermore our study population was a well medicated group with a very 
high incidence of statin use. The vast majority of patients were significantly 
symptomatic and had evidence of ischaemia on functional testing.
Conclusion
Screening patients with IHD who have had coronary angiogram for inclusion into 
interventional studies is a difficult undertaking, the majority of the non-selected 
population has multivessel disease and a significant proportion have had recent MI, 
although this practice has now changed with the majority of patients with MI having 
coronary angiogram performed acutely followed by PCI if indicated. In addition the 
difficulties increase when a complex protocol was discussed and patients prefer to
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undergo a relatively simpler procedure without inclusion into the study due to 
anxieties regarding the procedure itself.
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Chapter 4 Effect of PCI on coronary and 
microvascular physiology
4.1 Introduction
There is growing interest in myocardial microvascular function particularly in relation 
to revascularisation procedures such as coronary artery bypass grafting (CABG) and 
percutaneous coronary angioplasty (PCI), since microvascular patency is now 
recognised as one of the key factors which may be important for a favourable 
outcome. Impairment of the microcirculation despite normal epicardial flow is 
associated with a poor prognosis following acute myocardial infarction (Ito et aL,
1992b), and microvascular injury following reperfusion is a predictor of adverse 
outcomes (Gibson et aL, 2000;Yamamuro et aL, 2002). Despite apparently normal 
epicardial flow, microvascular flow can still be impaired and this is associated with 
adverse events (Ito et aL, 2004). Assessment of the microcirculation may also provide 
a better understanding of the no-reflow phenomenon described earlier (Kloner el aL, 
1974b). It is becoming apparent that microcirculatory patency has a strong association 
with improved prognosis in many different clinical settings and assessment of this 
compartment could answer some of the questions which remain unanswered in relation 
to successful revascularisation.
The focus of revascularisation therapies has been on restoring flow through the 
epicardial vessel, and the concept of PCI and CABG relies on the assumption that
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restoring epicardial flow will restore perfusion and hence improve myocardial 
function, reduce myocardial ischaemia and improve prognosis and symptoms. 
However, although it is widely accepted that these forms of revascularisation do 
improve myocardial perfusion, the assumption that restoration of epicardial flow will 
necessarily restore microvascular flow has been challenged (Uren et a!., 1993;Kern et 
al, 1999). One could assume that if epicardial vessel patency is restored, then 
microvascular flow will improve, however there is some suggestion that 
reperfusion/revascularisation processes themselves cause microvascular dysfunction to 
some degree (Selvanayagam et aL, 2007). In the setting of true reperfusion such as in 
acute myocardial infarction treated with either thrombolysis or PCI, reperfusion injury, 
which is the end result of activation of multiple mechanisms resulting in profound 
microvascular damage is very common (Braunwald and Kloner, 1985). However in 
stable angina patients undergoing PCI, microvascular injury is less clearly defined. We 
are particularly interested in the effect of PCI on microvascular function in this group 
of patients. If PCI does cause microvascular dysfunction in stable angina then we aim 
to explore underlying factors which may account for this. These aims are the focus of 
this chapter.
Historically interest in the microvascular compartment in relation to coronary 
revascularisation began in the mid 80’s. The concept that revascularisation can 
normalise microvascular function was investigated by Bates et al; they studied 
patients, who had undergone revascularisation with either balloon angioplasty or
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CABG. They found CFR remains below levels seen in normal individuals but was 
improved compared to patients with significant CAD pre revascularisation (Bates et 
al, 1985). The inability to normalise CFR was assumed to be secondary to diffuse 
atherosclerosis. Wilson et al. showed in up to 50% of cases CFR, when measured 
immediately post-PCI remains abnormal in patients undergoing single vessel PCI. 
There was further improvement in CFR when assessed 5 months later in patients who 
did not develop restenosis. Of those whom subsequently developed restenosis, a 
reduction in CFR was seen following PCI (Wilson et ah, 1988).
Zijlstra et al. found immediate improvement in CFR post-PCI, but this was still below 
normal levels, and they found a further increase in CFR at five months, they put this 
down to late improvement in luminal area of vessel (Zijlstra et al, 1988). Abnormal 
CFR may have been secondary to a less than optimal result from coronary angioplasty 
with balloon inflation alone and the additional effect of stenting on CFR was assessed 
by Kern et al. CFR was measured pre and post balloon angioplasty and post stenting, 
they found stenting improved CFR more than balloon angioplasty alone, yet despite 
stenting, CFR failed to normalise in a third of subjects (Kern et al, 1999). However 
the addition of stenting the coronary artery does not always seem to further improve 
CFR when compared with balloon angioplasty alone (van Liebergen et al, 1998). 
Persistently abnormal CFR following PCI was thought to be also secondary to 
generalised underlying microvascular dysfunction as defined by an abnormal CFR in 
the reference vessel pre-PCI (Kern et al, 1999). An increase in basal flow was seen as
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a common factor responsible for reduced CFR in many of these studies. Although a 
picture was emerging of some degree of microvascular dysfunction immediately 
following angioplasty, the medium to long term effects of PCI on MR was less well 
defined.
Manyari el at. found an immediate microvascular dysfunction (lack of normalisation) 
followed by a medium to long term improvement back to normal levels following PCI. 
They showed the persistence of perfusion defects post-PCI in patients with single 
vessel disease one week post-PCI, but when reassessed at three months there had been 
a full recovery (Manyari et al, 1988). Conversely, data from patients undergoing PCI 
for single vessel disease, showed persistent impairment of microvascular function at 3 
months with intracoronary Doppler and PET (Uren et al, 1993a). Concordant short 
term results were found by subgroup analysis of the DEBATE study, 50% of patients 
had abnormal CFR immediately post-PCI and this was associated with increased 
revascularisation and angina at 6 months. Once again lack of normalisation of CFR 
was attributed to an increase in basal flow, in addition patients with abnormal CFR in 
the reference vessel was predictive of poor outcome post-PCI (Pick et al., 2001).
The much larger DEBATE II study showed that over a third of patients had impaired 
CFR post-PCI despite a normalisation of the epicardial obstruction, those with 
abnormal CFR once again demonstrated increased baseline flow (Albertal et al,
2002). In this study impaired CFR was associated with raised CKMB, suggesting that
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periprocedural myocardial injury and necrosis may account for the increase in basal 
flow due to the release of endogenous adenosine (Hori et ai, 1986). Patients with 
CFR<2.5 immediately post-PCI had a worse prognosis as demonstrated by an increase 
in major adverse clinical events (MACE) at 30 days. However if the early 
complications were excluded then there was no difference in longer term prognosis 
(Albertal et al., 2002). Hence the authors suggested procedural factors related to the 
PCI were responsible for MACE.
All the above studies demonstrated impaired CFR post-PCI in predominantly stable 
angina patients. There seemed to be a common finding of an increase in basal flow 
which was a factor in post procedural reduction in CFR. Given that CFR is a less than 
ideal measure of microvascular function as discussed earlier, researchers have used the 
concept of minimal microvascular resistance, which is defined as microvascular 
resistance at maximal hyperaemia. Initially a small number of studies used the Doppler 
catheter and wire to assess MRV in patients undergoing PCI.
Chamuleau et ciL assessed MR before and after PCI using hyperaemic minimal MR 
(MRV) with the Doppler wire. They were able to show firstly that vessels with severe 
stenosis had greater MRV in the territory supplied by the diseased artery, and by 
performing PCI, MRV improves. However when the data was analysed more closely, in 
25% of patients, there was either an increase in MRV or little change compared to pre- 
PCI levels (Chamuleau et aL, 2003a). A further study demonstrated a 34% reduction
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in MRV in response to PCI, the authors suggested that PCI increased distal pressure 
and hence flow, thereby reducing microvascular resistance (Verhoeff et ah, 2005). 
More recently an elegant MRI study indicates that in up to 50% of cases there is 
evidence of distal microvascular injury post-PCI, detected by delayed enhancement 
with MRI. This corresponds with reduced CFR in the same area; again suggesting 
distal microvascular injury is the underlying cause. The authors speculate that this was 
due to distal embolisation, however any other cause of microvascular disturbance 
could have resulted in a similar pattern of microvascular damage (Selvanayagam et a!., 
2007).
The conclusion from these studies was that a very substantial proportion (30- 
50%) of patients undergoing coronary intervention either have persistent 
microcirculatory dysfunction or in some cases develop a worsening of 
microcirculatory function to some degree, which in some cases is associated with poor 
outcome. Yet despite the clinical implications and importance of microvascular 
dysfunction secondary to PCI, in the stable angina patients, the effect of PCI on 
microvascular function is poorly defined and underlying mechanisms are still poorly 
understood.
This chapter describes the findings of haemodynamic physiology in relation to PCI in 
our study population, particularly investigating the microvascular compartment in two 
vessel territory to gain an insight into the factors which affect MR in stable angina.
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The use of IMR to assess the effect of PCI on MR had not to our knowledge been 
performed prior to the start of this project. We must also take into consideration the 
contribution of collateral flow when measuring microvascular function. Collateral 
component of myocardial flow cannot be ignored or assumed to be insignificant as 
discussed earlier in Chapter 2, particularly when we are looking at vessels with severe 
stenosis (Aarnoudse et ah, 2004c). The greater the stenosis we would expect more 
collateralisation and hence a very significant proportion of myocardial flow would be 
collaterally derived. Therefore we set out to investigate the microcirculation from a 
different perspective using the novel recently described method of IMR and corrected 
IMR which takes into account the contribution of collateral flow (Aarnoudse et al, 
2004a;Fearon et al, 2004a).
4.2 Methods
For a detailed description see Chapter 2 page 60. In brief, 39 patients with single 
vessel CAD symptomatic with angina scheduled for elective PCI were included in the 
study. All patients were given aspirin 600 mg and clopidrogel 600mg at least 12 hours 
before the PCI and normal medications were continued. PCI was performed from the 
right radial artery using 6-F guiding catheters. All patients received a bolus of heparin 
75IU/kg at the beginning of PCI and an intra-coronary injection of 200mcg of glyceryl 
dintrate every 30 minutes. Each patient had measurement of Pa, Pd, Tmn at rest and 
hyperaemia in both the reference vessel and target vessel before and after PCI. FFR, 
CFR, IMRhyper, IMRrest, was calculated in both vessels as described before and
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immediately post-PCI. Coronary wedge pressure was measured in all patients during 
30 second balloon inflation in the target vessel. 17 patients underwent second 
measurement of wedge pressure 5 minutes after first recording of wedge pressure to 
assess acute changes in coronary wedge pressure following PCI. CFI was calculated as 
described in Chapter 2.
All intracoronary haemodynamic measurements were performed with RADI pressure 
wire© and recorded on RADI analyser© (Upsulla, Sweden). Off line analysis was 
performed with RADIview©. Hyperaemia was induced with IV adenosine at dose of 
140pg/kg/min. PCI was performed in the standard manner. IMRunc0rrected was 
calculated as Pt| x Tnin and IMRconecied was calculated as follows Pa x ((Pd-Pw)/(Pa-P\v)) 
x Tmn, these measurements were all performed at maximal hyperaemia. We also 
calculated resting IMR in both vessels.
4.2.1 Statistical analysis
Data were checked for normality and reported as mean+/-SEM if normally distributed 
or median and inter quartile range if not normally distributed. Comparisons between 
baseline factors was performed with either y2 or Fisher’s exact test as appropriate. 
Comparisons were made between pre and post haemodynamic parameters in the same 
individuals with Student’s paired t-test or Wilcoxon rank as appropriate. Comparisons 
between unpaired data were made with unpaired t-test or Mann-Whitney U test as 
appropriate. Results were classed as significant if P<0.05. Correlation co-efficient
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were calculated using Pearson’s co-efficient or Spearman’s rank as appropriate. 
Statistical analysis was performed with SPSS v.17 (SPSS inc. Chicago Illinois, USA). 
Variability between the three measurements of Tmn was defined as follows;
Vaital ,a2,a3)= max lai-a I
•,2.3 -
4.3 Results
We recorded haemodynamic data on 39 patients. We were unable to acquire a 
complete set of haemodynamic data before and after the PCI in both vessels in a 
number of patients. Full data were not obtainable in 4 target vessels and 5 reference 
vessels. This was due to three cases of severe stenosis in the target vessel whereby Tm„ 
was unrecordable since the lesion was so severe that not enough injectate was able to 
pass beyond the lesion to the sensor to get adequate signal and reading of Tmn. In one 
patient we were unable to pass the pressure wire through the stenosis and had to use a 
standard angioplasty guide wire to negotiate the lesion hence were unable to get 
readings on the target vessel and unable to measure wedge pressure. In the reference 
vessel we did not have full data on 5 patients, this was due to 2 patients refusal for 
repeat IMR in the reference vessel post-PCI due to the side effects of adenosine, 
inability to get good signal in two patients and a malfunction of pressure wire in one 
patient. Hence we had out of 39 patients, full data on target vessel in 35 patients and 
34 patients in the reference vessel.
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4.3.1 Procedural factors
Table 4.1 Procedural characteristics of subjects undergoing PCI. 
tmedian(IQR),;!:mean+/-SEM (95%CI).
No of stents f 1 (1-2)
No of inflations'15 4.05 ±0.32 (3.39-4.71)
Total time of ischaemia due to balloon 
occlusion during PCI'15, seconds
71 ±6.72 (54.45-84.55)
Procedure time, minutes'15 98.28 ±4.08 (89.95-106.71)
Total length of stent, mmf. 18 (15-23)
Stent Diameter, mm'15. 2.88 ±0.72
Table 4.1 describes procedural factors related to PCI in our study group.
4.3.2 General data
Figure 4.1 Haemodynamic data as measured by the pressure wire.
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Tracing on top represents pre-PCI haemodynamic data in the target vessel, tracing on 
bottom represents post-PCI data in the target vessel as shown in Figure 4.1. Red 
tracing indicates aortic pressure!Pa), green tracing indicates distal coronary 
pressure!Pd), the number in yellow on the right hand side is the calculated FFR. P(i is
dissociated from Pa waveform and resembles ventricular pressure wave form pre-PCI. 
Post-PCI Pd waveform normalises and resembles aortic pressure waveform.
Table 4.2 Effect of PCI on haemodynamic parameters, comparison between the same 
vessel pre and post-PCI. 'i!P<0.05:|!:i:P<0.01 ii:*:i:P<0.001
Reference
Pre (n=34)
Reference 
Post (n=34)
Target
Pre (n=35)
Target
Post (n=35)
Pa rest 
(mmHg)
97
(93-106)
100
(92-107)
100
(92.3-107)
101
(91.5-111.8)
Pd rest 
(mmHg)
99
(90-105)
98
(88-104.5)
70.5
(61.8-86) ***
100
(86-105)
Pa hyp 
(mmHg)
93
(82-103)
92
(78-100.5)
94.5
(82.5-106.3)
90.5
(81.25-102.8)
Pd hyp 
(mmHg)
87.3
(83.3-91.4)
86
(74.5-100.8)
.58
(45.3-65.8)***
83.5
(74.5-90.5)
Tinn i est 
(seconds)
0.73
(0.53-1.01)**
0.57
(0.28-0.75)
0.69
(0.52-1.1)
0.60
(0.33-0.85)
Tmn hyp 
(seconds)
0.27
(0.19-0.35)**
0.21
(0.17-0.27)
0.35
(0.25-0.74)*** 0.20 (0.17-0.32)
CFR 2.99+/-0.25 2.57+/-0.2 1.96+/-0.12 * 2.67+/-0.24
FFR 0.96+/-0.01 0.96+/-0.01 0.63+/- 0.01 *** 0.91+/-0.01
IMR hyp
uncorrcctcd
23.7
(15.8-31.4)**
17.9
(12.4-24.1)
24.0
(14.3-35.7)*
17.0
(13.3-24.6)
IMR hyp
corrected
14.6
(10.9-24.5)
15.9
(12.4-23.9)
IMR rest
uncorrcctcd
72.3 (56.4- 
97.5) ***
56.8
(26.7-73.1)
47.2
(32.9-68.7) 60.0(36.3-93.8)
IMR rest
corrected
22.6
(16.8-48.7)*** 55.7 (29.0-87.6)
Table 4.2 summarises all the haemodynamic data before and after angioplasty, at rest 
and at hyperaemia. The individual findings are discussed in detail below in the 
appropriate sections. (Pa rest, resting aortic pressure; P(i rest, resting distal coronary 
pressure; P« hyp, hyperaemic aortic pressure; P(t hyp, hyperaemic distal pressure; Tnm 
rest, resting mean transit time; TIIW hyp, hyperaemic mean transit time; CFR, coronary 
flow reserve; FFR, fractional flow reserve; IMR hyplimotrccle(i, hyperaemic index 
microcirculatory resistance uncorrected; IMR hypcom>ae(h hyperaemic index 
microcirculatory resistance corrected; IMR restmcmrcc,e(j, resting index 
microcirculatory resistance uncorrected; IMR resconvc!e(j, resting index 
microcirculatory resistance corrected).
Variability of Tmn
The variability in measurements of Tmn was 9.34+7-0.004% for resting Tmn and 
11.45+/-0.01% for hyperaemic Tmn.
Effect of PCI on heart rate
Resting heart rate increases slightly following PCI (68.7+7- 2.0 vs. 71.8+7- 1.9 P= 
0.007), there is no difference in hyperaemic heart rate following PCI (86.7 +7- 2.5 vs. 
87.0 +7- 2.0 P=ns).
Effect of adenosine on haemodynamics
Adenosine reduces mean arterial pressure (99.5[92.3-107.5] mmHg vs. 92.5[81-104.4] 
mmHg PcO.OOl) and increases heart rate (70.1+7-2.0 vs. 86.86+7-2.2 PcO.OOl).
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4.3.3 Fractional flow reserve and coronary flow reserve
The next set of data summaries the effect of PCI on fractional flow reserve, coronary 
flow reserve and index of microcirculatory resistance on both vessels following PCI.
Figure 4.2 Effect of PCI on FFR. Mean +/- SEM ***P<0.001
There was no change of FFR in the reference vessel in response to PCI, as shown in 
Figure 4.2 (0.96+/-0.01 vs. 0.96+/-0.01 n=34 P=0.31). We demonstrate an 
improvement in FFR in the target vessel post procedure (0.63+/-0.02 vs. 0.91 +/-0.01 
n=35 P<0.001).
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Figure 4.3 Effect of PCI on CFR measured with thermodilution. Mean +/- SEM
*/)<0.05
ns
i
Reference Target
Figure 4.3 shows that there was no significant change in the CFR post-PCI in the 
reference vessel (2.99 +/- 0.25 vs. 2.57 +/- 0.2 n=34 P=0.08). The CFR in the target 
vessel increased in response to PCI (1.96 +/- 0.22 vs. 2.61+1- 0.24 n=35 F><0.05).
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4.3.4 IMR
In order to investigate the effect of PCI on microvascular function we measured 
IMRcon-ectcd ^nd IMRuncorrec,ed in both vessels, before and after PCI.
Figure 4.4 Effect of PCI on IMRuneoirected (IMR=Pd.Tmn). Median (IQR) *P<0.05 
**P<0.01
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There is a significant reduction in reference vessel IMR post procedure compared with 
pre-PCI (23.7[ 15.8-31.4] vs. 17.6[ 12.4-24.1 ] n=34 P<0.01). There is a significant 
reduction in IMRlincorrectcd in the target vessel in response to PCI when collateralisation 
is not taken into account, as shown in Figure 4.4 (24.0[ 14.3-35.6] vs. 17.0 f 13.3-24.6] 
n=35 PcO.OS).
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Figure 4.5 Effect of PCI on IMRcorrccted = Pa.Tmn[(Pd-Pw)/(Pa-Pw)] Median(IQR). 
**P<0.01
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Figure 4.5 shows that when collateral flow is accounted for in the calculation of IMR. 
in the form of IMRconected, we see a heterogenous response to PCI in the target vessel. 
In some cases values increased, whilst in others a decrease was observed, thus overall 
changes were not found to be statistically significant (14.6[ 10.9-24.5] vs. 15.9[12.4- 
23.9] n=35 P=0.99). Given the heterogenous nature of the response to PCI, we 
analysed the degree of change in IMR from baseline to identify the group of patients 
who in fact had an increase in IMR following PCI. It should be noted that in the 
reference vessel there is no difference between IMRcorrec,ed and IMRuncorrected since we 
assume P\V=0 in the non diseased vessel.
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Figure 4.6 Acute change in coronary wedge pressure following PCI. Mean+-SEM
ns
wedge 1 wedge 2
There was no acute change in coronary wedge pressure when measured 5 minutes 
apart, as shown in Figure 4.6 (23.39+/-1.77mmHg vs. 21.67+/-1.7 mmHg n=17 
P=ns).
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Figure 4.7 Distribution of patients according to change in IMR. increase/decrease is 
defined as increase/decrease of >15% of baseline IMR post-PCI respectively
] increase
IMR reference IMR target nc IMR target corrected
We have defined increase/decrease of IMR in response to PCI as a 15% 
increase/decrease from pre-PCI levels on the basis of variability of hyperaemic Tmn of 
11.5% observed in our study. In the reference vessel, IMR increases in 6/34patients 
(17.6%), no change in 10/34 patients (29.4%) and decreases in 18/34patients (52.9%).
IMRuncorrected increases in 9/35 patients (25.7%), decreases in 21/35 patients (60%) and 
is unchanged in 5/35 patients (14.3%) following PCI. 11/35 patients (31.4%) 
developed an increase in IMRcorrected following PCI, there was a decrease of IMRcorrected 
in 11/35 patients (31.4%) and no change in 13/35 patients (37.1%).
The IMR in the reference vessel is calculated by the same method as uncorrected IMR, 
since there is no epicardial stenosis and wedge pressure is assumed to be venous
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pressure which is approximated to zero, hence the reference vessel IMR consists of P(i 
multiplied by Tmn. Since it could be argued that a reduction in IMR is seen due to 
change in baseline conditions such as blood pressure thereby accounting for the 
reduction in IMR in the reference vessel, therefore we assessed the individual 
components of Pt| and Tmn separately.
Figure 4.8 Effect of PCI on mean transit time in the reference vessel. Mean +/-SEM 
*P<0.05 **P<0.01
^ 0.2-
There is a reduction in hyperaemic Tmn post-PCI in the reference vessel territory 
(0.27[0.19-0.35] seconds vs. 0.21 [0.17-0.27] seconds n=34 P<0.01) as shown in 
Figure 4.8. When we analysed changes in basal flow assessed by resting Tmn in the 
reference vessel pre vs. post-PCI, a reduction in resting Tmn resting is seen (0.73[0.53- 
1.01] seconds vs. 0.57[0.28-0.75] seconds P<0.01) There is no significant difference 
in resting flow in the target vessel; Tmn (0.69[0.52-l.l] seconds vs. 0.60[0.33-0.85]
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seconds P=ns) as shown in Table 4.2. Hyperaemic flow in both vessels increases 
following PCI as seen by a reduction in Tmn in the reference vessel and target vessel 
respectively (0.27[0.19-0.35] seconds vs. 0.21 [0.17-0.27] seconds P<0.01; 
0.35[0.25-0.74] vs. 0.20[0.17-0.32] seconds PcO.OOl).
Figure 4.9 Effect of PCI on distal coronary pressure in the reference vessel. Median
(IQR)
130 -
120 -
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There is no change in Pjin the reference vessel following PCI (87.3mmHg [83.3-91.3] 
vs. 86mmHg [74.5-100.8] n=34 P=0.77), therefore the reduction in IMR is due to a 
reduction in the Tmn component of IMR.
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4.3.5 Effect of PCI on resting IMR
Although IMRcorrected is an accepted measure of microvascular function, we 
investigated the effect of PCI on resting IMR (without administration of adenosine) to 
assess how the basal microcirculation responds to PCI.
Figure 4.10 Effect of PCI on IMRres,ing Median(IQR) **Ji:/5<0.001
150-
100-
Pre post 
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There is a decrease in resting IMRuncorrected in the reference vessel in response to PCI 
(72.3 [56.3-97.5] vs. 56.8[27.0-73.1] n=34 PcO.OOl). There is no significant effect of 
PCI on resting IMRuncorrected in the target vessel (48.2[33.1-73.2] vs. 56.5[29.3-87.2] 
n=35 P=0.18). However if IMRCorrected is calculated for the target vessel then there is a 
marked increase in basal microvascular resistance (22.6 [16.8-48.7] vs. 55.7[29.0- 
87.5] n=35 PcO.OOl).
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4.3.6 Collateral flow index and IMR
In order to investigate the interaction between collateral flow and microvascular 
function we analysed the data by comparing change in IMR vs CFI since collateral 
flow may be an important factor on microvascular dysfunction following PCI.
Figure 4.11. Relationship between collateral flow index and IMR
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There is no relationship between CFI and IMR in either reference and target vessel 
when IMRuncorrected in used, however with IMRCorrected there is a negative correlation as 
CFI increases IMR is reduced in the target vessel. R -0.36 P=0.04. Hence the greater 
the collateral contribution the less the IMR in the target vessel when corrected for 
collateral flow as shown in Figure 4.11. We also investigated the relationship between 
collateral flow index and FFR pre-PCI in the target vessel (R =-0.31 P=0.07).
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4.3.7 Comparison of good collateral vs. poor collateral groups
Since collateral flow has been implicated by earlier studies as a potentially important 
factor on microvascular function and outcome of PCI, we have split the data into poor 
collateral (CFI<0.2) and good collaterals (CFI>0.2) and compared clinical and 
haemodynamic factors.
Table 4.3 Comparison of baseline factors between patients with poor and good 
collateral flow. **P<0.01
CFI<0.20
n=16
CFI>0.20
n=22
Hypertension 56.3% 72.7%
Hypercholesteraemia 87.5% 100%
Diabetes 18.7% 27.3%
Smoking history<12/12 43.8% 40.9%
Family history IHD 81.3% 47.8% **
CCS class I 12.5% 9.1%
II 62.5% 40.9%
III 25% 50%
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Apart from an increased percentage of patients with a family history of IHD in the 
poor collateral group, there are no other differences between baseline characteristics as 
shown in Table 4.3.
Table 4.4 Difference in haemodynamic data pre and post-PCI in patients with poor 
and good collaterals
CFI<0.20 CFI>0.20
CFR ref pre PCI 2.93+/-0.47 (n =12) 3.02+/-0.32 (n=22) P=0.77
CFR ref post PCI 2.63+/-0.38 (n=12) 2.54+/-0.26 (n=22) P=0.89
CFR tar pre PCI 2.39+/-0.42 (n=16) 1.61+/-0.16 (n=19) P=0.07
CFR tar post PCI 2.82+/-0.40 (n=16) 2.53+/-0.30 (n=19) P=0.45
This table compares pre and post CFR in both vessels before and after PCI comparing 
poor vs. good collaterals. Overall there is no statistically significant difference 
between the groups, however there does seem to be a trend towards reduced CFR in 
the target vessel pre-PCI in good collateral group compared to the poor collateral 
group (2.39+/-0.42 vs. 1.61+/-0.16 P=0.07).
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Table 4.5 Micro vascular resistance before and after PCI in patients with poor and
good collaterals. ;|:P<0.05
CFI<0.20 CFI>0.20
IMR ref pre hyp 27.7(24.6-37.6)!l!
11=12
17.8(15.1-29.3) 
n=22 P=0.04
IMR ref post hyp 23.2(18.3-30.8) * 
n=12
16.1(11.3-21.8) 
n=22 />=0.02
IMRuncorrcctcd tar pre 25.8(14.6-41.7)
n=16
24.9(15.5-46.2) 
n=19 P=0.87
IMRuncorrcctcd tar post 18.0(14.7-25.8)
n=16
15.73(12.5-23.7) 
n=19 P=0.26
IMRcorrcctod tar pre 23.47(12.6-28.4)
n=16
14.4(8.2-21.0) 
n=19 P=0.08
IMRcorroctCd tar post 17.2(14.3-25.1)
n=16
14.6(12.3-23.5) 
n=19 P=0.23
IMR in the reference vessel, both before and after PCI, is significantly less in patients 
with good collaterals compared to those with poor collaterals respectively (27.7[24.6- 
37.6] vs. 17.8[15.1-29.3] P=0.04) (23.2[18.3-30.8] vs. 16.1[11.3-21.8] P=0.02) as 
shown in Table 4.5. There is a trend towards lower IMRcon.ected in the good collateral 
group (23.47[12.6-28.4] vs.14.4 [8.2-21.01] P=0.08).
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Table 4.6 Comparison of resting microvascular resistance between poor and good
collateral groups. :i:P<0.05
CFI<0.20 CFI>0.20
IMRrcsting ref pre 86.8 (63.9-111.9) 
n=12
71.1 (41.0-98.4) 
n=22 P=0.15
IMRrcsting ref post 73.7 (28.3-108.0) 
n=12
54.7 (28.3-69.4) 
n=22 P=0.11
IMRunc0iTected resting tar pi’C 48.3 (38.8-89.5) 
n=16
45.0 (22.5-70.5) 
n=19 P=0.26
UVIRuncoerected resting tar post 60.7 (40.6-101.9) 
n=16
41.6 (23.1-83.2) 
n=19P=0.26
IMRcorrected resting tar pi’C 42.2 (29.7-88. l)i!; 
n=16
31.3 (20.0-41.9) 
n=19 jp=0.03
HVIRcorrected resting tar post 60.3 (39.5-100.9) 
n=16
39.4 (21.9-82.1) 
n=19 P=0.23
There appears to be a trend towards a reduction in basal microvascular resistance in 
the good collateral group (CFI>0.2) compared to the poor collateral group (CFI<0.20) 
as shown in Table 4.6. Yet this only statistically significant for IMRCorrected resting in the 
target vessel pre-PCI (42.2[29.7-88.2] vs. 31.3[20.0-41.9] P=0.03).
4.3.7 Procedural factors and microvascular dysfunction
In order to identify factors which may be relevant in patients who develop 
microvascular dysfunction following PCI, we have compared baseline, procedural and 
haemodynamic factors with the degree of change in microvascular resistance.
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Table 4.7 Correlation between procedural factors and outcome of IMR expressed as 
ratio of IMR post/pre-PCI for reference vessel and target vessel corrected for collateral 
flow. *P<0.05
IMR ref post/pre
R n=34 P
IMRconecled tar pOSt/pi'C
R 11=35 P
CFI -0.01 0.96 0.14 0.43
Number of stents 0.16 0.38 0.32 0.06
Number -0.21 -0.25 0.26 0.13
of inflations
Total inflation time -0.13 0.45 0.34* 0.04
Length of stent -0.10 0.57 0.02 0.93
Stent Diameter -0.39* 0.02 -0.16 0.36
Table 4.7 analyses the relationship between procedural factors and the degree of 
change in IMR in response to PCI, there is no relationship between CFI, number of 
inflations and length of stent used. There is a positive correlation between total 
inflation time of the angioplasty balloon and degree of change in IMRConected in the 
target vessel (R= 0.34 and P<0.05) There is a trend towards a correlation between 
number of stents used and degree of change in IMRConecied- We also see a negative 
correlation between the diameter of vessel undergoing PCI and change in reference 
vessel IMR (R= -0.39 P<0.05), suggesting that the greater the diameter of the target 
vessel treated, a greater reduction in IMR is seen in the reference vessel.
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Table 4.8 Baseline characteristics of patients with increase of lMRconected in the target 
vessel following PCI compared with reduction or no change in IMRconecteci. *Mean+/-
SEM
IMRcorrectccl tai*
nochange/reduction
(n=24)
IlVIRcorrected tai’ 
increase
(n=ll)
Age* 60.2+/-1.75 60.45+/-2.53 />=0.94
BMI* 29.6+/-0.96 30.35+/-1.28 jP=0.65
Hypercholesteraemia 95.8% (23) 90.9% (10) P=0.99
Hypertension 70.8% (17) 54.5% (6) P=0.34
Diabetes 25% (6) 18.2% (2) P=0.65
Smoking history in
12 months before PCI
45.8% (11) 45.5% (5) P=0.99
Family history CAD 66.7% (16) 63.6% (7) P=0.86
CCS class I 12.5%(3) 9.1% (1) P=0.49
CCS class II 54.2%(13) 36.4%(4) P=0.49
CCS class III 33.3%(8) 54.5%(6) P=0.49
Aspirin (n) 95.8% (23) 100% (11) P=0.67
Beta-blockers(n) 79.2% (19) 72.8% (8) P=0.67
Ca antagonist(n) 45.8% (11) 63.6% (7) P=0.86
Nitrates(n) 33.3% (8) 36.4% (4) P= 0.33
Nicorandil(n) 29.2% (7) 18.2% (2) P=0.49
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ACE-I (n) 45.8% (11) 45.5% (5) P=0.98
Bare metal stent (n) 50% (12) 45.5% (5) P=0.80
Drug eluting stent (n) 50% (12) 55.5% (6) P=0.80
LDL, mmol/1 * 1.82 (+/-0.12) 2.06 (+/-0.19) P=0.73
There is no difference in baseline characteristics between the patients who developed 
an increase in IMR post-PCI compared with those that had either a reduction or no 
overall change as shown in Figure 4.8.
Table 4.9 Comparison of haemodynamic characteristics of patients with increase of 
IMRconecied in the target vessel following PCI compared with reduction or no change in 
IMRcorrecied. *P<0.05, **P<0.01
IMRcorrected target 
nochange/ reduction 
(n=24)
IlVIRcorrcctcd target
increase
(n=H)
CFR ref pre 1.70+/-0.15 2.54+/-0.58 P=0.07
CFR tar pre 3.08+/-0.35 2.74+/-0.48 P=0.59
FFR tar pre 0.62+/-0.02 0.69+/-0.04 P=0.17
CFI 0.21 (0.15-0.27) 0.21 (0.15-0.37) P=0.74
IMR ref pre 26.2 (17.0-34.1) 23.0(13.4-32.0) P=0.33
HMRuncorrected
tar pre
25.7 (17.0-27.2):!! 12.9 (10.1-28.6) P=0.03
IMEC()rrcctecl 
tar pre
17.3 (13.6-27.2)j!;:1' 8.2 (5.6-13.6) P=0.002
IMRresting ref 
rest pre
83.9 (60.3-103.9) 68.3 (33.5-100.7) P=0.25
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IMRuncorrccted resting
tar pre
47.1 (39.1-58.2) 33.1 (19.3-67.8) P=0.85
IMRC(irrcctcd resting 
tar pre
33.8 (29.1-51.2) 29.1 (15.2-67.7) P=0.79
Periprocedural 
myocardial injury
25% (7) 27.3%(9) P=0.62
CF1, collateral flow index; IMR, Index inicrocirculatory resistance; ref= reference
vessel; tar, target vessel; CFR, coronary flow reserve; FFR, fractional flow reserve.
We find a marked reduction in IMR in the target vessel pre-PCI (both uncorrected and 
corrected respectively) in the group of patients with an increase of IMR when 
compared with either no change or a decrease of IMR (25.7[17.0-27.2] vs. 12.9[10.1- 
28.6] PcO.OS) (17.3[13.6-27.2] vs. 8.2[5.6-13.6] PcO.Ol) respectively. There appears 
to be a trend of impaired CFR in the reference vessel in the group which have no 
change or decrease of IMR although this is just below the level of significance (1.7+/- 
0.15 vs. 2.54+/-0.58 P=0.07).
4.4 Discussion
The results obtained during this study shows the effect of PCI on microvascular 
function immediately following the procedure in stable angina. Our findings are 
consistent with previous data obtained by other studies in the target vessel when 
collateral flow is not taken into account. In addition to this however, we obtained 
novel data on the target vessel corrected MR and the reference vessel which has not, to 
our knowledge, been previously reported.
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We find a heterogenous response in target vessel IMRCo,iecteci- The only procedural 
factor associated with an increase of 1MR is number of inflations. The only 
haemodynamic predictor of increase of IMR in the target vessel is a low pre-PCI 
IMRcon-ected in the target vessel. We also found IMRimcoiTeCied overestimates pre-PCI MR 
significantly, in some cases we found that Pw is nearly as high as Pfi, the greater the Pw 
the greater the overestimation of IMRunco„-ected* We found a reduction in the reference 
vessel microvascular resistance in response to PCI in the target vessel, which is a 
novel finding. IMRcolTected resting increases in the target and goes down in the reference 
vessel following PCI. The underlying mechanisms for microvascular dysfunction in 
target vessel and an apparent improvement in MR in the reference vessel requires 
further investigation.
This is the first study to provide a detailed invasive assessment of the microcirculation 
in both vessels taking into account the role of collateral circulation using the 
thermodilution method. We found a heterogenous response in IMR in the target vessel 
and no overall change when collateral flow is taken into account and a reduction in 
target vessel IMR when collateral flow is ignored. In addition we found a reduction in 
IMR in the reference vessel territory. There is a debate regarding best measurement of 
MR (see chapter 2 page 48). CFR has its limitations due to dependency on basal 
conditions and haemodynamic factors. A few studies have used a Doppler derived 
minimal MRV, yet although this resolves issues with variability in basal flow it does 
not account for collateral flow. As a result significant reductions in MR following PCI
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were found in the early Doppler studies. In our study IMRimc01Tecied is equivalent to 
MRV hyperaemic in Doppler studies. IMRcon-eCteci is the only method of microvascular 
assessment which is not only independent of haemodynamic factors, but also corrects 
for collateral flow.
The microvascular response to PCI measured in terms of actual microvascular 
resistance has only been studied by a small number of investigators. The earlier studies 
used a combination of Doppler catheter to measure coronary artery velocity proximal 
to the stenosis, a pressure wire to measure distal coronary pressure and QCA to 
measure the cross sectional area of the vessel. These studies found a trend in reduction 
in MRV however they failed to reach statistical significance (Sambuceti et aLt 
2001;Marzilli et al., 2002). They may have overestimated the flow in the vessels since 
they measured velocity proximal to the lesion in the pre stenotic segment with the 
Doppler catheter and we know that the velocity distal to lesion can be reduced.
We see a reduction in IMRuncorrected in response to PCI. We may expect to see a 
reduction in the target vessel since pressure is increased and hence flow will increase 
and resistance will be less, however this is only true if the contribution of collateral 
flow is not taken into account. The improvement in IMRuncorrected post-PCI is similar to 
data from Doppler studies which have calculated minimal MR based on distal pressure 
and velocity, and not accounted for collateral flow (Chamuleau et al, 2003;Siebes et 
al, 2004), Verhoeff et al. have confirmed similar findings of a reduction in IMR
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following PCI, to the extent that MRV post-PCI is actually less than MRV in reference 
vessel (Verhoeff et aL, 2005). We see a comparable degree of reduction in 
IMRimcoi,.ecled, overall there was a 40% reduction in IMRlinc01Tected following PCI. We 
also found a correlation between FFR pre and degree of change in IMRunconec(ed R=
0.51 P<0.01, yet there was no similar relationship when reference vessel IMR and 
target vessel IMRcon-ected were compared (reference R=0.27 P=0.14 target corrected R= 
0.23 P=0.J9). This would suggest those subjects with more severe stenosis have more 
reduction in microvascular resistance following PCI if IMRuncorrCcted is used. One 
would assume this was because more severe stenosis will have greater collateralisation 
and hence pre-PCI IMRllllcorJected would be overestimated in those with the more severe 
the stenosis. We tested this by comparing the association between Pw and FFR target 
vessel pre-PCI. We find a significant inverse association between Pw and FFR pre-PCI 
in the target vessel (R= -0.44 PcO.Ol). This finding supports the notion that greater 
degrees of collateralisation are found in patients with greater severity of epicardial 
stenosis. Previous data has shown that coronary artery lesion severity is an 
independent predictor of the degree of collateralisation (Pohl et aL, 2001). There are 
significant differences in interpretation depending on which method is utilised to 
assess IMR particularly when epicardial stenosis is present.
The inclusion of the collateral component of flow is essential in our study population 
since we have a population of haemodynamically significant single vessel disease as 
seen by a mean FFR of 0.61 in our study population. Thus we have included
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IMRCorrecied the main marker of microvascular function in the target vessel. The 
greater collateral contribution the greater the over estimation of MR, therefore in these 
patients pre-PCI IMR will be overestimated, due to this it seems apparent that IMR 
actually decreases post-PCI, but actually when we observe changes in IMRC01TCcteci? we 
see that although the response is heterogenous and IMR goes up as well as down in 
different patients, overall as a group, there is no change in IMR in response to PCI 
(Figure 4.5). Our data are similar to recent findings by Fearon’s group, which also 
found overall no change in IMRcorrecteci following PCI to the LAD in patients with 
stable angina (Ho et al., 2010).
The heterogenous response of IMR following PCI implies differing effects on MR in 
different patients. Of particular interest is the group of patients that have an increase in 
microvascular resistance following PCI, since these are the ones associated with poor 
outcome in previous studies when CFR was used a the measure of microvascular 
function. A third of our study population develop an increase of IMRcomscied. the 
underlying cause of increased IMR post-PCI is still unclear, although there are many 
hypothesis for potential mechanisms. Traditionally one of the key mechanisms 
suggested for periprocedural microvascular injury is that of distal embolisation (DE) 
of plaque and thrombus material following PCI (Kotani et al., 2002). Despite the fact 
that distal protection devices have been shown to eliminate evidence of DE as detected 
by high intensity signals with a Doppler wire (Okamura et al, 2005), there is no 
transferred beneficial effect on microvascular integrity and cardiac events. This raises
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questions as to the role of DE in micro vascular dysfunction in native vessels. In 
addition we see no relationship between peri procedural myocardial necrosis and 
change in IMR (data presented in chapter 5), suggesting that mechanisms separate to 
myocardial necrosis may be responsible for microvascular dysfunction.
From our data so far, we have established the only haemodynamic factor which seems 
to be predictive of increase in IMR in the target vessel is the IMR pre-PCI in the target 
vessel. Very low baseline IMR is associated with an increase of IMR. This may be 
explained by the fact that very low IMR is found in certain patients due to prolonged 
ischaemia, but following successful PCI, to prevent sudden increase in pressure and 
therefore potential microvascular injury, a vasoprotective mechanism could be 
responsible for an increase in IMR. This mechanism could be a myogenic reflex, 
which is vasoconstriction in response to increases in pressure to regulate flow and 
prevent microvascular damage by sudden upsurge in pressure. However, this 
mechanism may appear to be in contrast to findings by Marzilli et al Contrary to 
popular opinion, they found resting microvascular vasoconstriction in response to 
ischaemia rather than vasodilation, this was reversed with adenosine (Marzilli et al., 
2000). It should be noted the study by Marzilli et al. assessed resting MR, we find a 
low hyperaemic MR is associated with an increase in IMR.
The only procedural factor which is associated with upregulation of IMR is the total 
duration of balloon inflation. These findings are similar to this study by Cuisset et al
138
(Cuisset et at, 2008). They found direct stenting had better post-PCI IMR compared 
with predilation and stenting. This would support the original notion that it is the 
repeated cessation and restoration of flow which allows for a greater interaction of 
inflammatory cells with their respective cellular adhesion molecules, and this creates 
conditions in which microvascular dysfunction is promoted. However, it must be 
noted that this could as well be a confounding factor in as much as more difficult 
procedures will need more inflations, and hence greater risk of microvascular injury.
Our data show that the mean FFR increases from 0.6 to 0.91 post-PCI in the target 
vessel. This reflects firstly the haemodynamic significance of lesions in our study; 
FFR less than 0.75 has been accepted as a reliable indicator of haemodynamic 
significance of the lesion and revascularisation should be performed (Pijls et aL, 
2007). Secondly the improvement in FFR to above 0.9 indicates a successful 
procedure in terms of epicardial revascularisation particularly since FFR greater than 
0.9 equates with good medium term outcome (Pijls et al, 2002b). In addition, FFR in 
the reference vessel is 0.95 thereby demonstrating that we have a sample in which the 
reference vessel is haemodynamically normal. We could not always achieve a post- 
PCI FFR >0.9 post-PCI in the target vessel. In these cases a hyperaemic pullback 
measurement of FFR was performed. Suboptimal FFR was due to diffuse coronary 
artery disease in the vessel as seen by a gradual increase in FFR as the pullback was 
performed. The FAME study has recently confirmed the efficacy of using FFR as a 
tool to guide decision making and has shown that death, MI and repeat
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revascularisation are reduced in patients with therapy guided by FFR (Tonino el al, 
2009).
The earlier studies which measured CFR before and after PCI suggested impaired CFR 
was due to a combination of an increase in baseline flow, diffuse atherosclerosis and a 
more generalised microvascular dysfunction, causing reduced CFR. In some patients 
following PCI there was a deterioration in microvascular function, with potentially 
severe consequences, where no obvious underlying cause can be found. It is this subtle 
form of microvascular injury which is of particular interest. Although the limitations 
of CFR are well documented we have included CFR in our analysis since it is a useful 
marker for comparison with earlier studies.
We found that in target vessel there is an overall increase in CFR which would be 
expected, since CFR is a combined measure of epicardial and microvascular resistance 
(see Chapter 2 Figure 2.1). PCI relieves the epicardial stenosis and hence epicardial 
resistance is reduced. Earlier investigators have pointed out abnormal CFR in the 
reference vessel pre-PCI as a marker of a more generalised microvascular dysfunction, 
and if this is the case then the chance of successful microvascular reperfusion and 
normalisation of CFR in the target vessel is less (Kern et al., 1999) However, this 
could also have been due to increase in basal flow due to supply of resting collateral 
flow, therefore resting flow would need to be higher than if no stenosis was present in 
an adjacent vessel.
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It is well established that CFR is dependent on the effect of baseline flow, hyperaemic 
flow and any residual epicardial resistance. In our data both resting and hyperaemic 
flow increase following PCI, yet the degrees of improvement in each (resting and 
hyperaemic) will determine CFR. In the target vessel there is more of an increase in 
hyperaemic flow than in baseline flow following PCI, whereas in the reference vessel 
there is more of increase in basal flow compared with hyperaemic flow, this could 
explain the trend towards reduction in CFR in the reference vessel.
The effect of PCI on CFR in the target vessel has earlier been discussed earlier but 
there is sparse and conflicting data on the effect of PCI on the reference vessel. Zijlstra 
found no change in reference vessel microvascular function post-PCI for single vessel 
CAD, however they only had 12 patients in the reference vessel arm (Zijlstra et al, 
1988). Foley found no change in reference vessel CFR in response to PCI in the target 
vessel but again there were only 10 patients in the study (Foley et al, 1995). A few 
studies have assumed pre-PCI CFR in the reference vessel will be the same as CFR 
post-PCI (Kern et al, 1999), and this assumption was used to measure relative CFR, 
which was a predecessor to FFR as a means of assessing epicardial lesion severity. 
This assumption can lead to inaccuracies since microvascular function in the reference 
vessel can be dynamic following PCI rather than fixed, as we have demonstrated here.
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Another small study showed improvement in CFR in reference vessel following PCI 
when there were visible collaterals, however the increase in CFR was due to a 
reduction in resting flow post-PCI rather than an increase in hyperaemic flow 
(Kyriakides et al, 1998). CFR immediately post-PCI was found to be normal in the 
reference vessel of patients undergoing PCI of a target vessel however they did not 
measure CFR immediately pre-PCI to see how CFR changes with PCI (van Liebergen 
etal, 1998).
These data conflict with our own: firstly we see an increase in resting flow post-PCI in 
the reference vessel, but we also see an increase in hyperaemic flow as well, but the 
increase in resting flow is greater than increase in hyperaemic flow, such that the CFR 
post-PCI in the reference vessel in our study has a downward trend. The most 
interesting haemodynamic finding in this study is the novel reduction in IMR of the 
reference vessel, we observe a 25% reduction of hyperaemic IMR in reference vessel. 
The reduction of IMR in the reference vessel could simply be explained by changes in 
arterial pressure following PCI, however we have ruled this out, since Pd does not 
change in the reference vessel post-PCI. All of the reduction in IMR is due a reduction 
in Tmn, and thus due to an increase in hyperaemic flow. There are sparse data on the 
effect of PCI on the reference vessel, and many of the studies which have investigated 
adjacent vessel bed flow have used CFR as a marker of micro vascular function 
(Zijlstra et ai, 1988;Foley et al, 1995;Kyriakides et al., 1998;Pacella and Villanueva, 
2006). There is only one previous study which has measured IMR in the reference
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vessel following PCI in the target vessel (HOOLE et aL, 2010). The results from this 
small study contradicts our own, they found the reference vessel IMR increased 
following PCI, however most of the reference vessels in this study had 
haemodynamically significant lesions. The investigators did not measure coronary 
wedge pressure, which is will be important for assessment of IMR if significant 
epicardial stenosis is present as IMR will be overestimated as discussed earlier. In 
view of these disparities comparing our findings with their study has to be done with 
caution.
There is further evidence of changes in adjacent vessel haemodynamics as shown by a 
myocardial contrast echo model of induced epicardial stenosis in the LAD of canines. 
This showed presence of a stenosis reduced hyperaemic blood flow and increased 
resting blood flow in the circumflex territory when compared to the same vessel before 
stenosis was created. It was suggested the underlying mechanism may be related to 
recruitment of collateral microvessels allowing diversion of blood supply to the 
stenotic bed (Pacella and Villanueva, 2006). Although our study is in some ways 
reverse version of Pacella’s, we have some similar findings. Since we relieve 
obstruction in one territory and microvascular function improves in the adjacent bed 
and hyperaemic flow improves, whilst they create a stenosis in the LAD causing 
resting flow to increase in the adjacent epicardial vessel and hyperaemic epicardial and 
microvascular flow to reduce in the adjacent vessel bed with an increase in MR in the 
adjacent vessel territory. It must be noted however that the stenosis in this experiment
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was created acutely, however in patients with chronic stenosis there is evidence of 
microvascular remodelling to compensate for chronic low distal pressure, and hence 
distal micro vasculature may behave differently when the stenosis is relieved (Bakker 
et ah, 2002).
There is evidence of impaired coronary flow in patients with single vessel disease in 
an adjacent normal vessel (Sambuceti et al, 1993;Uren et ai, 1994). The underlying 
mechanism responsible for a reduction in hyperaemic and basal IMR in the reference 
vessel may be related to collateral flow from the donor vessel, yet we found no 
relationship between CFI and baseline IMR and degree of change in IMR in the 
reference vessel. If collateral flow is not a significant factor in the reduction of IMR in 
the reference vessel, then it points to another mechanism causing further vasodilation 
of the microcirculation over and above that of adenosine and intracoronary nitrates. It 
seems plausible that either a mechanical pathway is activated which responds to 
increase in stretch in the epicardial vessel with a vasodilatory effect in the reference 
vessel territory, for example a neurally mediated reflex, yet if this was the case we 
would expect an increase in IMR in the reference vessel (Gregorini et«/., 1994), since 
balloon dilation of the target vessel may cause activation of stretch receptors in the 
collateral bed leading to vasoconstriction and hence increase in IMR. When 
intracoronary nitrates are administered and adenosine then there are only a few agents 
which can cause further vasodilation, such as yohimbe, urapadil or phentolamine 
(alpha adrenoreceptors antagonists) (Barbato et al, 2004b). Alpha adrenoreceptors are
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important in maintaining epicardial and microvascular tone, alpha-] adrenoreceptors 
predominate at epicardial level and alpha-2 adrenoreceptors at the microcirculatory 
level. It is well known that PCI can activate both alpha-1 and alpha-2 adrenoreceptors 
causing epicardial and microvascular vasoconstriction (Gregorini et ai, 2002). We 
may expect to see vasoconstriction in the adjacent vessel territory in response to 
stretching the target vessel however we observe the reverse of this. To our knowledge 
the action of adrenoreceptors activity on the reference vessel territory has not been 
investigated. Other possibilities to explain the reduction in IMR in the reference vessel 
include release of vasoactive mediators in the target vessel territory or via changes in 
collateral flow. Our findings regarding the changes seen in the reference vessel are 
worthy of further investigation to understand better the complex interactions between 
microcirculation in adjacent vessel beds.
We found an inverse association between IMRconected in the target vessel pre-PCI and 
CFI (R= -0.36 P<0.05), there was no association between IMR in the reference vessel 
and CFI. Other studies have shown CFR in the target vessel is related to adjacent 
vessel resistance and inversely related to collateral resistance (Billinger et aL, 2001). 
Our data would suggest the greater the CFI the lower the IMR in the target vessel. 
These findings are suggestive of collateral vessels playing an important role in the 
regulation of microvascular function between different vessel beds. Therefore we 
chose to analyse collateral flow by comparing patients with good collaterals vs. poor 
collaterals. We find there is a trend towards a worse CFR pre-PCI in the target vessel
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with high CFI compared with low CFI (1.61+/-0.16 vs. 2.39+/-0.42) respectively, yet 
this is not statistically significant and these are similar findings to the study by 
Billinger et al. This could be explained by greater basal flow supplying the target 
vessel territory in the good collateral group.
We find significantly lower microvascular resistance in the reference vessel pre and 
post-PCI in the high CFI group compared with low CFI. In the target vessel although 
there are trends of reduced IMRCO]iecied and IMRunco,TCcied in the good collateral group, 
this does not reach significance. The lower microvascular resistance in the reference 
vessel may be explained by the need for a pressure gradient from high to low to 
maintain collateral flow from the reference vessel to the target vessel territory in those 
subjects with good collateralisation. The lower IMR in the reference vessel in patients 
with better collaterals is a novel finding, most of the data on collateral function has 
been on patients with CTO (Zimarino et al, 2006;Werner et al, 2006a). The 
physiological response of collateral flow and microvascular function cannot be 
assumed to be the same in patients with complete occlusion of the vessel and those 
with patent anterograde flow. What we see in the good collateral group may reflect a 
microvascular system which is better functioning and more adaptive to acute changes 
in coronary physiology.
We have also assessed the differences in basal microvascular resistance in response to 
PCI, we find that both resting and hyperaemic IMR is reduced following PCI in the
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reference vessel. IMRcolTectedresting increases in the target vessel and there is a 
reduction in IMRul1C01Tecied hyperaemic in the target vessel. Resting IMR may be useful 
since it gives an indication to the basal tone of the microcirculation in response to PCI, 
thus more reflective of the “real-life” clinical scenario. However, resting IMR has the 
same limitations as CFR since both are dependent on basal haemodynamic conditions 
which are variable. There are sparse data on basal microvascular tone in vivo models 
in response to PCI. A non significant increase in basal tone was seen by Sambuceti et 
al. following PCI (Sambuceti et aL, 2001). Verhoeff found no effect of PCI on basal 
microvascular tone (Verhoeff et al., 2005). However once again collateral flow was 
not accounted for, which may explain why they found no change in resting MR. When 
we calculated IMRU]lcolTected resting we see no overall significant change, although there 
is trend towards increase in IMR which is similar to data from Sambuceti. There is a 
large increase in resting IMRcolTected in response to PCI in the target vessel which 
implies a marked increase in basal tone, thereby pointing towards vasoconstriction in 
the microcirculation in the “real life” post-PCI scenario. When adenosine is given, this 
increase in basal tone is reversed. This may explain why adenosine can be a useful 
adjunct in no-reflow in certain patients following PCI (Mahaffey et al., 
1999;Vijayalakshmi etal, 2006). The underlying mechanism responsible for the 
increase in basal resistance post-PCI may be due to autoregulatory microvascular 
control to prevent microvascular damage and if this is the case, may be mediated by 
the myogenic pathway. It is thought that a rise in intraluminal pressure activates 
stretch receptors on the surface of the smooth muscle cell, causing cation influx and
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subsequent depolarisation of the smooth muscle cell activating the voltage gated 
calcium channel (L type), allowing for calcium influx into the cell (Nelson et al., 
1990;Davis et aL, 1992). When we assessed the relationship between change in Pd 
resting post-PCI vs. change in resting IMRCorrected we fail to see any relationship (r= - 
0.26 P=0.13). This finding does not necessarily rule out the myogenic response as a 
mediator, but it is more likely that there are several factors responsible, since the 
regulation of the microcirculation is a delicate balance between several different 
mechanism including, flow mediated dilation, myogenic, metabolic, neurally 
mediated, and as well as physical forces such as left ventricular end diastolic pressure 
and left ventricular wall tension.
4.5 Limitations
We acknowledge there some limitations to our experiment in measuring certain 
haemodynamic indices. We measured wedge pressure for CFI and IMRcorrecjed- It may 
be argued that the wedge pressure will change acutely post-PCI and hence inclusion of 
the first wedge pressure measured pre-PCI to correct for IMR post-PCI is not valid. 
Although this may be true in certain patients with CTO (Zimarino et al, 2006), the 
evidence is equivocal. Perera found no change in CFI at 24 hours in patients with CTO 
(Perera et al., 2007). Our data have shown there is no difference in coronary wedge 
pressure acutely following PCI, which is similar to other studies (Jensen et al., 2007). 
In addition our study group consists of patients with stable angina rather than CTO, we
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would expect more severe changes in collateral flow in CTO purely due to the much 
greater role collaterals play in this group of patients (Werner el al.t 2006b).
The IMR in the distal vessel may be overestimated particularly if the increase in flow 
and pressure causes passive distension of the vessel. Since the thermodilution method 
assumes that the volume between the proximal shaft and distal sensor remain 
unchanged, if volume was to increase then true MR would be less than calculated if 
volume truly remained unchanged. It should also be noted that we may have 
introduced some bias into the data because we were unable to record pre-PCI data in 
the target vessel in three patients with very tight stenosis due to unrecordable transit 
time.
The measurement of IMR is dependent on the distance between the distal sensor in the 
coronary artery and the tip of the guide catheter. If there is a difference in this distance 
between patients, differing values of IMR will be calculated. We were unable to 
ensure that this distance was equal in all patients due to anatomical variations, but we 
did however ensure the wire was as distal as possible in all vessels. This limitation has 
to be taken into consideration when the data is pooled and is particularly problematic 
if we are comparing individual inter-patient differences in IMR, although we have not 
analysed data in this way. However, since the majority of our data is comparing intra­
patient changes in IMR, this limitation has little effect on the overall results.
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CFI was calculated by estimating venous pressure (Pv) to be 5mmHg since we did not 
measure Pv for our study. Although the addition of Pv will provide a more accurate 
CFI for the purpose or our study, it has been shown that CFI can be overestimated if Pv 
is estimated rather than measured and a small percentage of subjects may be 
misclassified (Perera et al., 2004). hi our data the margin of error will be small by 
failing to measure Pv making it unlikely to have a significant impact on the outcome of 
our data. In addition, given that Pv does not change acutely following PCI (de Marchi 
et al., 2005), then failure to assess Pv for the purpose of IMR should make little 
difference, since we are comparing changes in IMR in the same patient and same 
vessel.
Ideally central administration of adenosine is recommended for haemodynamic 
measurements, however in our study group, since we are comparing like for like 
before and after PCI, overall changes will be negligible. In addition there is emerging 
evidence of little difference between central and peripheral administration of 
adenosine (Seo et al, 2010). We did not measure wedge pressure in the reference 
vessel for obvious reasons such as the risk of arterial injury, endothelial dysfunction, 
dissection and development of atheroma in normal vessels. We assume that collateral 
flow is negligible and close to zero, hence in the reference vessel it is justified to use 
the IMR uncorrected equation.
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Ill summary therefore, the results obtained during these studies provided baseline data 
on the natural history of microvascular function in response to PCI which was 
consistent with previous data obtained by other workers in the target vessel when 
collateral flow not taken into account. In addition to this however, we obtained novel 
data on the target vessel corrected MR and reference vessel data which has not, to our 
knowledge, been previously reported.
This is the first study to use IMR as a measure of MR and assess the effect of PCI on 
the microcirculation. We find a heterogenous response in target vessel IMRCo1Tected- The 
only procedural factor associated with upregulation of IMR is the number of inflations. 
The only haemodynamic predictor of upregulation of IMR is a low pre-PCI IMRconeC(ed 
in the target vessel. We found IMRlincorrecled overestimates pre-PCI MR significantly, in 
some cases we found that Pw is nearly as high as Pd, the greater the Pw the greater the 
overestimation of IMRimConecied- The reduction in the reference vessel microvascular 
resistance in response to PCI in the target vessel is a novel finding. The underlying 
mechanisms for microvascular dysfunction in target vessel and an apparent 
improvement in MR in the reference vessel requires further investigation.
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Chapter 5 Inflammation
5.1 Introduction
A large number of studies have identified the crucial role of inflammation in the 
pathogenesis of atherosclerosis from the very earliest detectable phase to the 
development of plaque rupture resulting in acute coronary syndromes (Ross, 
1999b;Libby and Ridker, 2006). Increased levels of various circulating inflammatory 
markers predict an increased risk of vascular events such as Ml, stroke, peripheral 
vascular disease and sudden death in previously healthy populations (Ridker et a!., 
1997;Ridker et ah, 2000a). Patients with ACS have higher levels of baseline CRP 
compared to stable angina (Berk et al, 1990); (Cusack et al., 2002). In addition it was 
noted that increased levels of inflammation in patients diagnosed with acute coronary 
syndrome or acute MI confers a worse prognosis (Liuzzo et al, 1994). Morrow et al 
identified increased CRP as an powerful predictor of early mortality in 541 patients 
with acute coronary syndrome when combined with circulating troponin-T levels, 
moreover CRP remained a strong predictor of mortality independent of troponin-T 
(Morrow et al, 1998). The CAPTURE study identified elevated baseline CRP as a 
strong independent predictor of MI and death six months following PCI (Heeschen et 
al, 2000).
Similarly many studies have shown that increased basal levels of inflammation before 
PCI are associated with a worse outcome. Buffon et al. first described the relationship
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between increased baseJine levels of inflammation and increased early and late 
complications in patients undergoing PCI (Buffon el ai, 1999). They found that 
inflammatory activation is even more a predictor of complications than the clinical 
presentation of unstable angina. A small study of 62 patients undergoing PCI for 
unstable angina found those with normal CRP pre-procedure have excellent 12 month 
prognosis, whereas only 40% of those with raised CRP pre-PCI were event-free at 12 
months (Versaci et ai, 2000). The first large study to evaluate the significance of 
elevated basal inflammation on outcome following PCI was performed by Chew et ai. 
They studied over 700 patients undergoing PCI for stable or unstable angina and found 
those patients in the highest quartile for baseline CRP had over 3.5 fold increase in 30- 
day death or MI compared with those in lowest quartile (Chew et ah, 2001b). A 
similar increase in mortality and MI was detected at 2-year follow up in patients with 
elevated baseline inflammation (de Winter et ai, 2002).
PCI causes trauma to the endothelium of the coronary artery due to balloon inflation 
against the vessel wall, which also causes plaque rupture and triggers immune 
mediated mechanisms which include leukocyte, platelet and endothelial activation 
both locally and systemically (Inoue et ah, 1996;Serrano et ai, 1997). Inflammatory 
activation can be easily detected by a systemic rise in cytokines following PCI (Azar 
et al.t 1997). Higher levels of peak CRP post-infarction in patients with acute MI is 
associated with increased risk of heart failure and death, independent of conventional 
risk factors and independent of left ventricular dysfunction (Suleiman et al, 2006).
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Similar data suggests elevated CRP post-MI is a risk factor for death and heart failure, 
independent of troponin-T rise and traditional risk factors (Bursi et al., 2007). An 
experimental MI study in rats has shown the addition of pure human CRP increases 
infarct size by 40% compared with controls (Griselli et al, 1999). Furthermore the 
increase in infarct size was abolished by complement depletion with the addition of 
cobra venom factor, therefore suggesting a combination of CRP and activation of the 
complement system was responsible for further myocardial necrosis. Grisselli’s study 
suggests the inflammatory response is more detrimental than levels of basal 
inflammation per se. These findings have been reflected clinically in patients 
undergoing PCI; many studies have found an association between adverse prognosis 
and increased inflammatory response following coronary angioplasty (Gottsauner- 
Wolf et al, 2000;Saleh et al, 2005;Gach et al, 2007). Moreover sustained increase in 
inflammation following PCI is associated with worse outcome (Gaspardone et al, 
1998). These observations suggest inflammation is important not only in the 
pathogenesis of atherosclerosis and myocardial infarction but also in predicting 
complications from PCI. The inflammatory response to PCI seems to provide 
additional prognostic information yet the underlying mechanisms are poorly 
understood.
5.2 Justification of use of clinical markers
The markers we decided to use provide a measure of different aspects of the overall 
inflammatory process, endothelial activation, platelet activation and myocardial
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necrosis. CRP is an acute phase protein produced by hepatocytes in response to 
inflammatory cytokines such as IL-6 and IL-1 (Moshage et aL, 1988). CRP is stable 
clinical marker stable with very little fluctuation except in case of acute phase 
response where there can be a massive increase in circulating levels, in fact the 
stability of CRP is similar to blood pressure measurements and LDL levels over time 
(Danesh et al., 2000). It is also the most extensively studied inflammatory marker and 
there is a huge amount of data examining the role of CRP in coronary artery disease. 
IL-6 is a circulating cytokine which is secreted from a number of different cell types 
including lymphocytes and activated macrophages. IL-6 has been shown to be 
produced in the myocardial microcirculation, (Cusack et al, 2002) and is known to be 
a major initiator of the acute phase response by stimulating production of CRP in the 
liver (Heinrich et al., 1990). In addition, IL-6 has been shown to be independent 
predictor of the risk of developing IHD (Biasucci et al, 1996;Harris et al, 1999)
(Rifai etal, 1999). IL-6 is detectable as soon as 15 minutes following an 
inflammatory stimulus, hence it may be a useful marker to assess the extent of 
systemic inflammatory response immediately post-PCI, this is the main reason why it 
was included in this study. We measured markers of endothelial activation by 
measuring soluble ICAM-1 and VCAM-1. Both of these are transmembrane proteins 
from the immunoglobulin gene superfamily. ICAM-1 is expressed on endothelial cells, 
leukocytes and other cells such as smooth muscle cells and fibroblasts. ICAM-1 
promotes leukocyte arrest and adhesion. VCAM-1 is also expressed by many different 
cell types but mainly on endothelial cells and is more specific for endothelial
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activation than ICAM-1 (Ballantyne and Entman, 2002). Soluble ICAM-1 and 
VCAM-1 are accepted as a measures of endothelial activation, as these molecule are 
expressed by activated endothelium and then shed and are detectable in the circulation 
(Mizia-Stec et al, 2002;Wu et al., 2003). The degree of detectable circulating ICAM-1 
is directly correlated with surface expression of ICAM-1 in human umbilical vein 
endothelial cells (Leeuwenberg et ah, 1992), and circulating VCAM-1 correlates well 
with expression of VCAM-1 mRNA in human atherosclerotic lesions (Nakai et ah, 
1995). In patients with established CAD, elevated VCAM-1 is predictive of 
cardiovascular events (Blankenberg et al, 2001) and plasma levels of VCAM-1 are 
associated with degree of atherosclerotic burden (van, I et al, 2002). In view of this 
we chose to include ICAM-1 and V-CAM-1 as markers of endothelial activation 
which can be readily detected and are correlated with their expression on the 
endothelial surface. We chose soluble P-selectin as a marker of platelet activation, 
since it is accepted that the inflammatory response is not confined to leukocyte- 
endothelial interaction but also complex platelet, leukocyte and endothelial interaction. 
sP-seiectin is platelet specific cell surface glycoprotein also know as CD62p. It is 
expressed following an inflammatory stimulus and is found predominantly on the 
platelet surface but is also present on the endothelium (Blann et al., 2003). sP-selectin 
mediates leukocyte rolling and recruitment via sP-selectin glycoprotein ligand-1 found 
on most leukocytes and is also responsible in part for platelet to platelet aggregation 
(Merten and Thiagarajan, 2000). sP-selectin is easy to measure with ELISA and 
peripheral levels reflect intracoronary levels (Jaumdally et al, 2007). We also
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measured serum levels of endothelin-l(ET-l). Although ET-1 is potent 
vasoconstrictor, it is also a modulator of neutrophil and leukocyte function and 
stimulates adhesion molecule expression. Since underlying mechanisms responsible 
for microcirculatory dysfunction may be multifactorial, we have included ET-1 in our 
analysis. Endothelin-1 has been shown to be an important peptide in the regulation of 
coronary macro and microcirculation (MacCarthy et al., 2001). There is evidence that 
ET-1 may be a significant factor in microcirculatory dysfunction following both PCI 
in stable angina and primary PCI (Niccoli et al., 2006;Papadogeorgos et al, 2009). We 
measured expression of neutrophil MAC-1 receptor CD! lb/CD18, which is a beta 2 
integrin and a key component facilitating adhesion of leukocytes to activated 
endothelium. The activation of leukocytes has been implicated in ischaemia 
reperfusion injury and inhibition of the MAC-1 receptor CD1 lb/CD18 has shown a 
reduction in myocardial injury in experimental models (Simpson et al, 1988).
Whilst the inflammatory regulation is thought to be a homogenous phenomenon, the 
inflammatory response is in fact a sequence of interactions between humoral signalling 
molecules, cell surface receptors and endothelial adhesion molecules. We chose to 
measure each of these processes with our choice of inflammatory markers and 
included certain additional ones such as endothelin-1 and sP selectin, which we 
suspect may be important in the mechanism of microvascular dysfunction.
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5.3 Methods
Patients with symptomatic single vessel CAD were prospectively recruited. All 
patients had undergone prior coronary angiography and were symptomatic with 
angina. The protocol was approved by the Liverpool Research Ethics Committee and 
all patients gave written informed consent. Subjects with recent ACS or Ml within the 
previous three months, and with active inflammatory disease were excluded on 
account of potential effects on microvascular function and inflammatory status. 
Multivessel disease, previous transmural myocardial infarct in the territory of the 
vessel to be dilated and chronic total occlusion of the target vessel, previous CABG or 
PCI in target vessel, short left main coronary artery, separate origin of LAD and 
circumflex artery and patients with contraindication to adenosine were all excluded.
All subjects attended the Liverpool Heart and Chest Hospital on the morning of the 
angioplasty and had blood samples taken from a vein in the antecubetal fossa, 30mls 
of blood was collected and placed in tubes with either serum gel or EDTA as 
appropriate. All normal medications were continued and all patients were given 600 
mg aspirin and 600mg clopidogrel at least 12 hours before PCI. Coronary angioplasty 
was carried out in the standard manner and measurements of lMRhyP, IMRres, FFR and 
CFR before and after PCI, as described in Chapter 2. Ail subjects had repeat blood 
samples taken one hour post angioplasty and 24 hours later. Serum blood samples 
were immediately spun down at 3000rpm and transferred into labelled tubes and 
stored at -80°C until analysis. EDTA samples were analysed as described below.
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5.3.1 ELISA
Levels of CRP, IL-6, sICAM-1, sVCAM-1, sP-selectin and ET-1 were measured using 
commercially-available ELISA assay kits (R&D Systems Europe, Ltd. 19 Barton 
Lane, Abingdon Science Park,. Abingdon, 0X14 3NB). Samples were analysed in 
duplicate and the analysis was performed in the research laboratory at the LHCH.
5.3.2 Flow cytometry
Blood samples were collected into tubes containing liquid potassium EDTA (Becton 
Dickinson; 0.25% final concentration), mixed gently and kept at room temperature 
before analysis as described in chapter within 30 minutes, hi separate tubes, 50pl of 
whole blood was added to 5pl of FITC-labelled CD45 and 5pi of pycoerythrin (PE)- 
labelled mouse anti-CD 1 lb or PE labelled mouse immunoglobulin isotype control 
(BD Pharmingen). Cell preparations were incubated for 1 hour with gentle mixing at 
4°C followed by erythrocyte lysis and cell fixation by incubating for 10 minutes at 
room temperatures with equal volumes of optilyse B (Becton Coulter Ltd) followed by 
the addition of 500pl of distilled water and further incubation for 10 minutes at room 
temperature.
All flow cytometric measurements were performed using Becton Dickinson 
FACScalibur, flow cytometer. Day to day alignment and calibration of this instrument
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was achieved with commercial preparations of fluorescent micro-spheres (Coulter 
electronics Ltd, Luton, Bedfordshire, UK).
Leukocyte populations were isolated by CD45 fluorescence and forward and side 
scatter dot plots. The mean fluorescence intensity (MFI) of 10,000 cells was measured 
and compared to that of control cells incubated with matched PE-labelled isotope 
controls.
5.3.3 Statistical analysis
Data was analysed for normality and reported as mean +/- SEM (95% Cl) or median 
and inter-quartile range as appropriate. Comparisons between two groups were made 
with Students paired t-test or Wilcoxon rank test as appropriate. Correlation 
coefficients were calculated using Pearson’s coefficient or Spearman’s Rank as 
appropriate. To obtain normally distributed data IMR was naturally log transformed. 
Multivariate analysis of linear regression was performed using change in IMR as the 
dependent variable. Those variables in the univariate analysis with P<0.25 were 
included in the multivariate linear analysis using backward selection procedure. Data 
analysis was performed using SPSS statistical software version 17.0 (SPSS Inc. 
Chicago Illinois).
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5.4 Results
5.4.1 The effect of PCI on circulating inflammatory markers, adhesion molecules 
and endothelin-1
The next set of data describes the detectable changes in the circulating blood of 
subjects in relation to PCI.
Figure 5.1 Effect of PCI on HsCRP levels pre, 1 hour post and 24 hours post-PCI. 
Mean and SEM displayed in Figure. n=39 **/)<0.01
1 hour post 24 hour post
Figure 5.1 shows that there was no significant difference in HsCRP levels 1 hour post- 
PCI when compared with pre-PCI levels (2.47+/-0.34 mg/1 vs. 2.36+/-0.3 mg/1 
P=0.14). There is a significant increase in HsCRP 24 hours post-PCI compared with 
pre-PCI levels (2.47-I-/-0.34 mg/1 vs. 2.86+/-0.28 mg/1 PcO.Ol), and also an increase
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in HsCRP between 1 hour post and 24 hour post levels (2.36+/-0.33 mg/1 vs. 2.86+/- 
0.28 mg/1 P<0.01).
Figure 5.2 Effect of PCI on IL-6 levels pre, 1 hour post and 24 hours post-PCI. Mean 
and SEM displayed in Figure. n=39 ***/><0.001
1 hour post 24 hours post
Figure 5.2 demonstrates a significant increase in systemic IL-6 levels one hour post- 
PCI (5.35+/-0.72 pg/ml vs. 9.36+/-0.99 pg/ml PcO.OOl), and 24 hours post-PCI 
(5.35+/-0.72 pg/ml vs. 10.71+/-1.26 pg/ml F><0.001), when compared with pre levels 
There was no significant difference between l hour post and 24 hours post levels of 
IL-6 (9.36+/-0.72 pg/ml vs. 10.71+/-L26 pg/ml P=0.63).
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Figure 5.3 Effect of PCI on soluble ICAM-1 levels pre. 1 hour post and 24 hours post- 
PCI. Mean and SEM displayed in Figure. n=39 **P<0.01
Cp 150-
1 hour post 24 hour post
Figure 5.3 shows that we observed no significant change in soluble ICAM-l l hour 
post-PCI (236.8+/-13.1 ng/ml vs. 222.9+/-9.9 ng/ml P- 0.06). There was a small 
increase in soluble ICAM-l between l hour post and 24 hour post samples (222.9+/- 
9.9 ng/ml vs. 240.3+/-12.3 ng/ml PcO.Ol). However overall between the pre and 24 
post levels of soluble ICAM-l there was no significant difference (236+/-13.12 ng/ml 
vs. 240.3+/-12.3 ng/ml P=0.17).
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Figure 5.4 Effect of PCI on soluble VCAM-1 levels pre, I hour post and 24 hours 
post-PCI. Mean and SEM displayed in Figure. n=39 **,P<O.OI H"i:ii:/><0.001
900-
800-
700-
600-
500-
400-
100-
1 hour post 24 hour post
Figure 5.4 demonstrates an increase in soluble VCAM-1 1 hour post-PCI (782.5+/- 
39.6 ng/ml vs. 889.4+/-42.2 ng/ml PcO.OOl), there was no significant difference 
between 1 hour post and 24 hour post levels of VCAM-1 (889.4+7-42.2 ng/ml vs. 
864.4+/-47.1 ng/ml P=0.44). The increase in VCAM-1 between pre and 24 post-PCI 
levels remains significant (782.5+7-39.6 ng/ml vs. 864.4+/^17.l ng/ml /^O.Ol).
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Figure 5.5 Effect of PCI on soluble P-selectin levels pre, I hour post and 24 hours 
post-PCI. Mean and SEM displayed in Figure. n=39 *5|'"i:/5<0.001
ns
C 50-
0 30-
1 hour post
Figure 5.5 shows that we observed a decreased in soluble P-selectin 1 hour post-PCI 
(78.3+7-4.3 ng/ml vs. 62.7+7-3.6 ng/ml PcO.OOl). There was an increase in soluble P- 
selectin between 1 hour post and 24 hour post-PCI (62.7+7-3.6 ng/ml vs. 81.9+/-4.9 
ng/ml PcO.OOl), however overall between pre and 24 hour post levels there was no 
significant difference (78.3+7-4.3 pg/ml vs. 81.9+7-4.9 ng/ml P=0.17).
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Figure 5.6 Effect of PCI on endothelin-1 levels pre. 1 hour post and 24 hours post- 
PCI. Mean and SEM displayed in Figure. n=39 *P<0.05 **P<0.01
4 0-
1.5-
0.5-
1 hour post 24 hour post
Figure 5.6 demonstrates an increase in endothelin-1 hour post-PCI (3.49+/-0.11 pg/ml 
vs. 3.78+/-0.08 pg/ml P<0.01). There was a mild reduction in endothelin-1 levels 
between 1 hour post and 24 hour post-PCI (3.78-I-/-0.08 pg/ml vs. 3.48 +/-0.11 pg/ml 
P<0.05) however overall between pre and 24 hour post levels there was no significant 
difference (3.49+/-0.11 pg/ml vs. 3.48+/-0.11 pg/ml P=0.97).
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Figure 5.7 Effect of PCI on neutrophil MAC-1 receptor CD1 lb/CD18 expression pre, 
1 hour post and 24 hours post-PCI. Mean and SEM displayed in Figure. n=34 
**P<0.01
300n
250-
200-
150-
100-
1 hour post 24 hour post
We observed a reduction in MFI in neutrophil MAC-1 receptor CD1 lb/CD18 1 hour 
post-PCI (307.6+/-31.7 vs. 237.9+/-32.1 P<0.01), there was no difference between 
the 1 hour post and 24 hour post sample (237.9+/-32.1 vs. 265.7 +/-24.4 P=0.17) as 
shown in Figure 5.7. Of note however, there is no significant difference between pre 
and 24 hour post levels although there is a trend towards a reduction (307.6+/-31.7 vs 
265.7 +/-24.4 P=0.14).
In summary we have shown that there is a varied response to different inflammatory 
markers and mediators following PCI in stable angina patients. We see an increase in 
CRP, IL-6 and sVCAM-1 post-PCI, although this is most marked in IL-6. Overall at
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24 hours there was no change in endothelin-1 and ICAM-1 and early reduction in sP- 
selectin and neutrophil MAC-1 receptor CD1 lb/CD18 which returns to pre-PCI levels 
at 24 hours.
5.4.2 Baseline inflammatory markers vs. pre PCI markers of microvascular 
function.
Given that we have demonstrated certain changes in inflammatory markers in our 
patient group, we analysed the relationship between inflammatory state and coronary 
microcirculatory dysfunction. This was performed by correlating basal levels of 
inflammation with markers of microcirculatory dysfunction pre-PCI.
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Table 5.1 Relationship between baseline inflammatory markers and pre-PCI CFR in
reference and target vessel. Pearson’s correlation coefficient
Pre-PCI Reference
R (n=37) P
Target
R (n=35) P
HsCRP 0.25 0.12 -0.18 0.31
IL-6 0.15 0.36 -0.05 0.78
ICAM-1 0.03 0.86 0.11 0.53
VCAM-1 0.28 0.09 0.05 0.77
ET-1 -0.01 0.93 -0.13 0.44
sP-selectin -0.24 0.15 0.19 0.29
Reference Target
otn1!3 P R (n=28) P
CDllb/CD18 0.08 0.66 0.01 0.99
We see no relationship between baseline CFR and baseline inflammatory markers in 
both the reference and target vessels pre-PCI.
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Table 5.2 Relationship between baseline inflammatory markers and pre-PCI IMR in 
the reference and target vessels. Spearman’s rank coefficient
Pre PCI IMR Reference
R (n=37) P
IMRcorrc(;tcdTarget 
R (n=35) P
HsCRP -0.42 0.80 0.18 0.29
IL-6 -0.03 0.87 0.06 0.72
ICAM-1 -0.01 0.41 -0.18 0.29
VCAM-1 0.03 0.88 -0.14 0.94
ET-1 0.17 0.31 0.32 0.07
sP-selectin 0.23 0.16 -0.02 0.92
IMR Reference IMRCOn‘CCtet| T arget
R (n=30) P R (n=28) P
CDllb/CD18 0.13 0.50 -0.07 0.71
There is no relationship between baseline inflammatory markers, adhesion molecules 
and endothelin-1 and pre-PCI microvascular resistance in either the target or reference 
vessel as shown in Table 5.2.
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5.4.3 Basal inflammation vs. change in microvascular function following PCI as 
assessed by IMR and CFR.
We have assessed the relationship between basal levels of inflammation on the effect 
of PCI on microvascular function by correlating change in IMR and CFR against basal 
markers of inflammation, endothelial activation and platelet activation. Many of the 
earlier clinical studies suggest there may be an association between higher levels of 
basal inflammation and worse outcome following PCI (Buffon etal, 1999;Saadeddin 
et at., 2002;Iijima et aL, 2009), in addition this analysis is central to the main 
hypothesis of increased levels of basal inflammation predicting outcome of 
microvascular function.
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Table 5.3 Relationship between baseline inflammatory markers and change in CFR 
expressed as CFRpost/CFRpre-PCL Pearson’s correlation coefficient. *P<0.05
Pre-PCI CFR Reference 
Post/pre PCI
R (n=34) P
CFR Target 
Post/pre PCI
R (n=35) P
HsCRP -0.04 0.81 -0.09 0.62
IL-6 0.01 0.97 -0.12 0.51
ICAM-1 -0.08 0.64 -0.23 0.18
VC AM-1 0.35 0.05 -0.17 0.33
ET-1 0.34 0.05 -0.02 0.93
sP-selectin 0.29 0.09 0.06 0.73
Reference
R (n=29) P
Target
R (n=28) P
CDllb/CD18 0.08 0.61 -0.24 0.25
There are no associations between baseline inflammatory markers and change in CFR 
in the reference vessel.
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Table 5.4 Relationship between baseline inflammatory markers and change in IMR 
expressed as IMR post/IMR pre-PCI. Spearman’s rank coefficient. ^PcO.OS
Pre-PCI IMR Reference 
Post/Pre PCI
R (n =34) P
IMRcon.cctCd Target 
Post/Pre PCI
R (n=35) P
HsCRP 0.18 0.32 -021 0.11
IL-6 0.02 0.89 -0.10 0.58
ICAM-1 0.35 0.05 0.24 0.16
VCAM-1 -0.06 0.74 0.18 0.32
ET-1 -0.20 0.25 -0.23 0.19
sP-selectin -0.06 0.72 -0.15 0.37
IMR Reference 
Post/Pre PCI
R (n= 29) P
IMRconectcd Target 
Post/Pre PCI
R (n=28) P
CDllb/CD18 -0.32 0.09 0.17 0.40
There is no relationship between basal inflammatory markers and change in IMR in 
either vessel as shown in Table 5.4.
5.4.4 Comparison between the ratio of inflammatory response at 1 hour vs. 
change in microvascular function post/pre PCI
While there was little correlation between baseline levels of inflammatory markers and 
the change in IMR or CFR, given the evidence that the extent of the inflammatory
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response may be important we looked at the magnitude of the response expressed as 
the ratio between pre and post levels (Saleh et al, 2005;Gach et al., 2007).
Table 5.5 Relationship between change in inflammatory markers at 1 hour post-PCI 
expressed as inflammatory marker 1 hour post-PCI/pre-PCI levels and change in CFR 
expressed as CFRpost/CFRpre-PCI. Pearson’s correlation coefficient
Pre-PCI CFR Reference 
Post/pre PCI
R (n=34) P
CFR Target 
Post/pre PCI
R (n=35) P
HsCRP 0.05 0.80 0.01 0.96
IL-6 -0.27 0.12 -0.22 0.21
ICAM-1 0.20 0.25 0.30 0.08
VC AM-1 0.17 0.35 0.21 0.22
ET-1 -0.16 0.38 -0.07 0.70
sP-selectin -0.03 0.85 0.25 0.14
Reference Target
R (n=29) P R (n=28) P
CDllb/CD18 0.15 0.43 -0.08 0.68
There is no association between change in inflammatory markers at 1 hour and change 
in CFR in both vessels in response to PCI as shown in Table 5.5.
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Table 5.6 Relationship between change in inflammatory markers at 1 hour compared 
with pre-PCI levels expressed as inflammatory marker at 1 hour/inflammatory marker 
pre and change in IMR expressed as IMR post/IMR pre-PCI. Spearman’s rank 
coefficient. H:P<0.05
1 hour Post/pre IMR Reference 
Post/pre PCI
R (n =34) P
IMRCOrrected Target 
Post/pre PCI
R (n=35) P
HsCRP -0.16 0.36 -0.16 0.36
IL-6 -0.04 0.81 0.06 0.73
ICAM-1 -0.34 0.05 -0.31 0.07
VCAM-1 0.21 0.24 -0.17 0.33
ET-1 0.14 0.43 0.09 0.62
sP-selectin -0.22 0.22 0.14 0.42
IMR Reference 
Post/pre PCI
R (n =29) P
IMRcoircctcd Target 
Post/pre PCI
R (n=28) P
CDllb/CD18 -0.11 0.56 -0.26 0.18
There is no relationship between change in inflammatory markers at 1 hour post-PCI 
and change in IMR as shown in Table 5.6.
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5.4.5 Comparison between the ratio of inflammatory response at 24 hours vs.
change in micro vascular function post/pre PCI
Table 5.7 Relationship between change in inflammatory markers at 24 hour post-PCI 
expressed as inflammatory marker 24 hours post-PCI/pre-PCI levels and change in 
CFR expressed as CFRpost/CFRpre-PCL Pearson’s correlation coefficient.
1 hour
Post/Pre
CFR Reference 
Post/pre PCI
R (n=34) P
CFR Target
Post/pre PCI
R (n=35) P
HsCRP -0.03 0.89 -0.04 0.84
IL-6 -0.27 0.13 -0.16 0.35
ICAM-1 0.02 0.90 0.16 0.36
VCAM-1 -0.01 0.97 0.02 0.89
ET-1 -0.13 0.49 -0.1 0.58
SP-selectin 0.17 0.34 0.22 0.20
CFR Reference 
Post/pre PCI
R (n=29) P
CFR Target
Post/pre PCI
R (n=28) P
CDllb -0.03 0.88 -0.10 0.62
There is no relationship between modification of CFR and modification of 
inflammation following PCI as shown in Table 5.7.
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Table 5.8 Relationship between change in inflammatory markers at 24 hour compared 
with pre-PCI levels expressed as inflammatory marker at 24 hours/inflammatory 
marker pre-PCI vs. degree of change in 1MR expressed as IMR post/IMR pre-PCI. 
Spearman’s rank coefficient. * Pc 0.05
24 hour post/pre 
PCI
IMR Reference 
Post/pre PCI
R (n =34) P
IMRcorrccted Tui get 
Post/pre PCI
R (n=35) P
HsCRP -0.22 0.22 0.42* 0.01
IL-6 0.19 0.29 0.18 0.32
ICAM-1 -0.17 0.34 -0.09 0.61
VCAM-1 0.17 0.33 -0.01 0.96
ET 1 0.24 0.16 0.34* 0.04
sP-selectin -0.04 0.81 0.21 0.22
IMR Reference 
Post/pre PCI
R (n =29) P
HVIRcorrected TiirgCt
Post/pre PCI
R (n=28) P
CDllb/CD18 0.28 0.25 0.19 0.33
There is a positive association between both change in CRP and change in ET-1 at 24 
hours and change in IMR, (R=0.42 P<0.05, R=0.34 P<0.05) respectively. There is no 
association between any of the other markers.
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In summary we see no association between basal levels of inflammation and pre-PCI 
microvascular function as assessed by both CFR and IMR. There is also no association 
between basal inflammation and response to microvascular function following PCI in 
the target vessel. We do however see association between the degree of change in CRP 
at 24 hours and change in IMR. We also see similar association between change in 
ET-1 and change in IMR.
5.4.6 Comparison between of inflammation and resting microvascular resistance
While there is a correlation between the magnitude of inflammatory change and 
minimal microvascular resistance, given there is evidence that inflammation can affect 
basal microvascular tone (Fichtlscherer et al, 2004). We assessed the relationship 
between inflammatory markers and resting IMR, which is a reflection of basal 
microvascular tone.
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Table 5.9 Relationship between baseline inflammatory markers and pre-PCI resting 
IMR in the reference and target vessels. Spearmans rank coefficient.
Pre-PCI IMRvcsting Reference
R (11=37) P
IMRresthlg corrected
Target
R (n=35) P
HsCRP 0.25 0.16 -0.01 0.94
IL-6 -0.09 0.60 0.11 0.53
ICAM-I -0.12 0.50 -0.02 0.91
VCAM-1 0.25 0.15 0.21 0.22
ET-1 0.23 0.20 0.23 0.19
sP-selectin 0.13 0.43 0.02 0.92
Baseline IMRresting Reference IMRresting corrected 
Target
R (n=30) P R (n=28) P
CDllb/CD18 0.16 0.42 0.02 0.93
There is no relationship between baseline inflammatory markers and basal levels of 
microvascular resistance in either the target or reference vessel as shown in Table 5.9.
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Table 5.10 Relationship between baseline inflammatory markers and change in resting 
IMR post-PCI in reference and target vessels. Spearman’s rank coefficient. *P<0.05
Pre-PCI IMRrcsting Reference 
Post/pre
R (n=34) P
IMRrcsting corrected 
Post/pre Target
R (n=35) P
HsCRP 0.03 0.88 -0.12 0.48
IL-6 0.20 0.27 -0.07 0.69
ICAM-1 0.13 0.48 -0.04 0.84
VC AM-1 0.34 0.05 -0.11 0.55
ET-1 0.17 0.32 -0.24 0.18
sP-selectin 0.20 0.25 0.08 0.63
IMRrestjng
Post/pre Reference 
R (n=29) P
IMRrcsting corrected 
Post/pre Target
R (n=28) P
CDllb/CD18 -0.13 0.52 0.016 0.95
There is no relationship between baseline inflammatory markers and degree of change 
in microvascular function in both vessels.
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Table 5.11 Relationship between change in inflammatory markers at 24 hours and 
change in resting IMR in reference and target vessels following PCI. Spearman’s rank 
coefficient. ;|:P<0.05
24 hours 
Post/pre
IMRresting
Post/pre Reference
R (n=34) P
IMRresting corrected
Post/pre Target 
R (n=35) P
HsCRP -0.20 0.24 0.14 0.44
IL-6 -0.22 0.21 0.13 0.46
ICAM-1 -0.06 0.73 -0.17 0.33
VCAM-1 0.07 0.69 0.04 0.80
ET-1 0.11 0.54 0.07 0.67
sP-selectin 0.15 0.40 0.39'S: 0.02
IMRrcsti„g
Post/pre reference
R (n=29) P
IMRresting correctec
Post/pre Target 
R (n=28) P
CDllb/CD18 0.19 0.33 0.03 0.90
There is a positive association between the activation of sP-selectin and change in 
IMR resting in the target vessel (R=0.39 and P<0.05) as shown in Table 5.11.
5.4.6 Periprocedural myocardial injury
11 out of 39 patients developed periprocedural myocardial injury,classified as 
troponin-T>0.04pg/l. All the patients in the study had troponin-T<0.01 pg/1 pre-PCI.
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We analysed the relationship between baseline inflammatory markers and procedural 
factors to identify factors associated with peri-procedural myocardial injury.
Table 5.12 Relationship between inflammatory markers and procedural factors vs. 
troponin-T post-PCI as dependent variable. Spearman’s rank :!'P<0.05 **P<0.0\
***P<0.001
R n
CRP pre -0.14 39
IL-6 pre -0.04 39
ICAM-1 pre 0.017 39
VCAM-1 pre 0.43** 39
ET-1 pre -0.25 39
sP-selectin pre -0.11 39
Neutrophil -0.07 34
CDllb/CD18 pre
CRP 24/pre 0.22 39
IL-6 24/pre 0.14 39
ICAM-1 24/pre -0.08 39
VCAM-1 24/pre 0.03 39
ET-1 24/pre 0.36* 39
sP-selectin 24/pre -0.01 39
LDL pre 0.23 39
Inflation time 0.50*** 39
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FFR pre -0.09 35
IMRcorrccte(] target 
pre
-0.28 35
I-MRcorrccted target 
post
0.014 35
IMRcorrccteti
pre/post ratio
0.33 35
There is a relationship between VCAM-1 levels pre-PCI elevation of troponin-T post- 
PCI (R=0.43 P<0.01), and between degree of change of ET-1 and elevation of 
troponin-T. There is also a relationship between the total inflation time of the balloon 
during the angioplasty and troponin-T post-PCI (R=0.5 RcO.OOl).
5.4.7 Linear regression model to assess the relationship between change in IMR 
and independent variables
Since we are interested in factors which may account for microvascular disturbance 
following PCI, we performed multivariate linear regression analysis to determine 
which factors are associated with deterioration in microvascular function. We naturally 
log transformed non-normally distributed data and performed univariate linear 
regression analysis to determine which variables to include in the multivariate linear 
regression model. This model was then used determine which combination of 
explanatory variables related to the outcome variable IMR. Change in IMR pre/post-
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PCI is the dependent variable. If P<0.25 in the univariate analysis then these variables 
were retained for inclusion in the multivariate model.
Table 5.13 Univariate regression between log IMR (dependent) post/pre ratio vs.
independent variables in table. *P<0.05 ^PcO.Ol ^"^PcO.OOl
Age R= -0.19 P= 0.28 n=35
BMI R= -0.07 P=0.69 n=35
LDL R= 0.35 P=0.06 n=35
CRP pre R= -0.26 P~0.13 n=35
IL-6 pre R= -0.16 P=036 n=35
ICAM-1 pre R= 0.15 P=0.38 n=35
VCAM-1 pre R=0.09 P=0.62 n=35
ET-1 pre R= -0.22 P=0.21 n=35
sP-selectin pre R= -0.04 P=0.81 n=35
CDllb/CD18 
neutrophil pre
R=0.21 P=0.28 n=28
Duration of 
balloon inflation
R=0.25 P=0.15 n=35
FFR Target pre R=0.06 P=0.75 n=35
CFR Target pre R=0.15 P=0.40 n=35
IMR Reference 
log pre
R= -0.28 P=0.10 n=35
IMR Target
Log pre
R= P<0.001 n=35
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CFI R= 0.33 P=0.05 n=35
In the univariate analysis we find that log 1MR target vessel pre-PCI is the only 
variable pre-PCI which is associated with change in IMR as shown in Table 5.13.
Figure 5.8 Relationship between log lMRconected target vessel pre-PCI vs. log change 
IMRcorrected target vessel
= 0.53
y=2.35-0.81 x
Log IMRcorrected
Figure 5.8 demonstrates association between log IMR target vessel pre-PCI vs. 
the degree of change in IMR post-PCI. Univariate linear regression analysis 
shows a close relationship between the two variables. R=0.73 R2 =0.53 y=2.35- 
0.8lx PcO.OOl.
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We proceeded to input all the pre-PCI variables with a p<0.25 into a multivariate 
linear regression model. We put the following independent variables into the model; 
CFT, log IMR reference pre, log IMRconecied target pre, duration of balloon inflation, 
ET-1 pre, CRP pre and LDL. The dependent variable was log IMRConected post/pre 
ratio. In the multivariate model, log IMRcorrecteci pre was the only variable associated 
with log change IMRC01Tecied post/pre ratio. y=2.4-0.85x (R2 = 0.55 PcO.OO 1).
5.5 Discussion
Pre procedural increased inflammatory state in patients undergoing PCI has generated 
a lot of interest in view of data suggesting an increased risk of restenosis following 
PCI in subjects with higher levels of basal inflammation. There is a strong association 
between increased pre-procedural inflammation and death and recurrent ischaemia in 
patients undergoing PCI. This relationship is independent of the incidence of 
restenosis (Zairis et al., 2002;Dibra et al, 2003), hence suggesting an alternative 
mechanism to restenosis affecting the adverse outcome. In addition, the acute 
inflammatory response (i.e. the change in the level of circulating inflammatory 
markers) triggered by PCI is related to adverse outcomes after PCI (Buffon et al., 
1999;Walter et al, 2001). Whilst there is an association between increased 
inflammatory response to PCI and the incidence of restenosis, this alone does not 
explain the increase in mortality and adverse events in this group of patients. The 
focus of interventional cardiologists has remained on epicardial vessel patency and 
there has been little research performed on the effect of inflammation on
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microvascular function. This is the first study to investigate the association between 
inflammation and microvascular function in response to PCI with IMR.
We see a modest increase in CRP 24 hours post-PCI. There have been inconsistencies 
in previous studies, it seemed that in some patients there was increase in CRP post- 
PCI whereas in others there was little or no change, and the inflammatory response 
was seen in those whom had an already increased baseline levels of inflammation 
(Liuzzo et al, 1998). Azar et al. demonstrated an increase in CRP in patients 
undergoing both PCI and coronary angiography but was more marked in PCI patients 
(Azar et al, 1997). There were discordant findings from a small study which showed 
greater increase in CRP in patients with stable angina compared with unstable angina, 
which the authors suggested may be due to plaque disruption in stable patients, despite 
the unstable angina group having greater CRP to begin with (Almagor et al., 2003).
Our patient group consisted solely of stable angina patients, and we saw a modest 
increase in CRP at 24 hours. Our rise in CRP is more in keeping with findings by 
Gautsenner-Wolf et aL, who demonstrated a 20-30% increase in CRP at 24 hours post- 
PCI (Gottsauner-Wolf et al, 2000). A more marked inflammatory response is seen in 
patients with unstable angina (Tomoda and Aoki, 2001).
Our data show a marked early inflammatory rise in IL-6, which is similar to other 
studies. IL-6 begins to increase 15 minutes post inflammatory stimulus such as PCI,
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and peaks at 2-3 hours (van Deventer et a},, 1990;Aggarwal et al., 2003). In our study 
we do not see an overall change in ICAM-1 following PCI, and there is a very small 
increase in VCAM-1 post-PCI. Our data are similar to findings in a number of studies 
which failed to detect a rise in ICAM following PCI (Kurz et al, 1994); (Ferns et al, 
2000;Mulvihill et al, 2001). There is conflicting evidence on the effect of PCI on 
circulating ICAM-1. Some studies have suggested a rise in ICAM-1, particularly when 
sampled from the coronary sinus (Siminiak et al, 1997), but there is conflicting data. 
Others have demonstrated no difference between coronary sinus and peripheral blood 
sampling when measuring ICAM-1 (Mulvihill et al, 2001). The ARMYDA-CAM 
study did demonstrate an increase in ICAM-1 levels post-PCI, this inflammatory 
response was attenuated by pre treatment with atorvastatin 40mg daily for one week 
prior to PCI (Patti et al, 2006). It should be noted that the ARYMDA-CAM study did 
have patients with more complex lesions including total chronic occlusions and multi- 
vessel disease which may explain a more marked inflammatory response, since 
complex anatomy is often associated with more complex procedures and a greater 
degree of instrumentation, and longer segments of disease requiring stenting, all of 
which can increase the inflammatory response further. In our data we find inflation 
time is associated with periprocedural myocardial injury, supporting the notion 
increased instrumentation may cause increased secondary inflammatory response to 
myocardial necrosis.
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We find no overall difference in circulating endothelin-1 following PCI. There are few 
data on the effect of PCI on circulating endothelin levels. Increased levels of 
endothelin-1 are associated with no-reflow in acute MI (Niccoli et alf 2006). Blockade 
of endothelin, with both selective and non selective antagonists improves 
microvascular function in diabetics following PCI (Papadogeorgos et ol, 2009). In our 
study the lack of a rise in ET-1 post-PCI may not be surprising since endothelin-1 is 
preferentially secreted towards vascular smooth muscle cells rather than the lumen and 
seems to have more of a paracrine effect (Yoshimoto et al, 1991).
There are conflicting reports of the effect of PCI on sP-selectin levels. Inoue et al 
found an increase in sP-selectin following PCI in samples from the coronary sinus 
(Inoue et al, 1999). There are a number of later studies suggesting no difference 
between coronary sinus sampling and peripheral blood sampling (Mulvihill et al, 
2001;Jaumdally et al, 2007). Although the same investigators also found conflicting 
results on the effect of PCI on sP-selectin levels; Jaumdally et al found an increase 
post-PCI whereas Mulvihill et al found an acute reduction followed by an increase 
back to baseline levels at 24 hours. More recently an acute reduction in sP-selectin 
following PCI, which lasts for up to a week was seen in patients with stable angina 
(Munk et al, 2011). In our study, we initially see an acute reduction in sP-selectin 
followed by an increase at 24 hours, back to pre-PCI levels. The ARM YD A 2 
substudy attributed high dose (600mg) clopidogrel to reduction in sP-selectin post- 
PCI. This could explain our findings since all our patients were given 600mg
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clopidogrel loading pre procedure instead of 300mg. In addition the administration of 
adenosine and heparin may have a significant effect upon sP-selectin. Unfractionated 
heparin increases activity of sP-selectin (Harding et a}., 2006). However, we see a 
reduction in sP-selectin immediately post-PCI. The use of adenosine may be an 
additional reason that we see an acute reduction of sP-selectin at one hour.
Endogenous adenosine is known to reduce expression of P-selectin (Kitakaze el aL, 
1991). Clearly there remains conflicting data on the effect of PCI on sP-selectin levels. 
It may be that circulating sP-selectin attaches to the activated endothelium in the 
myocardium, thus reducing the detectable amount in peripheral blood. The use of high 
dose clopidogrel and adenosine are important factors in our study.
We find an acute downregulation of the neutrophil MAC-1 receptor CD1 lb/CD18 
expression 1 hour post-PCI, with a subsequent rise at 24 hours. Initial data on 
activation of neutrophil MAC-1 receptor shows PCI increases CD1 lb/CD18 
expression, as demonstrated by early studies in which expression of CD1 lb/CD18 
increased 15 minutes following coronary angioplasty (Inoue et aL, 1996;Serrano et aL, 
1997). It is interesting that we see a down regulation in CD1 lb/CD18 post-PCI, our 
study only the second study recently to demonstrate these findings. More recently 
there has been evidence of early deactivation and down regulation CD1 lb/CD18 
(Tiong et aL, 8 A.D.), which is similar to our data. The authors suggested modern 
adjunctive pharmacotherapy may be responsible for the attenuated inflammatory 
response. These unusual data may be due to the fact that most of the earlier studies
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were performed before the current drug therapy regimes for PCI as discussed above. 
Also there has been a significant improvement in stent technology. We may be 
detecting the combined benefits of these advances related to PCI in these patients. 
However, a down regulation would suggest that CD1 lb/CD18 is deactivated. It is 
much easier to understand a lack of increase in CD1 Ib/CDl 8 but a deactivation would 
suggest that some of the interventions currently used have the reverse effect.
In summary the dampened inflammatory response may be due to a number of factors, 
firstly all of our patients had stable angina and therefore a degree of plaque stability 
and less disruption of plaque during the procedure as well as less pro-inflammatory 
factors released from the plaque itself during the procedure. Secondly we have not 
controlled for all the baseline characteristics which may have an effect on the 
inflammatory response. Thirdly in the contemporary age of PCI, many additional 
drugs are used which are now considered routine for the procedure, such as the loading 
of dual anti-platelet therapy, and drugs used for primary or secondary prevention, such 
as high dose statins and ACE-inhibitors. Statins attenuate inflammatory response and 
reduce adverse events such as myocardial infarction and procedure related 
complications in patients undergoing revascularisation (Briguori et al, 2004;Pasceri et 
al, 2004;Radaelli et al, 2007). The JUPITER study recently demonstrated the 
addition of a statin to patients with elevated CRP but normal LDL reduced 
cardiovascular events (Ridker et al, 2008). There is now evidence that clopidogrel 
also attenuates inflammatory response to PCI (Vivekananthan et al, 2004). In our
191
study all the patients were pre-treated with dual anti-platelet therapy as is now the 
norm. High dose clopidogrel has been shown to further attenuate inflammatory 
response (Klinkhardt et aL, 2002;Patti et aL, 2011). In addition 94.9% of patients were 
established on a statin and 46% were taking an ACE-I and an additional 10% were on 
angiotensin II receptor blocker. The high percentage of patients treated with stains and 
ACE-I in our group may account for the attenuated response in inflammation 
following PCI compared with other studies.
We fail to see an association between pre-PCI IMR and basal inflammation in our 
study. This is in contrast to a small study by Tomai et aL, where they found increased 
basal CRP is associated with impaired endothelial and non-endothelial-dependent 
microvascular function (Tomai et aL, 2005). Date et aL also found an association 
between IL-6 produced in the myocardium and increased microvascular resistance 
with the Doppler wire in patients with normal coronary arteries (Date et aL, 2005). 
Conversely no relationship was found between circulating inflammatory markers and 
CFR in women with chest pain and no obstructive CAD (Marroquin et aL, 2005). 
More recently patients with chronic active inflammatory disease such as rheumatoid 
arthritis and lupus were found to have impaired microvascular function without the 
presence of significant epicardial disease, and the duration of disease was associated 
with lower CFR (Recio-Mayoral et aL, 2009). There are also some data suggesting 
that slow coronary flow is more prevalent in patients with increased inflammation (Li 
et aL, 2007), but there is no consensus as to the effect of inflammation on basal
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microvascular function. Earlier work by many investigators suggested CRP directly 
causes endothelial dysfunction but it must be noted that a lot of the earlier in vitro 
studies where CRP was added to endothelial cells were flawed due to the presence of 
azides and lipopolysacharrides in the CRP samples, which themselves rather than CRP 
itself, were toxic to the endothelium. Although the effect of inflammation on basal 
microvascular function is disputed it should be noted that in our study all of our 
patients were pre treated with glyceryl dinitrate, which is essential for both FFR and 
IMR measurements. GTN acts as NO donor and this may have counteracted some of 
the effect of inflammation seen particularly on the microvascular endothelial function. 
When we measured basal microvascular function in the form of resting IMR there was 
still no association with inflammation.
Of greater interest is the predictive effect of basal inflammation on outcome of 
microvascular resistance. Baseline CRP has predicted poor outcome in PCI in a 
number of different clinical settings (Buffon et al, 1999;Saadeddin et al., 
2002;Palmerini et al, 2005). In a pooled analysis of the four ISAR trials including 
over 4847 patients, high CRP predicted one year mortality and MACE (lijima et al, 
2009).
In our study we do not see any association between baseline levels of inflammation 
and outcome in degree of change in IMR. This is the first study of its kind specifically 
looking at outcome of IMR in association with inflammation, although there are a lot
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of data suggesting baseline inflammation does affect outcome of PCI adversely. 
Buffon et al. demonstrated an increase in immediate post procedural complications 
and late restenosis in patients with elevated CRP pre procedure. Versaci et al. found a 
large increase in mortality and MI at 12 months follow up in the high CRP group of 
unstable angina patients undergoing PCI (Versaci et al., 2000). Likewise Chew at al. 
found a 3 fold increase in death or MI at 12 months in patients with high CRP 
compared with normal CRP (Chew et al., 2001b). Another large study of 500 patients 
with stable angina showed over 3-fold increase in combined endpoint of death, MI, 
urgent revascularisation and admission to hospital for unstable angina in those with 
elevated CRP at 2 year follow up. Interestingly they found no association with 
restenosis in high CRP group (de Winter et al., 2002). Concordant results were seen in 
a study which showed a striking difference in mortality between high CRP and normal 
CRP, in patients undergoing unprotected left main coronary artery PCI at follow up of 
9 months (Palmerini et al., 2005). There are some studies that show basal CRP levels 
are not associated with poor outcome (Gach et al., 2009). Similarly Saleh et al. could 
not find any adverse effect of elevated baseline CRP in 850 patients undergoing PCI, 
yet rather than baseline levels predicting poor outcome, they found the inflammatory 
response was predictive of adverse events including restenosis and new lesion 
development (Saleh and Tornvall, 2007).
Our data suggest that baseline levels of inflammation are not predictive of poor 
outcome of IMR in the target vessel in response to PCI, and this is true for all the
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inflammatory markers, adhesion molecules and endothelin-1. The lack of association 
between baseline inflammation and outcome of IMR suggests that one of our main 
hypotheses is not supported. Baseline levels of inflammation do not predict outcome 
of microvascular function in patients undergoing PCI for stable angina. Although other 
studies as mentioned earlier did find strong evidence of increased CRP predictive of 
adverse events, the majority of these adverse events occurred after the first 24 hours, 
with the exception of Buffon’s study, where the early events occurred during the 
procedure, or before discharge from hospital. In our study we are looking at immediate 
changes in the microcirculation post-PCI and assessing acute microvascular 
dysfunction. In addition we are looking at the specific outcome of change in IMR 
whereas there were many different medium to long term clinical endpoints such MI, 
death and revascularisation in the other studies. It seems increased basal levels of 
inflammation are less important than the inflammatory response to PCI.
In our study there is an association between the inflammatory response to PCI as 
assessed by circulating CRP and the modification in IMR (R=0.42 P<0.05). There is 
also a relationship between change in ET-1 and change in IMR in the target vessel 
(R=0.34 P<0.05). We do not see any other correlations with any of the other markers 
that were studied. Our results are supported by a number of studies which also show 
more of an adverse prognostic effect of the degree of inflammatory response to PCI 
rather than pre intervention levels, however none of these studies assessed 
microvascular function. There are no data on comparing inflammatory response with
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change in IMR and our study is the first to report this. Although we failed to detect 
any relationship between basal inflammation and outcome of IMR, the relationship 
between inflammatory response and change in IMR is interesting. As suggested by 
experimental work by Griselli et aL, the inflammatory response rather than basal 
inflammation is much more challenging to myocardial salvage. Gach et aL showed in 
89 patients, over 6 year follow up that a significant increase in CRP at the time of PCI 
is a stronger predictor for long term mortality than pre-PCI levels (Gach et al., 2007). 
Two other studies have shown that the persistent elevated inflammatory markers 72-96 
hours post-PCI are poor prognostic indicators. Patients with sustained elevation of 
detectable inflammation have a 20% incidence of combined death, MI and recurrence 
of symptoms vs. none, in patients in whom CRP has returned to normal at 72 hrs 
(Gaspardone et al., 1998). Persistent elevated CRP at 96 hours is also a predictor of 
angiographic restenosis at 6 months (Gottsauner-Wolf et al, 2000). Saleh et al. also 
found the degree of inflammatory response is an predictor of death or Ml independent 
of myocardial necrosis in 891 patients (Saleh etaL, 2005).
The underlying mechanism behind the relationship between modification of CRP and 
modification of IMR is still unclear, since it cannot be said MR increases because of 
the acute inflammatory response, although that may be the case. However it could also 
be that microvascular damage causes a secondary elevation in CRP and hence may 
explain this finding. However there is no relationship between increase in IMR and 
periprocedural rise in troponin-T, which would suggest if anything an alternative
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mechanism to myocardial necrosis may be responsible for the rise in inflammatory 
markers and rise in 1MR. Also serum troponin-T level post procedure are not related to 
change in CRP in our study (r=0.21 P=QA9). Given that troponin-T levels are not 
associated with the increase in MR, this would also suggest that a mechanism 
independent of myocardial necrosis may responsible.
It is interesting that we also a relationship with endothelin-1 and IMR. It is possible 
that PCI releases vasoactive substances, such as endothelin-1, which are responsible 
for the increase in MR. However it should be noted that circulating endothelin-1 may 
not reflect endothelial and smooth muscle activity. Increased levels of endothelin-1 
have been shown to be an independent predictor of the no-reflow phenomenon 
(Niccoli etal, 2006). In addition, endothelin-1 blockade improves CFR post-PCI 
(Papadogeorgos et al.t 2009). The effect of endothelin on coronary microvascnlar 
dysfunction is an interesting area for further research.
The multiple regression model shows that the only pre-procedural factor associated to 
outcome of IMR in the target vessel is IMRcorrec(ed target pre-PCI. The lower IMR pre- 
PCI, the greater the degree of increase in IMR post-PCI. This is a strong relationship 
and does give rise to further questions. It is credible that the inflammatory response is 
associated with microvascular dysfunction for the reasons already discussed above, but 
the finding that very low IMR pre-PCI is a risk factor for worsening IMR is 
unexpected. It may be that those with very low IMR to start off with are those most at
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risk, since the IMR is at the most minimal due to significant epicardial disease. Upon 
performing angioplasty, the large increase in pressure and flow may lead to a 
protective vasoconstriction, possibly via a myogenic response, thereby increasing MR 
post procedure.
Our analysis of inflammatory markers and CFR shows no correlations between 
baseline inflammatory markers and baseline CFR, and change in CFR post-PCI 
against baseline inflammatory markers, which is similar to our IMR data. However we 
also fail to see a relationship between change in inflammatory markers and change in 
CFR, as is seen with change in both CRP and ET-1, with change in IMR. This would 
be expected since IMR is a much superior method for measuring MR as discussed 
earlier. When we compare change in sP-selectin vs. change in IMR resting in the 
target vessel we find a positive association (R=0.39 PcO.OS). This may not be 
surprising since sP-selectin is a key mediator in leukocyte rolling on the endothelium 
in response to endothelial activation. It should however be noted that resting IMR has 
similar methodological flaws to CFR, since basal microvascular tone and basal 
coronary flow are variable.
We have found relationships between baseline VCAM-1 and duration of balloon 
occlusion correlating with increase in troponin-T post-PCI. This may support the 
notion that increased activation of VCAM-1 will allow for greater myocardial necrosis 
following PCI due to increased adhesiveness of the endothelium distally. The
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association between length of time balloon occlusion may be confounded by the fact 
that more complex procedures generally require a greater number of inflations and 
hence were more likely to give rise periprocedural myocardial necrosis. These findings 
are concordant with those of a number of studies which have all demonstrated that 
increased number of inflations increases the risk of periprocedural MI (lakovou et al., 
2003). This could be because of more ischaemia with increased number inflations, yet 
a few seconds of ischaemia are on their own insufficient to cause myocardial necrosis. 
Our original premise of the cessation of flow being central to creating the ideal 
scenario for inflammatory mechanisms to cause microvascular dysfunction, could 
explain why we see this phenomena with increased number of inflations.
Conclusion
This is first study to describe a relationship between IMR and inflammatory markers 
and the relationship to the inflammatory response to PCI. There is a relationship 
between modification of CRP and ET-1 and modification of IMR only seen in target 
vessel, suggesting that there may be a locally acting phenomenon responsible in 
relation to PCI. However whether this is due to the inflammatory response having an 
adverse effect on the microcirculation, or whether the inflammatory response is 
secondary to another mechanism, and the subsequent microvascular injury causes a 
secondary inflammatory response is unclear.
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There is no relationship between baseline inflammatory markers and change in IMR, 
suggesting that baseline inflammatory cannot be used to predict outcome of IMR post- 
PCI, this also suggests main hypothesis is not supported.
Low IMR pre procedure is predictive of worsening of IMR post-PCI, which is a novel 
finding, worthy of further investigation to establish the underlying mechanism.
5.6 Limitations
There are a number of limitations to our study. We used venous blood sampling 
instead of coronary sinus blood sampling, there is some evidence of more sensitivity in 
CS sampling of inflammatory markers (Inoue et aL, 1999). However, there are a 
number of studies which demonstrate little difference between CS and peripheral 
sampling (Mulvihill et aL, 200I;Jaumdally etal, 2007). Hence we thought it was 
acceptable to use peripheral markers for estimates of local activation of inflammation 
as well as generalised inflammatory state.
We only sampled blood pre, 1 hour post and 24 hours post-PCI. We know that CRP 
peaks at 48 hours, and at I hour there is little change post inflammatory stimulus in 
most markers except IL-6, although changes are detectable within 24 hours in CRP, 
for ICAM, VCAM-1, sP-selectin and neutrophil CD1 Ib/CDIB.
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The use of adenosine may attenuate inflammatory response, and this drug was used in 
all patients to achieve hyperaemia. If adenosine was responsible for affecting the 
inflammatory response, then we would expect to see a stronger relationship between 
modification of IMR and modification of CRP.
All our study patients underwent the procedure from the radial artery and the effect of 
radial artery cannulation for the purpose of coronary angioplasty may have contributed 
to the inflammatory response, however in our study group there were no cases of 
radial artery spasm requiring treatment with vasodilators. Since all the patients 
underwent the procedure from the radial artery route and there was no clinically 
significant radial artery spasm any effect on inflammatory response due to radial artery 
sheath insertion would be expected to be similar throughout the study population.
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Chapter 6 Imaging myocardial 
inflammation
6.1 Introduction
According to our original notion, we would be able to predict an increase in 
inflammatory activity in the myocardial microcirculation of the territory supplied by 
the vessel undergoing coronary angioplasty in those patients with an increase in 
microvascular resistance following PCI. We have attempted to detect localised 
myocardial microvascular inflammation following angioplasty for evidence of active 
areas of suspected increased inflammation. Although there are many potential methods 
of imaging active inflammation, detecting inflammatory changes in the myocardium 
can be challenging owing to factors such as the availability of an agent which binds to 
inflamed tissue and can be readily detected by imaging techniques in humans. It is 
because of these limitations that in-vivo human data is limited. Despite these 
difficulties there are some useful methods available which are briefly reviewed.
Contrast-enhanced MRI has been utilised to detect myocardial inflammation especially 
in the diagnosis of acute viral myocarditis (Friedrich et al, 1998b). Gadolinium- 
diethyl-enetriamine penta-acetic acid (Gd-DTPA) enhances inflamed tissue by 
penetrating to the extracellular space due to increased permeability of the vascular 
wall in inflammation (Roditi et al, 2000). Gd-DTPA is detected as signal 
enhancement with MRI scanning and suggests the presence of inflammation. Similar
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changes may be seen with acute myocardial ischaemia and infarction. It is possible to 
differentiate ischaemia from myocarditis by the distribution of late enhancement, 
which is predominantly subendocardial in ischaemia versus epicardial and patchy in 
myocarditis (Laissy et aL, 2005).
More recently there has been the use of contrast enhanced MRI using ultra-small 
superparamagnetic iron-oxide (USPIO) to detect inflammation in carotid plaque 
(Trivedi et al, 2006). USPIO particles are taken up by plaque macrophages which can 
then be visualised within the plaque as signal intensity reduction. PET imaging with 
FIB fluorodeoxglucose (F18DG) has been used to demonstrate active inflammation in 
atherosclerotic plaque of arterial vessels. F18DG allows for imaging since 
inflammatory cells have much higher rate of glucose metabolism compared with 
neighbouring cell types. However it remains difficult to visualise inflammation in 
coronary arteries due to their small size and motion, and the fact that normal 
myocardium also takes up F18DG, hence making it difficult to differentiate changes 
related to the coronary vasculature (Rudd et al, 2010).
PET/CT has been shown to identify vascular wall inflammation in larger blood vessels 
such as the common carotid artery and has been used to detect temporal arteritis. This 
technique utilises the ligand [^Cj-PKl 1195, which binds to the peripheral 
benzodiazepine receptor which is highly expressed in macrophages (Pugliese et al, 
2010).
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The techniques described above demonstrate myocardial inflammation, or 
inflammation within atherosclerotic plaque and myocardial necrosis. However, we 
wish to detect inflammation in the microcirculation downstream from where the PCI 
was performed. We are interested in inflammation on the surface of the endothelium 
of the vasculature, the detection of which is more challenging.
It is possible to detect and quantify myocardial microvascular inflammation using 
microbubbles which can adhere to leukocytes in experimental models (Lindner et at., 
2000a). This technique was used in a canine model of ischaemia reperfusion whereby 
lipid microbubbles targeted towards leukocytes demonstrated areas of microvascular 
inflammation (Christiansen et al, 2002). It is also possible to label echogenic 
microbubbles targeted at specific cellular adhesion molecule, for example ICAM-1 
specific ligands have been used to detect transplant rejection in rats (Weller et aL, 
2003). Other ligands to cellular adhesion molecules such a VCAM-1 can detect 
inflammatory changes on the aortic wall in experimental models (Kaufmann et aL, 
2007). Most recently it has been possible to detect pre-atherosclerotic activation of 
VCAM-1 and sP-selectin using labelled microspheres and echocardiography 
(Kaufmann et aL, 2010). Despite exciting future prospects for detection of vascular 
inflammation, especially in the field of molecular imaging, there are sparse data in 
humans because there is a lack of contrast agents with ligands of proven safety and 
efficacy in humans.
204
More relevant to studies in humans than the above experimental approaches, is the 
well-established technique of imaging the distribution of radio labelled autologous 
leukocytes using gamma camera SPECTto detect localised inflammation. Neutrophils 
migrate to areas of acute inflammation, and "mTc Hexamethylpropyleneamine Oxime 
(HMPAO) selectively binds to granulocytes in leukocyte population. The principle of 
blood cell labelling is that lipophilic radiometal-chelate complexes such as "mTc- 
HMPAO are able to enter the cell membrane of the leukocytes. Once inside, the "niTc- 
HMPAO is transformed into a hydrophilic complex and irreversibly bound (Peters, 
1994a). This technique requires that leukocytes are separated from intravenous blood, 
and labelled in vitro. These labelled leukocytes can then be detected by gamma camera 
(Peters et al, 1986). This technique has been used to detect occult infection and 
inflammation in clinical settings and has been particularly useful for patients with 
orthopaedic infections and inflammatory bowel disease. In addition, radiolabelled 
leukocytes have been used to detect myocardial abscesses around bioprothetic aortic 
valves (Salem et aL, 2004) and myocarditis (Yen and Yeh, 1993;Sun et al, 2003). A 
similar technique was used with Indium-111 oxine to demonstrate myocardial 
inflammation in response to acute MI (Bell et al, 1987).
To investigate the possible mechanisms of downstream arterial effects, we employed 
radio-labelling of leukocytes with subsequent visualisation by SPECT scanning with 
"niTc-HMPAO-WBC due to superior quality of images and reduced radiation dose.
205
We propose post angioplasty inflammatory activation in the territory of the vessel 
which has undergone angioplasty in the form of activated endothelium and leukocyte 
complexes on the vessel walls of the microcirculation. It should be possible to detect 
this inflammation by imaging the bio-distribution of radiolabelled autologous 
leukocytes using a gamma camera. We chose to use this method as it is well 
established and safe for use in humans, and has the added advantage of being readily 
available locally.
6.2 Methods
We performed a pilot study on the first 9 patients investigated. Each patient underwent 
radiolabelled leukocyte scans on two occasions; the first 7 days prior to PCI and the 
second 24 hours post-PCI. SPECT scanning was performed 24 hours after reinjection 
of radiolabelled leukocytes. For detailed methods see Chapter 2 page 76.
6.3 Results
6.3.1 Visual Analysis
One patient refused to be scanned following reinjection of the "mTc-HMPAO- 
WBC99m due to claustrophobia, hi all 17 datasets acquired there was no observed 
evidence of "mTc-HMPAO WBC focal uptake in the region of the myocardium.as 
shown in Figure 6.1.
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Figure 6.1 Example of visual analysis of uptake of "mTc-HMPAO WBC
Figure 6.1 demonstrates the results of the SPECT scans. Bright signals are seen where 
uptake of leukocytes are detected, predominantly in the liver, spleen and bone marrow. 
Slices are chosen in the region of the myocardium. In the transverse slices the bright 
uptake seen in the spine (white arrow) and the sternum (red arrow). The slices seen at 
the bottom represent coronal slices, bright uptake is seen inferiorly in the liver (yellow 
arrow). There is no visual uptake seen in the region of the myocardium in all patients.
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6.3.2 Quantitative analysis of myocardial inflammation
Table 6.1 Summary of quantitative detection of myocardial inflammation with ""'Tc- 
HMPAO-WBC in 8 patients in response to PCI. Data is presented as Mean +/- SD
Patieni Radiation 
dose Activity 
(MBq)
ROI
(myocardial-background)
(counts/pixel)
Pre Post Pre Post
1 204.0 169.8 -0.37 0.12
2 194.3 178.3 1.84 0.18
3 194.3 172.0 -0.02 1.19
4 165.2 137.8 -0.31 -0.01
5 161.9 160.8 -0.56 0.20
6 118.9 183.3 -0.17 0.18
7 185.0 194.3 0.41 0.18
8 183.4 192.6 -1.73 -0.50
Mean+/-
SEM
(95%CI)
175.9+/-9.6
(153.2-198.6)
173.6+/-6.5
(158.2-188.9)
-0.11+/-0.16
(-0.95-0.72)
0.18+/-0.35
(-0.2-0.5)
Table 6.1 shows that the mean counts/pixel of the summated slices is close to zero in 
all data sets. The maximum uptake seen in our patient goup is 1.8 counts/pixel, this is 
the equivalent of 0.002 counts/mm3 and the mean counts/mm3 for the difference 
between the Post PCI (myocardial ROI and background ROI) -Pre PCI(myocardial
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ROI and background ROI) is 0.0003 counts/mm3. This level of activity can be 
considered to be no more than normal background levels.
Figure 6.2 Effect of PCI on myocardial inflammation presented as mean counts/pixel 
(background-ROI). Mean+/-SD, n=8
p=ns
a>x
a.
1/5
c
3oa
0.3- 
0.2- 
0.1 -
Post
There is no significant difference between the RORmyocardial-background) before 
and after PCI. (0.19+/-0.16 counts/pixel vs. -0.11-I-/-0.35 counts/pixel n=8 P=0.38)
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Discussion
This is a novel approach to identifying myocardial vascular inflammation, although 
there a few reports of similar techniques being used in the past to detect myocardial 
inflammation in response to myocardial infarction (Davies et aL, 1981 ;Bell et ai, 
1987). This is the first study which attempts to image myocardial inflammation in 
response to coronary angioplasty. We did not detect any visual uptake of leukocytes in 
the myocardium using the technique described, and even with quantification of 
detectable uptake was negligible. Since counts/pixel were close to zero in all cases the 
values which were detected are can be considered to be no more than background 
levels._These negative results could be explained by the following possibilities;
There is no significant adherence of leukocytes on to endothelium (as determined by 
myocardial uptake of radiolabelled leukocytes), suggesting that the original hypothesis 
of activated endothelium allowing for this process to occur downstream does not occur 
in the setting of angioplasty. However, given the limitations of the technique used, 
failure to detect inflammation does not rule out the possibility of microvascular 
inflammation following PCI. There are other potential explanations for these lack of 
positive findings.
Leukocyte adherence is transient and the leukocytes were no longer adherent by the 
imaging time 24 hours after the acute event. However as_previous studies have 
suggested, optimal timing for scans is 24 hours post insult although the timing of
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injection of labelled cells should be as soon as feasible post insult (Davies et ah,
1981), this seems unlikely. Our patients were injected with the radilolabelled 
leukocytes Ihour post angioplasty and the images obtained 24 hours later to allow for 
clearing of labelled leukocytes from the blood pool, as these would have obscured any 
additional uptake by the myocardium.
Finally and perhaps most likely, the short duration of ischaemia in this study resulted 
in insufficient leukocyte adherence onto the endothelium to allow detection by the 
method used. The data previously presented that led to our use of this technique 
described models of ischaemia reperfusion whereby up to 60 minutes of ischaemia had 
been induced followed by reperfusion (Christiansen et al., 2002). In our patients, the 
ischaemia induced lasts for no more than a few minutes at the most. Furthermore in 
the human studies, patients had imaging performed after established myocardial 
infarction secondary to prolonged ischaemia (Bell et al., 1987) (Davies et al, 1981).
Limitations
The technique used may not have the sensitivity required to detect inflammation at the 
microvascular level. However, it is a challenge to find the ideal imaging modality in 
humans, particularly if one is interested in microvascular inflammation. The use of a 
SPECT/CT acquisition rather than just a SPECT acquisition could have enabled 
anatomical mapping of the myocardial anatomy and permit localisation of any 
observed uptake in the myocardium and increase accuracy in the quantification. But
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since there was no uptake seen on plain SPECT imaging, this would have been little 
additional benefit with higher radiation doses for the subjects. If SPECT/CT would 
have been available locally at the start of the study we could have utilised this. The 
number of patients in this study was small, 2 patients in this subgroup had evidence of 
periprocedural myocardial injury but there was still no visible uptake of radioisotope.
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Chapter 7 Conclusions
Our aim was to describe the effect of PCI on microvascular function in patients 
undergoing coronary angioplasty for stable angina, and to identify mechanisms 
for microvascular disturbance with a view to potential clinical therapy. This 
study contributes to the understanding of pathophysiological mechanisms of 
microvascular injury following PCI, and for the first time demonstrates that PCI 
has an adverse effect on IMR in patients with stable angina. Furthermore we 
have found a complex interaction between the microcirculation in adjacent 
vessels during PCI. This study also compares the association between 
inflammation and microvascular function in relation to PCI. We showed pre-PCI 
inflammatory markers cannot be used as a predictor of outcome of microvascular 
function post-PCI, but there is an association between the degree of 
inflammatory response to PCI and the degree of microvascular dysfunction, 
when CRP and ET-1 are measured. Low pre-procedural microvascular resistance 
predicts patients with an increase in IMR and the only procedural factor which is 
associated with increase in IMR is the total duration of balloon inflation. One of 
the most significant results in this study is the reduction in IMR in the reference 
vessel following PCI in the adjacent vessel, which is a novel finding.
Microvascular dysfunction in PCI is of major interest and this study helps to 
further understand the underlying mechanisms. Our original hypothesis was
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based on inflammation being a key mediator of microvascular dysfunction and 
we expected increased levels of baseline inflammation would help to identify 
those patients most at risk of microvascular dysfunction. From our data this 
notion is not supported, we do however see an association between inflammatory 
activation and microvascular dysfunction in response to PCI, when CRP and ET- 
1 are measured.
It is apparent that from our data that locally acting mechanisms are responsible 
for microvascular disturbance in response to PCI. We suggest that microvascular 
disturbance is occurring due to PCI causing either a mechanical obstruction, or 
distal microcirculatory vasoconstriction. We suggest microvascular dysfunction 
would be due to either due to a release of vasoactive or prothrombotic mediators 
from the plaque, or from the microcirculation in response to ischaemia in 
response to balloon/stent inflation against the vessel wall disrupting 
atherosclerotic plaque. An alternative mechanism causing distal microcirculatory 
vasoconstriction may also occur via the activation of alpha adrenergic receptors. 
It is interesting, however, that the phenomenon of microvascular dysfunction 
seems to be independent of myocardial necrosis in our study, suggesting an 
alternative mechanism to myocardial necrosis responsible for the increase in 
inflammation and microvascular dysfunction.
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Release of endothelin from the plaque causing distal microcirculatory 
dysfunction is a possible mechanism supported by our data, alternative 
mechanisms include alpha adrenoreceptor mediated distal vasoconstriction in 
response to stretching of the epicardial vessel by PCI. We suggest a greater 
inflammatory response is seen in those with greater levels of plaque disruption, 
and hence any intervention which is able to stabilise the plaque during PCI may 
be beneficial. This may be the reason why statins are beneficial as pre-treatment 
before PCI.
The reference vessel reduction in microvascular resistance is an unexpected 
finding. We suggest this may be due to either an alpha adrenergic mediated 
microvascular vasodilation in the reference vessel territory or due to changes in 
collateral resistance. Another possibility is the release of other vasoactive 
mediators acting on the reference vessel bed.
We propose a unifying hypothesis which can explain these findings; Performing 
PCI causes microvascular dysfunction in a target vessel microvascular territory 
due to a release of vasoactive mediators from the plaque, the resultant increase in 
microavscular resistance in the target vessel causes a reduction of collateral 
resistance and thus a reduction in reference vessel resistance to compensate for 
the increase in target vessel resistance.
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This study was designed to understand the mechanism behind microvascular 
function with a view to clinical benefit. Our data has got clinical relevance 
particularly in the way in which commonly performed intracoronary 
physiological measurements are interpreted in the form of FFR. FFR is an 
increasingly popular measurement used to guide the need for coronary 
intervention. FFR measurement assumes minimal microvascular resistance 
remains constant. We have shown in our study that minimal microvascular 
resistance can be variable and is affected by PCI, particularly where 2-vessel PCI 
is being considered. We now know that IMR can be influenced by PCI in 
adjacent vessel territories and hence interpretation of FFR in these settings must 
be done with some degree of caution, particularly if the FFR result is close to the 
threshold for intervention. Our study was not powered for clinical outcomes and 
it would be difficult to derive conclusions based on clinical outcomes given the 
small number of subjects. However any future studies should include follow up 
to detect major adverse cardiac events. It would be interesting to know how acute 
microvascular dysfunction at the time of PCI affects clinical outcomes and also 
to see how microvascular function responds in medium to short term if acute 
microvascular injury is sustained.
This study has raised a number of questions which would require further 
investigation and could have clinical benefit. Firstly the mechanism behind 
microvascular dysfunction in stable angina setting could be investigated by
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assessing the role of endothelin and alpha adrenoreceptors. This could be done 
by the administration of the endothelin antagonist BQ123 and intra-corornary 
alpha-1 and alpha-2 adrenoreceptor antagonists respectively before PCI, and 
comparing this with control groups, and measuring changes in microvascular 
function. By sampling blood in the aorta, beyond the coronary lesion and in the 
microcirculation it could be assessed if vasoactive or prothrombotic mediators 
were released from the plaque or the microcirculation. These experiments would 
help to determine further the mechanisms responsible for peri-procedural 
microvascular dysfunction. The mechanism responsible for a reduction in IMR in 
the reference vessel can be tested by measuring IMR in all three major coronary 
arteries and assessing changes in collateral flow resistance and effects modifying 
alpha adrenergic activity and assessing response on IMR.
In summary the work presented here has 4 major findings, firstly there is an 
association between inflammatory activation when measured by CRP and ET-1 
and microvascular resistance. Baseline levels of inflammation do not predict 
which patients will develop increase in microvascular resistance. The only pre 
procedural factor associated with an increase in IMR is low EVER pre-procedure. 
There is a reduction in IMR in the reference vessel in response to PCI in the 
target vessel. This work further questions the mechanisms underlying 
microvascular dysfunction in PCI and suggests the role of inflammation is more 
a response rather than a cause of the mechanism responsible for microvascular
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dysfunction. Given that PCI in stable angina is predominantly a symptomatic 
treatment, any adverse effects from the procedure should be identified and 
minimised. This study adds to the understanding in this area and we have 
suggested areas for further development and research as outlined above.
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